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Newcastle disease virus (NDV) is a single-stranded, non-segmented, negative-sense 
enveloped RNA virus, which belongs to the Orthoavulavirus genus of Paramyxoviridae 
family. It is a well-known, economically important poultry pathogen worldwide. Over the 
last five decades, NDV is known to have oncolytic properties based on its tumour-
selective replication sparing the healthy cells and immunostimulation affirming potential 
candidate for oncovirotherapy.  
In this PhD project, the efficacy of naturally occurring and genetically modified GFP 
expressing non-pathogenic NDV strains investigated in various human cancer cell lines 
as an oncolytic virus. This study has demonstrated that the heterogeneous colorectal 
cancer cell line Caco-2 was the most susceptible to the cytotoxicity induced by avirulent 
NDV strains amongst the panel of diverse cell lines tested. Despite the high levels of 
cell cytotoxicity induced by NDV in Caco-2 cells, a small population of surviving cells 
was isolated from NDV superinfected Caco-2 cells 12 days post infection and named 
VR Caco-2 cells (virus-resistant Caco-2 cells). The persistent infection with avirulent 
strains of NDV was demonstrated in VR Caco-2 cells for the first time. 
An integrated approach of cellular, transcriptomic, and proteomic data was used to study 
differences between persistently NDV-infected VR Caco-2 cells,and acutely NDV-
infected and uninfected Caco-2 cells. This study has shown that persistent NDV-
infection resulted in slower cell proliferation of VR Caco-2 cells than parental Caco-2 
cells, and production of recoverable and replicating virus at lower titres. VR Caco-2 cells 
have demonstrated resistance to NDV re-infection. In contrast, VR Caco-2 cells were 
susceptible to other viruses such as avian influenza virus (H9N2) and vesicular 
stomatitis virus (VSV). Persistent NDV infection in VR Caco-2 cells resulted in reduced 
NDV-induced cytotoxicity, although VR Caco-2 cells were still sensitive to the increased 
cell cytotoxicity induced by the VSV infection. This would suggest that a combination of 
oncolytic viruses could be used to overcome the effects of NDV persistent infection.  
Potential mechanisms of persistence of NDV in Caco-2 cells were explored. Both Caco-
2 and VR Caco-2 cells demonstrated the lack of efficient induction of IFN-β and ISG15 
mRNAs, which could be a potential reason for the establishment of NDV persistent 
infection. RNA-seq data analysis demonstrated extensive regulation of thousands of 
genes and hundreds of cellular pathways in VR Caco-2 cells while maintaining 50-times 
lower viral load compared to acute NDV-infection (in Caco-2 cells). Fluctuation in 
SQSTM1/p62, a multifunctional and multidomain signalling adapter protein required in 
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selective autophagy, was also demonstrated suggesting the induction of autophagy in 
NDV-infected Caco-2 cells.  
The results generated in this PhD project strongly suggest that NDV not only establishes 
persistent infection but that too reduces NDV-induced cytotoxicity while regulating 
thousands of genes in Caco-2 cells. It also suggests the need for detailed investigation 
of persistent NDV-infection in vitro and in vivo models of Caco-2 cells before and after 
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LAS Leica application suite 
LB Luria Broth 
LC3 Microtubule-associated protein 1 light chain 3 
LFCs Log2 fold changes 
LGP2 Laboratory of Genetics and Physiology 2 
LHT Local hyperthermia 
LIR LC3 interacting region 
LN Lymph node 
LPS Lipopolysaccharide 
LXR Liver X receptors 




mAbs Monoclonal antibodies 
MAPK Mitogen-activated protein kinases 
MDA5 Melanoma differentiation-associated protein 5 
MDSC Myeloid-derived suppressor cells 
mEHT Moderate local electrohyperthermia 
MEM Minimum essential medium 
MHC-II Major histocompatibility complex class II 
miR MicroRNA 
MOI Multiplicity of infection 
MOMP Mitochondrial outer membrane permeabilization 
MS Mass spectrometry 
MS4A10 Membrane Spanning 4-Domains A10 
MSCs Mesenchymal stem cells 
MTD Maximum tolerable dose 
MUC 1/13/17 Mucins 1/13/17 
MuV Mumps virus 
MV Measles virus 
NADPH Nicotinamide adenine dinucleotide phosphate 
NBR1 Neighbour of Brca1 gene 
NDV Newcastle disease virus 
NF-kB Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NGF Nerve growth factor 
NHEJ Non-homologous end joining 
NK Natural killer cells 
NLS Nuclear localisation sequence 
NO Nitrous oxide 
NOS Nitric oxide synthase 
NOX2/4 NADPH oxidases2/4 
NP Nucleocapsid protein 
NRF2 Nuclear factor erythroid-2-related factor 2 
NS3 Non-structural protein 3 
NSCs Neural stem cells 
OASL  2'-5'-Oligoadenylate synthetase-like protein 
Orm1 Orosomucoid 1 
Orm2 Orosomucoid 2  
OVs Oncolytic viruses 
P Phosphoprotein 
p62/ SQSTM1 Sequestosome 1 
PAC Puromycin N-acetyltransferase  
PAGE Polyacrylamide gel electrophoresis 
PAGE4 P Antigen Family, Member 4 (Prostate Associated) 
PAMPs Pathogen-associated molecular patterns 
PB1 Phox and Bpem1 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffer saline 
PBSa Ca+2/Mg+2 free Phosphate buffer saline 
PCR Polymerase chain reaction 
PD-1 Programmed cell death protein-1 




PDGFRA Platelet-derived growth factor receptor alpha 
PD-L-1 Programmed cell death ligand -1 
PERK PKR-like endoplasmic reticulum kinase 
PFA Paraformaldehyde 
PFU Plaque-forming unit 
PI3K/AKT 
Phosphoinositide 3-kinases/RAC-alpha serine/threonine-protein 
kinase 
PIV5 Parainfluenza virus type 5 
PKR Protein kinase RNA-activated 
PMEL17 Premelanosome protein 17 
poly(I:C) Polyinosinic-polycytidylic acid 
PRRs Pattern associated receptors 
RANKL Receptor activator of nuclear factor kappa-Β ligand 
RANTES Regulated on activation, normal T cell expressed and secreted 
Rb Retinoblastoma 
RCC Renal cell carcinoma 
RE Restriction enzymes 
RFP Red fluorescent protein 
RGCC Regulator Of Cell Cycle 
RIG-1 Retinoic acid-inducible gene-1 
Rigvir Riga virus 
RIP1 Receptor-interacting serine/threonine-protein kinase 1 
RIPA Radio-Immuno precipitation assay 
RLR RIG-I like receptor 
RLU Relative light units 
RNAi RNA interference 
rNDVs Recombinant NDVs 
ROS Reactive oxygen species 
RPKM Reads Per Kilobase of transcript per Million reads 
RPMI Roswell Park Memorial Institute 
RSV Respiratory syncytial virus 
RT Radiotherapy 
RXRs Retinoid X receptors 
S DNA synthesis phase 
SCCHN Squamous cell carcinoma head and neck 
scFv single-chain Fv 
SDF-1 Stromal cell-derived factor-1 
SDS Sodium dodecyl sulfate 
SeV Sendai virus 
siRNA small interfering RNA 
SLC10A1 Solute Carrier Family 10 Member 1 
SLC38A4 Solute Carrier Family 38 Member 4 
SMAC Second mitochondria-derived activator of caspases 
SNPs Single nucleotide polymorphisms 
SP100 Speckled 100 KDa Nuclear Antigen 
STAT-1 Signal transducer and activator transcription factor 1 
STR Short tandem repeat 
TAAs Tumour associated antigens 
TBE Tris/borate/EDTA 




TCA Tricarboxylic acid cycle 
TCID50 Median Tissue Culture Infectious Dose 
TFBS Transcription factor binding sites 
TGFB1 Transforming growth factor beta 1 
TGF-α Transforming growth factor-alpha 
TIM3 T-cell immunoglobulin and mucin domain 3 
TK Thymidine kinase 
TLR Toll-like receptor 
TMT Tandem Mass Tag 
TMZ Temozolomide 
TNF Tumour necrosis factor 
TNFR2 Tumor necrosis factor receptor 2  
TRADD TNFR-1 associated death domain 
TRAF3 TNF associated factor 3 
TRAF6 Tumour necrosis-associated factor 6 
TRAIL TNF-related apoptosis-inducing ligand 
TTP Tristetraprolin 
T-VEC Talimogene laherparepvec 
UBA Ubiquitin-associated 
uPA Urokinase plasminogen activator 
UPR Unfolded protein response 
VEGF Vascular endothelial growth factor 
VGF Vaccinia growth factor  
VHL Von Hippel-Lindau 
VR Caco-2 Virus-Resistant Caco-2  
VSV Vesicular stomatitis virus 
VV Vaccinia viruses 
WB Western blot 
WT Wild-type 
XIAP X-linked inhibitor of apoptosis protein 
ZZ ZZ-type zinc finger 




1    Introduction 
1.1. General introduction to cancer  
 
Cancer is the second most leading cause of death worldwide followed by cardiovascular 
diseases, and according to the International Agency for Research on Cancer (IARC) 
report, 9.6 million deaths have been recorded, and 18.1 million new cases have 
escalated internationally, in 2018. The cancers of lung, colorectum, stomach, liver, and 
breast are the most common causes of cancer deaths and ranking first to fifth from the 
lung to mammary glands. 
 
Cancer is generic terminology used for malignancies of diverse tissues leading to the 
severe life-threatening diseases consequential of the complex process of tumorigenesis. 
Cancer is resulted from fundamental abnormalities in the regulation of the cell cycle (1). 
Under normal condition, cellular homeostasis maintained by cell proliferation, cell growth 
arrest, and apoptosis regulated by precise control of cell cycle checkpoints (1). The cell 
cycle is a tightly regulated process of cellular division achieved by intricate sequences 
divided into interphase and mitotic phase (M) controlled by various checkpoint regulators 
(illustrated in Figure 1.1.) (2, 3).  The interphase comprises gap 1 phase (G1), DNA 
synthesis phase (S), and gap 2 phase (G2). The G1 and G2 phases corresponds to 
obvious gaps in the cell cycle that occur between S phase and M phase. In G1 phase 
cell undergoes duplication of cellular constituents before DNA replication in S phase, 
whereas in G2 phase cell undergoes final protein synthesis and cellular growth 
preparation before M phase (4). The M phase constitutes of 4 different sub-phases 
[prophase (Pro), metaphase (Met), anaphase (Ana), and telophase (Tel)] of karyokinesis 
where cell divides into two daughter cells followed by cytokinesis. The gap 0 phase (G0) 
phase represents cell cycle arrest, where cells are reversibly reserved from cell division 
cycle in response to elevated cell density and mitogen deficiency (5). Cell cycle 
checkpoints are regulatory mechanisms of cell growth and proliferation governed by 
complex array regulatory proteins interactions (1). Checkpoints of the cell cycle confirm 
orderly succession of cell cycle, are crucial in the maintenance of genomic stability and 
deregulation of these checkpoints often result in carcinogenesis in the majority of 
cancers (2). Oncogenes (such as Her2/neu, Ras, c-Myc, etc.) and tumour suppressor 
genes (such as Rb, p53, Bcl-2, SWI/SNF etc.) are important two gene types play vital 
role in cycle and cancer development (1). 




Figure 1.1. Dagram illustrating cell cycle regulation, adapted from Bower et al. (2). 
The cell cycle phases [Interphase  covering gap 1 (G1), synthesis (S), and gap 2 (G2); 
Mitosis (M)  which consists of several sub-phases: prophase (Pro), metaphase (Met), 
anaphase (Ana), and telophase (Tel), and the gap 0 phase (G0)]are shown in the grey 
circle. The interphase is the longer phase of the cell cycle that consists of growth phases 
where cellular constituents grows before (G1) and after (G2) synthesis of DNA 
replication phase. The mitosis is a shorter phase consisting of subphases of 
karyokinesis followed by shortest cytokinesis phase. The G0 phase is a restriction point 
where cell cycle arrest designated by blue triangle with a black dual headed arrow to 
show changeable nature of cell cycle entry and dormancy. The cell cycle progression is 
activated by several checkpoints triggered by external factors while cell transitions from 
phases. Major cell checkpoint regulators are designated in red font at green triangle. 
Cell checkpoints regulation is important for accurate DNA replication and cell division. 
 
There are at least 4 different cell cycle checkpoints which are deregulated in cancer 
cells: the cell cycle arrest point (G0/G1), the G1 checkpoint, the G2 checkpoint, and the 
mitosis-associated spindle assembly checkpoint (SAC) (2). In the G0/G1 cell cycle arrest 
point, the transition from G1 constrains the induction of cell dormancy reversion due to 
lack of growth factors and regulates cell division (2). The Rb/E2F signalling pathway 
mainly controls G0/G1 checkpoint, where release of E2F transcription factors from Rb 
activates genes involved in the initiation of DNA repictaion at the start of S phase. Cyclin 
D1 and cyclin-dependent kinases (cdk) 4/6 are upstream regulators of Rb and 
overexpression or mutation in these regulators can lead to dysregulation of G0/G1 
checkpoint that results into early activation of DNA replication (2). The p53/p21/Mdm2 
pathway controls G1 checkpoint and regulates DNA damage in the cell. DNA damage 
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postpones the initiation of DNA replication which often resulted from inactivation or 
mutation of wild-type p53 and leads to error-prone synthesis of DNA in S phase (2).  Two 
types of G2 checkpoints are identified: G2 DNA damage checkpoint and decatenation 
G2 checkpoint. DNA damage delays initiation of mitosis by sequestering cyclin B1/cdk 
1 in the cell cytoplasm. The catalytic inhibition of topoisomerase IIα (topo IIα) without 
explicit DNA damage activates decatenation G2 checkpoint. The ATM/Chk2/p53 
pathway play major role controlling both G2 checkpoints and inactivation of either of G2 
checkpoints lead to chromosomal instability (2). Lastly,  SAC regulates mitosis at the 
onset of anaphase by controlling bipolar attachment of chromosomes to mitotic spindle. 
Regualtors such as APC/C, BubR1, and Mad2 play important role in SAC and 
impairment of SAC signalling result into multipolar spindles or inadequate separation of 
sister chromatids into daughter cells (2). Defects in any of these checkpoints lead to 
progression of tumorigenesis in a tumour. 
 
The complexity of tumorigenesis is fundamentally characterized by six principal 
hallmarks proposed by Hanahan and Weinberg (6, 7) which are self-containment of 
growth signals and unresponsiveness to anti-growth stimuli, unregulated cell 
proliferation, defective anti-survival pathways, constant genetic instability, enhanced 
angiogenesis, and activation of tissue invasion with metastasis (illustrated in Figure 
1.2). Unlike healthy cells, neoplastic cells proliferate in a disorderly and uncontrolled 
manner due to the aberrant growth stimuli regulations and responses.  Cancer cells 
become self-contained in growth signal production; such growth signals include platelet-
derived growth factor (PDGF), transforming growth factor-alpha (TGF-α) and by 
overexpression of receptors like epidermal growth factor receptor (EGFR) which are 
hyper-responsive to the ambient growth factors. Cancer cells become insensitive to anti-
growth factors as a result of a disruption in anti-survival pathways, retinoblastoma (Rb) 
pathway is one such example. In human cancers, disruption of the Rb/E2F pathway 
results from a mutation in p16, a cdk inhibitor 2A, which is responsible for the control of 
cyclin D/cdk4 kinase activity. The absence of p16 elevates cyclin/cdk4 kinase activity 
leading to Rb phosphorylation and release of E2F transcription factors which leads to 
uncontrolled cell proliferation (8). Cancer cells lose homeostasis by acquiring defects in 
anti-apoptotic and other cell death pathways via several mechanistic manipulations of 
regulatory molecules. For example, genetic alteration in anti-apoptotic Bcl-2 family of 
molecules disrupts mitochondrial apoptotic pathway in most of the cancers like 
melanoma, leukaemia and others (9).  The expression of vascular endothelial growth 
factor (VEGF), acidic and basic fibroblast growth factors (FGF1/2) governs the 
escalation in angiogenesis which accomplishes self-dependency of oxygen and 
Chapter 1 - Introduction 
24 
 
nutrients of neoplastic cells. The switch in angiogenesis inducers and inhibitors upsets 
the balance resulting in exponential tumour growth as a result of new vasculature 
supplementing nutrients to the hypoxic tumour microenvironment (6, 7). In the advanced 
phase of malignancy, cancer cells migrate from tumour origin to distant locations and 
establish new tumorigenic colonies. The establishment of tissue invasion and metastasis 
in cancer cells becomes plausible due to alterations in expressions of cell adhesion 
molecules (CAM) and E-cadherin molecules (6, 7).  
 
 
Figure 1.2. The principal hallmarks, which characterise the malignancy of 
abnormal neoplastic cells, adapted from Hanahan & Weinberg, 2000 (6) and 
Hanahan & Weinberg 2011 (7). A large group of diseases grouped under the category 
of cancer signifies these core hallmarks as a characterisation marker under malignancy 
umbrella. Cancer and its progression can be identified by self-sustenance by growth 
signals or receptors adequacy and insensitivity to anti-growth factors, uncontrolled cell 
proliferation, defects in cell death pathways, self-sustainable angiogenesis, activation of 
tissue invasion and metastasis, and genetic instability. 
 
 
The instability in the genetic makeup of cancer cells stands out as a critical feature for 
recognition of the status of the various cancers, which results from mutations in the DNA-
repair genes in the form of either chromosomal instability or microsatellite instability or 
karyotypic instability as a result of telomerase depletion. The genomic instability plays 
roles in both hereditary and non-hereditary types of cancers. The genomic instability 
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modifies cancer cells by reprogramming and deregulating cellular energetics to adapt 
with the continually changing complex tumour microenvironment for the supply of 
nutrients, oxygen, and growth stimulants under the metabolic stress (10). Tumour 
inflammation is evident in most of the neoplastic microenvironment due to infiltration of 
immune cells and release of inflammatory cytokines such as tumour necrosis factor 
(TNF), interleukin-1 (IL-1) and release of reactive oxygen species (ROS) at the site of 
inflammation. However, in some cancer cells modulation of immune checkpoints results 
in the evasion of the immunosurveillance; for example, overexpression of programmed 
cell death ligand -1 (PD-L-1), cytotoxic T lymphocyte-associated antigen-4-B7 (CTLA4-
B7), and T-cell immunoglobulin and mucin domain 3 (TIM3) on cancer cells inactivates 
or negatively regulates cytotoxic T lymphocytes (CTLs) activation and lead to CD4+ and 
CD8+ T-cells tolerant tumour microenvironment (7). Immune checkpoints are regulatory 
pathways of the immune system to modulate the extent and time of immune responses 
to maintain self-tolerance of the immune cells and prevent tissue damage in case of the 
pathogenic invasion in healthy cells. Tumour cells manipulate immune checkpoints to 
avoid the immune system. T-cell mediated cytotoxicity plays an inevitable role in tackling 
the rejection of tumours because of selective antigen presentation, direct CD8+ effector 
T-cell-mediated cytotoxicity in response to antigens, and dual functionality in the innate 
and adaptive immune system. T-cell mediated immune responses implicate multiple 
steps and complex array of molecules at each stage starting from antigen-specific clonal 
selection, activation, maturation, and proliferation in lymphoid organs, to interactions 
with APCs. Hence, each of these steps is regulated by counteracting co-stimulatory and 
co-inhibitory molecules to govern the normal functioning of T-cells (11). Tumour cells 
over-express inhibitory signals as membrane-bound receptors such as B7, programmed 
cell death ligand -1 (PD-L-1), and high mobility group box protein 1 (HMGB1) which 
interacts with their membrane-bound and soluble ligands such as CTLA4-B7, PD-1: PD-
L1/L2, and TIM3-HMGB1, which limit T-cells activation. The interactions mentioned 
above are the potential targets for currently used ICIs (12). ICI mainly comprises of 
CTLA-4 and PD-1. FDA approved targets as of prime importance are discussed below 
in relation with oncovirotherapy. 
 
CTLA-4 (also known as CD152) is an inhibitory molecule expressed on the activated T-
cell surface which prevents binding of B7 to CD28 molecules and leads to unfavourable 
regulatory T-cell functions. Prevention of B7-CD28 interaction results in disruption of 
naïve T-cell activation and ultimately decreased T-cell-mediated immune responses.  
Ipilimumab is a commercially available anti-CTLA-4 antibody used as ICI and its 
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improved antitumour activity facilitated by NK cells and CTL activation is reported in a 
murine melanoma model.  
 
PD-1 is a checkpoint immunoglobulin molecule expressed on activated T-cells, B-cells 
and NK cells for the extended time frame than CTLA-4 (13). The  PD-1 signalling inhibits 
T-cell activation in a late stage of activation of the immune response to tumours and 
tissues, whereas CTLA-4 inhibits T-cell activation occurs in early stages. PD-1 has 
appeared as a most promising target of ICI which can promote antitumor immune 
reactions. PD-1 is overexpressed on regulatory T-cells; hence, blockade therapy might 
help in enhancing the T-cell activation of the immune response by reducing the 
suppressor activity of regulatory T-cells. PD-1 mainly interacts with PD-L-1 and PD-L-2 
ligands. In many cancers such as lung, ovarian, and melanoma, PD-L-1 upregulation is 
very common; moreover, it is also usually overexpressed on myeloid cells in the tumour 
microenvironment, perhaps an adaptation to the immune response development in the 
tumour microenvironment. Numerous anti-PD-1 and anti-PD-L1 inhibitors have been 
developed for blockade therapy, and in 2014 FDA approved the first PD-1 inhibitor 
pembrolizumab for the melanoma treatment.  
 
1.2. Types and stages of cancer  
 
More than 100 types of cancers are identified and named for the organs or tissues of 
origins. Most of cancers are grouped into one of 3 main categories: carcinoma, sarcoma, 
and lymphoma or leukemia. Carcinomas are most common types of cancers and include 
≥ 90% of human cancers derived from malignancies of epithelial cells. Carcinomas have 
specific names based on types of epithelial cells such as adenocarcinoma (epithelial 
cells producing mucus or fluids in tissues e.g. colon, breast, prostate etc.) and squamous 
cell carcinoma (epithelial squamous cells from skin, lung, thyroid, vagina etc.).   
Sarcomas are rare form of cancers comprising solid tumours of connective tissues, 
including cartilage, bone (osteosarcoma), muscles, and fibrous tissues. Lymphomas and 
leukemias are malignancies derived from immune cells and blood forming cells, which 
comprises ≥ 8% of human cancers (14). 
 
Tumorigenesis is a complex multistep process of cancer cell development including 
mutation and clonal selection of cells with uncontrolled cellular proliferation, survival, 
invasion, and metastasis (14). Stages of cancer are defined by the American Joint 
Committee on Cancer (AJCC) (15), and are based on clinical, pathological, and post-
therapy identification. The cancer staging is dependent on various elements such as 
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location of primary tumour, size of tumour, involvement of lymph node, and presence or 
absence of metastasis at distant sites in the body. TNM staging is widely used cancer 
staging system and regulated by the AJCC and the Union for International Cancer 
Control (UICC). TNM system of cancer stage classification based on the level of the 
tumour (T), the degree of spread to lymph nodes (N), and the evidence of metastasis 
(M). TNM staging further categorised in different groups as shown in Table 1.1. 
 
                       Table 1.1: TNM based cancer categorisation 
Categorization based on primary tumour (T)  
TX Primary tumour evaluation is impossible   
T0 No evidence for primary tumour 
Tis Abnormal cells/tissue in situ 
T1-T4 size and extent of tumour 
Categorization based on lymph node (N)  
NX Evaluation of regional N is impossible   
N0 No evidence of regional N involvement 
N1-N3 Involvement of regional N 
Categorization based on distant metastasis (M)  
M0 No distant metastasis 
M1 Evidence of distant metastasis 
 
Once the status of the T, N, and M are determined, cancer is broadly classified in 5 
broad stages. The classification of cancer vary based on the type of cancer and each 
stage further subdivided based on type of cancer using letters e.g., IA, IIB, IIIC etc. 
These broad stages of cancer are described as below. 
Stage 0: abnormal cells growing in situ. 
Stage I: cancers localised to one specific part of body. 
Stage II: locally advanced cancer without any sign of spread to other tissue or organs. 
Stage III: locally advanced cancer with the evidence of invasion of neighboring tissues 
and regional spread. 
Stage IV: advanced cancer with metastasis at distant sites in the body. 
 
1.3. Oncovirotherapy as a cutting-edge treatment for cancer  
 
From the early 19th-century, surgery followed by radiation therapy has been employed 
to treat cancers. The first successful surgical partial mastectomy was performed under 
general anaesthesia for a breast cancer patient in 1804 by Seishu Hanaoka (16). After 
the discovery of X-ray by Wilhelm Roentgen in 1895 and the radioactive radium and 
polonium discovery by Marie and Pierre Curie in 1898 led to the use of radioisotopes in 
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radiation therapy as a new avenue for cancer treatment (17). In 1903, S.W. Goldberg 
and Efim London demonstrated the use of radiation to treat 2 patients with basal cell 
skin carcinoma with complete eradication of cancer cells. Surgery is still used today to 
remove localised tumours if recognised in early stages of diagnosis and remain essential 
backbone treatment for cancers of various tissues. Radiotherapy also has dominated 
since its emergence until the discoveries in the field of anti-metabolites, e.g. 
methotrexate and alkylating agents such as nitrogen mustard, potential cytotoxic 
chemicals which cause inhibition of DNA synthesis and a cascade of other cytotoxic 
effects in cells (18, 19). Despite the success of nitrous oxide and methotrexate in 
lymphoma and leukaemia cancer patients, by 1950 physicians noticed limitations and 
were disappointed with chemotherapy as a result of failed durability and remission of 
tumours leading to the advanced stage. 
 
Conventional methods have significant drawbacks and enormous side effects because 
of poor specificity. The need of target-specific cancer treatment became promising with 
everyday scientific advancements in molecular biology, immunology, cancer biology, 
and virology to manage cancer. Targeted therapy included novel approaches to tackle 
cancer, such as monoclonal antibodies, antibody-drug conjugates, tyrosine kinase 
inhibitors, immune checkpoint inhibitors, hormonal agents, antitumor vaccines and 
oncolytic viruses (OVs). The extensive study of OVs in recent times has resulted from 
inquisitive and vigilant observations of the last century in cancer patients where 
remission of tumours was linked to patients contracting infectious diseases. The first 
such instance was presented in 1910 at the International Cancer Congress, Paris, by 
Italian clinician, N. G. De Pace where the dramatic remission documented in rabies virus 
vaccinated uterine cervical cancer patients and likewise similar effects documented in 
African Burkitt’s lymphoma positive children with measles virus infections (20, 21). There 
are historical accounts of oncolytic activity accredited to replicating viruses available in 
the scientific domain as published case reports as early as 1912, where sporadic but 
dramatic reactions in cancer patients recovered from viral vaccinations have been 
recorded (22, 23). In the 1950s–1970s, live viruses were injected into cancer patients 
and presented promising cytotoxic activity, notably Egypt 101 West Nile virus (4/34 
transient regressions), adenovirus lysates (26/40 showing localised tumour necrosis), 
and Urabe strain of mumps virus (37/90 complete remission or partial responses) (23). 
In contrast, virus-induced oncolysis noted in these early studies are principally from 
naturally occurring wild type Egypt 101 strain of West Nile virus injected in immune-
suppressed patients with leukaemia or lymphoma. Virus-infected 5 of 8 patients were 
sensitised by a viral infection and experienced severe encephalitis (23).  
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Oncolytic viruses include naturally occurring or genetically engineered non-pathogenic 
and replication-competent viruses that favourably replicate in tumour cells sparing the 
healthy cells resulting in tumour cell lysis (24). Viruses inclusive of both DNA and RNA 
genomic classes are identified to have oncolytic properties, e.g. adenoviruses (Ad), 
herpes simplex virus type-1 (HSV-1), vaccinia viruses (VV), poxviruses, Newcastle 
disease virus (NDV), Measles virus (MV), Mumps virus (MuV), Sendai virus (SeV), 
Marba virus, parvovirus, reovirus, vesicular stomatitis virus (VSV) and Coxsackievirus 
etc. The details of identified OVs are listed in Table 1.2. 
 
Oncolytic viruses are usually administered either locally via intra-tumoural route or 
systemically via intravenously and intraperitoneally into test animals and/or paitients 
(25). Local administration of OV through inntra-tumoural route ensures direct entry of 
viral particles to tumour. Systemic administration of OV provides few benefits such as 
introduction of viral particles to distant tumour sites as well as the site of primary leison. 
However, the efficacy of administration of OV via either of the routes depend upon 
various factors e.g., type of cancer, type of OV, dose of OV etc. (25). 
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1.4. Commercially approved OVs for cancer treatment 
Noteworthy progress has been accomplished in the field of oncovirotherapy, from 
naturally occurring viruses to genetically engineered viruses. Recombinant viruses 
include improved tumour-specificity, where virus replication is mediated through target-
oriented cell entry and transcription. Additionally, expression of reporter genes for 
noninvasive monitoring, and insertion of immunomodulating genes have enhanced OV-
induced cytotoxicity and provide superior immunostimulation. To date, three oncolytic 
viruses are commercially available for cancer treatment; Rigvir (picornavirus) was 
approved in Latvia, Georgia, and Armenia; Oncorine H101 (adenovirus) was approved 
in China; talimogene laherparepvec (T-VEC) (herpesvirus) was approved in the USA 
and Europe.  
 
1.4.1. Rigvir 
Rigvir (Riga virus) is natural Enteric Cytopathogenic Human Orphan type 7 (ECHO-7) 
picornavirus. Rigvir became the first approved oncovirotherapy worldwide in 2004 with 
regulatory approvals internationally; in Latvia from 2004, in Georgia from 2015, and 
Armenia as of 2016 (27).  Despite being the first-ever approved OV, there are minimal 
data available in the English language, including the one review on the clinical trial of 
three patients with advanced stage cancers: melanoma (stage IV M1c), small cell lung 
cancer (stage IIIA), and histiocytic sarcoma (stage IV) (28) and other study from Lativian 
clinical trial on 79 patients in early stage melanoma (27).  
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In pioneering study in Latavia, melanoma patients at various stages of cancer (early 
stages with different subclasses based on tumour thickness, spread, and ulceration IB, 
IIA, IIB, and IIC) received surgical resection and Rigvir. Patients who received surgical 
resection and Rigvir (n=52) survived significantly longer than patients from control 
surgical resection only group (n=27). Rigvir was injected intramuscularly in localized 
tumours in patients (surgical resection+OV group)  postoperatively when surgical 
wounds were healed; patients showed remarkable disease-free survival. Rigvir was 
postoperatively injected intramuscularly in locoregional tumours with a minimum median 
tissue culture infectious dose (TCID50) level of 1 x 106/ml in 2 ml volume without any 
dose optimisation in patients under the study. Each patient received about 33 doses 
over 3 years: first dose of 2 ml was administered at localised tumour for 3 successive 
days, then after 4 weeks, same dose was repeated for 3 successive days and repeated 
4 weeks later. Later, a single dose was administered at monthly intervals throughout first 
year. In second year, dose was administered at 6 weeks interval for first 6 moths and in 
last 6 months repeated after 2 months. In third year, dose was administered at every 3 
months until end. The effects of Rigvir, are reported only from low-grade melanoma, 
whereas the status in high-grade aggressive melanoma remains unclear. Nevertheless, 
future studies are required to be done in the non-resectable melanoma in advanced 
stage to get a clear understanding of the mechanism and efficacy of Rigvir-mediated 
oncolysis for a potential future oncovirotherapy (27, 29). 
 
1.4.2. Oncorine 
Oncorine is a genetically modified adenovirus H101 which has been approved by the 
China Food and Drug Administration for the treatment of advanced head and neck 
cancer with a combination of chemotherapy in 2005 (30, 31). Oncorine is previously 
known as Onyx-015, which is an attenuated serotype 5 adenoviral vector modified by 
deletion of E1B-55k along with four other deletions in the viral E3 unit. It is hypothesised 
that Oncorine selectively replicates in p53 deficient tumours, as E1B-55k is a potent p53 
repressor. The E1B-55k inhibits infection-induced apoptosis and allows viral replication 
in p53-normal cells. 
 
Nevertheless, adenoviruses with E1B-55k deletion have been shown to infect and 
replicate in p53 positive tumours indicating an alternate mechanism of tumour-selective 
viral replication (32-34). A patient-approved clinical trial of Oncorine was performed 
comprising of an extensive, multi-centre, open, randomised use of Oncorine in 
combination with chemotherapy against chemotherapy alone in head and neck 
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squamous cell carcinoma (HNSCC) or oesophagal cancer patients. Patients who 
received a combination of cisplatin and 5-fluorouracil (5-FU) with or without Oncorine at 
5 x 1011 to 1.5 x 1012 viral particles/day for 5 successive days every 3 weeks and 
repeated every 3 weeks while all patients received minimum 2 cycles of chemotherapy. 
Combinational Oncorine and chemotherapy arm had a significant 78.8% (41/52) 
response rate compared with a 39.6% (21/53) response rate of chemotherapy alone 
patients (35). 
 
There is a practical limitation to deliver Oncorine intravenously to treat highly metastatic 
disease due to high antibody occurrence against several adenovirus serotypes, 
including the backbone of Oncorine, serotype 5. Some clinical trials (VCN-01 
NCT02045602, Enadenotucirev NCT02028442) are ongoing to circumvent pre-existing 
immunity against existing adenoviral vectors and focusing on the reduced 
seroprevalence or modified adenoviral knob proteins to test its safety and efficacy via 
intravenous Oncorine delivery. Although oncolytic adenoviruses have been in 
development for over 20 years, Oncorine remains the only approved adenovirus for 
cancer therapy and administer with combinational chemotherapy only (35-37). 
 
1.4.3. T-VEC (Imlygic™) 
IMLYGIC™ (T-VEC/Talimogene Laherparepvec), a genetically engineered live-
attenuated HSV-1, was approved in 2015 by the United States Food and Drug 
Administration and European Union to treat cutaneous, subcutaneous and unresectable 
lesions intratumorally post-operation in advanced melanoma patients (38-41).  T-VEC is 
a recombinant human HSV-1 deleted for both copies of the viral gamma 34.5 and viral 
ICP47, which elevates the expression of US11, and encodes two copies of human 
granulocyte-macrophage colony-stimulating factor (GM-CSF) under cytomegalovirus 
(CMV) promoters (42). Since February 2018, 23 clinical trials are ongoing, evaluating 
the safety and efficacy of T-VEC as a single agent or as a combination with checkpoint 
inhibitors, chemotherapy, or radiation therapy in melanoma and other indications in 
patients with liver, pancreatic, and advanced non-central nervous system solid tumours. 
A phase II trial has revealed encouraging results in late-stage melanoma patients treated 
with a combination of T-VEC and programmed cell death protein-1 (PD-1) inhibitor 
pembrolizumab published in 2017 (43). The combination therapy of T-vec with  
pembrolizumab had confirmed complete response in 21% (7/33) patients with advanced 
melanoma with metastases (43). 
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Amongst the plethora of OV families, recently finished clinical trials of successful 
candidates are listed in Table 1.3. Herein the thesis focus is on the NDV and 
development of NDV as an oncovirotherapy. 
 



































cisplatin or adriamycin 
(47) 













IT I/II SCCHN Radiation, cisplatin (50) 




G207 IT I Glioma Radiation (52) 





















Note: IT- intratumoral; IV-intravenous; CTLA-4 –Cytotoxic T Lymphocyte antigen 4 
 
 
1.5. Mouse models used in the study of oncovirotherapy  
Mouse models are widely used in the field of cancer therapy to conduct in vivo studies 
in pre-clinical trials to study the efficacy of type of the therapy used in the study. Mouse 
models provide relative similarities in genetic and physiological make-up of tumour 
biology between humans and mice (54). 
Conventionally, immunocompetent immunocopromised mice are used to study cancer 
biology. Based on the origin of tumour and host used, there are two widely used tumour 
mouse models: syngeneic and xenograft tumour models. In syngeneic models, murine 
cancer cell lines or tumour tissues are used for transplantation in inbred animals with 
same genetic make-up. Syngeneic mouse models provide advantages of tumour 
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tissues, tumour microenvironment, and host are from the same species e.g., 
Leukemia1210 (L1210) cell line derived from L1210 of DBA/2 mouse transplanted in 
animals of same species (55). In xenograft models, athymic (nude) or severe combined 
immunodeficiency (SCID) mice are injected with the tumour cell lines or tissues derived 
from humans, e.g. human non-small cell lungcancer cells (A549) injected in Balb/c nude 
mice (55). Genetically engineered mouse models are also used commonly, where 
immunocompetent mice with genetic defects are introduced using RNA interference, 
inducible gene expression, viruses, DNA recombination techniques, or CRISPR/Cas9 
methods are used (56). 
 
Transplantaion of tumours are achieved by using either orthotopic or heterotopic 
methods. Orthotopic tumour transplantation refers to introduction of tumour cells into the 
organ of origin (anatomic location from where cells or tissues are derived) in 
immunocompromised mice. Orthotopic transplantation is achieved either by surgery at 
the original location or by direct injection of tumour cells (55, 56). Whereas, the 
heterotropic transplantation refers to introduction of tumour cells to the sites other than 
its origin. Heterotropic tumour transplantation is accomplished by transplantation under 




1.6. General mechanisms of oncolytic viruses 
The mechanisms of how OVs mediate tumour cell lysis are not entirely understood. The 
majority of OVs directly kill tumours cells by infecting, replicating, burdening the host cell 
machinery, and invoking the antiviral responses. The oncolytic efficacy of a virus 
depends upon multiple factors like efficiency of infection in cancer cells, type of virus, 
natural and induced viral tropisms leading to the kind of cell deaths (apoptosis, necrosis, 
necroptosis, pyroptosis and autophagy). OV characterises oncotropism due to defective 
mechanisms of cell death and weaker antiviral responses in cancer cells compared to 
the healthy cells. In healthy cells, the virus does not proceed beyond infection because 
of intact and effective antiviral mechanisms in play comprising various pathways 
participating in clearing the virus. 
Primary infection in healthy cells stimulates type-I interferons (IFNs) secreted after 
pathogen-associated molecular patterns (PAMPs) such as viral proteins, and nucleic 
acids are recognised by pattern associated receptors (PRRs) like toll-like receptor (TLR) 
family (TLR-TLR 3/5/7/9). TLR signalling then activates antiviral elements and systemic 
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innate immune mediators in the infected host cells including tumour necrosis factor 
(TNF) associated factor 3 (TRAF3), IFN regulatory factor-3 (IRF-3), IRF-7 and retinoic 
acid-inducible gene-1 (RIG‑1). These elements then consecutively activate the JAK-
STAT (Janus kinase–signal transducer and activator of transcription) pathway, which in 
response collaborates with a complex array of antiviral molecules and enzymes such as 
kinases -protein kinase RNA-activated (PKR). PKR recognises PAMPs in the infected 
host cells and activates transcription factors, terminates host cell protein synthesis, 
induces response type-I IFNs to clear the virus by killing the infected cancer cells (57). 
Based on the type of OV, viruses can manipulate different abnormal signalling factors 
to block apoptosis in the tumour cells, which favours more time for the virus to complete 
its life cycle. Most oncolytic viruses induce cell death by active virus replication and 
burdening host cell machinery as well as activation of the immune system. Activation of 
host cell immunity significantly happens due to cell death and release of danger signals 
from dying cells (apoptotic, necrotic, autophagic, and pyroptotic cell deaths) (58). For 
efficient OV-mediated clearance of tumours, virus critically needs to activate both innate 
and tumour-specific adaptive immune molecules to participate in the oncolysis. 
Following the cancer cell demise exposure of tumour associated antigens (TAAs) along 
with viral proteins, can play a crucial role in interlinking the innate and adaptive immune 
systems leading to the abscopal effect regressing the distant untreated tumours. 
Along with PAMPs, dying cancer cells also release damage-associated molecular 
patterns (DAMPs) such as DNA, RNA, or metabolic products (ATP, and uric acid), 
proteins, such as calreticulin, high-mobility group box 1 (HMGB1), heat-shock proteins 
(HSPs), and proteins in the intracellular matrix generated following injury, such as 
hyaluronan fragments (58) and secretes several cytokines (type-I IFNs, TNFα, IFNγ, 
and interleukin‑12 (IL‑12)), and chemokines (RANTES, IP-10, CCL22 and CXCL12). All 
these different types of danger signals promote maturation of natural killer cells (NK) 
and antigen-presenting cells (APCs) such as dendritic cells (DC), which then activate 
antigen-specific CD4+ and CD8+ T-cells. Activated CD8+ T-cells can expand to CTLs, 
which migrate to the tumour and diminish tumour cells via antigen-specific cytotoxicity. 
Type-I IFNs are also known to activate NK cells and DC cells and connect the innate 
and adaptive immune systems. Viruses naturally induce host antiviral immune 
responses, which result in the clearance of the virus by invoking neutralising antiviral 
antibodies and CTL-mediated immune responses. However, the extent of neutralising 
antiviral antibody production and its effect on anti-tumour immunity is complex and can 
Chapter 1 - Introduction 
36 
 
depend on many variables, especially on the characteristics of the virus and the tumour 
microenvironment (26). 
 
Figure 1.3. The mechanisms of action of oncolytic viruses adapted from 
Fountzilas et al., 2017 (59). Oncolytic viruses (natural or genetically modified) exploit 
favourable conditions provided within tumour cells to promote viral genome replication, 
transcription, and egress of viral particles. Viruses such as Seneca valley virus, 
Coxsackie virus, NDV etc. induce cancer cell death by active viral replication leading to 
substantial stress on host cellular machinery and caused direct cell death. Genetically 
engineered viruses such as Onyx015, HSV1 etc. use specific pathways like the p53 
pathway and induce cell death. Virus replication and release result in activation of 
pathogen-associated molecular patterns (PAMPs) like viral DNA, ss RNA, ds RNA, and 
viral glycoproteins which are recognised by pattern associated receptors (PRRs) such 
as RIG-I, TLR3, and TLR5, which then activate type-I IFN pathways. Stimulation of IFNs 
induces caspases and cause cell death. Damage-associated molecular patterns 
(DAMPs) like calreticulin and heat shock proteins (HSPs) also released as a result of 
viral replication. PAMPs and DAMPs together activate innate immune responses and 
adaptive immune responses, ultimately resulting in immunogenic cell death. By and 
large, all oncolytic viruses-mediate tumour cell lysis by first direct cell death pathways 
activated by caspases and second by indirectly enabling the immune system. 
NA-Nucleic acid, DAF–Decay accelerating factor, GM-CSF-Granulocyte monocyte-
colony stimulating factor, HSV – Herpes Simplex Virus, hTERT–Human telomerase, 
ICAM-1–Intercellular adhesion molecule-1, ICP–Infectious cell protein, IFN-β-Interferon 
beta, NDV–Newcastle Disease Virus, VSV–Vesicular Stomatitis Virus. 
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A distinct characteristic of an OV is to establish a lytic cycle either by naturally 
manipulating inherent tumour weaknesses or by genetic modification. Different OVs 
utilise various ways to enter the cancer cell, determining the targeted tumour-selective 
replication. For example, measles virus uses CD46 surface receptor, NDV-HN protein 
binds to sialic acid conjugates, Coxsackievirus uses intercellular adhesion molecule 1 
(ICAM‑1; also known as CD54) and decay-accelerating factor (DAF; also known as 
CD55), HSV‑1 uses the herpesvirus entry mediator (HVEM) and selected nectins for cell 
entry (Table 1.2). Also, tumour-specific oncotropism precisely can be achieved by 
means of genetic modifications for instance adenovirus Ad5/3‑Δ24 was modified to bind 
to the integrins that are overexpressed on ovarian cancer cells (60), and ICP 34.5 
deleted HSV-1 expressing a 68-amino acid fragment of US11 containing a novel proline-
rich basic RNA binding domain, which inhibits PKR activation and results in cell death 
of tumour cells (61). Figure 1.3 and Figure 1.7 illustrate the mechanisms of action of 
oncolysis broadly shared by most oncolytic viruses on a primary basis. The mechanisms 
of NDV-induced oncolysis are discussed in length in section 1.11. of this chapter.  
Genetically engineered replication restrictive ICP34.5 deleted HSV-1, modified 
adenoviruses, such as Onyx015, H101, and naturally occurring parvovirus exploit pro-
apoptotic p53 tumour suppressor protein. Modified viruses developed by eliminating p53 
binding viral proteins such as E1B in case of adenoviruses, preferentially replicate in 
p53-deficient tumour cells (26). Adenovirus KH901 express E1A (a viral protein that 
inhibits the cell cycle) regulated under the human telomerase reverse transcriptase 
(hTERT) promoter. The hTERT abundantly expresses on cancer cells, which assures 
selectively higher virus replication in the cancer cells (26). Another example of promoter-
controlled virus replication is CG0070 oncolytic mutant of adenovirus, where E1A 
expression is regulated under E2F1 promoter, which favours viral replication in 
Rb‑defective cells. In healthy cells, E2F1 inhibits Rb expression results in the inhibition 
of viral E1A expression restricting to the cancer cells only (26). Vaccinia growth factor 
(VGF) protein of vaccinia virus binds to EGFR receptors to induce RAS signalling 
pathways, which results in the activation of cell proliferation increase in thymidine kinase 
(TK) production; which promote virus replication in infected cells. However, deletion of 
VGF restricts vaccinia virus replication only to the cancer cells showing anomalous 
EGFR-RAS regulation (26).  
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1.7. Potential limitations of oncovirotherapy 
 
A plethora of natural as well as genetically modified viruses has been reported as 
potential OV candidates. However, genetically modified HSV-1, adenoviruses, and VV 
are in most ongoing clinical trials. Genetically modified viruses have significant 
advantages in providing efficient oncolysis and stronger antitumour immune responses 
than their natural wild-type counterparts. However, there are disadvantages of 
genetically engineered viruses in terms of the spread of virus compromised as a result 
of the deletion of pathogenic elements in mutant viruses. For example, HSV‑1 does not 
spread from cell to cell naturally to cause viraemia. Hence, oncolytic HSV‑1, like T‑VEC 
and G47∆, are best administered intratumorally, and intravenous delivery may not be 
preferred. However, the phase III study of T‑Vec in melanoma patients at advanced 
stages, with local intralesional injections of oncolytic HSV‑1 have shown promotion of 
abscopal antitumour immunity at remote untreated lesions through induction of systemic 
antitumor immunity and prolonged survival (62). It has also been demonstrated that GM‑
CSF expression does not increase the efficacy of oncolytic HSV‑1, except IL‑12 
expression, in immunocompetent mouse tumour models. So, it could be possible that 
the systemic effect via antitumor immunity is the outcome of HSV‑1 infection itself and 
not GM‑CSF effect (63). 
 
Another main concern of oncolytic virus therapy has been  the presence of pre-existing 
immunity against OVs, which can reduce the efficacy of oncovirotherapy. Naturally 
occurring viruses producing viraemia are likely to be inactivated by neutralising 
antibodies; thus, intravenous administration for such viruses may be inadequate in 
previously OV vector vaccinated patients. An adverse effect of circulating neutralising 
antiviral antibodies has been reported in an oncolytic measles virus (MV‑NIS) clinical 
trial with multiple myeloma patients (64). In this dose-escalation study, a very high dose 
of 1011 TCID50 was required for intravenous infusion to show efficiency with MV‑NIS 
(64). Preclinical research in the tumour-bearing immunocompetent murine model, 
reovirus intravenous administration has resulted in recurrence of tumours within three 
weeks after injection, which is explained by augmented anti‑reovirus antibody titres in 
the serum. In the phase-I clinical trial, data have shown the presence of maximum 
neutralising anti‑reovirus antibody titres were attained by 7th day in 36% (12/33) of 
patients, and by 14th day in 75% (20/33) of patients (64). 
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However, this problem has been addressed by other researchers in case of modified 
adenoviruses; it is reported that well-tolerated oral doses of adenovirus permitted the 
repeated adenovirus-directed gene transfer despite the presence of a residual antibody 
titer from previous adenoviral exposure (65). Ricca et al. have reported that intratumoral 
administration of LaSota augmented the antitumoral immune response despite the 
preexisting neutralising antibodies in NDV immunised syngeneic mouse tumour models  
(66). Moreover, use of cell carriers can also improve the antitumour efficacy not only 
fighting the pre-existing immunity but also improves systematic delivery of OV at the 
distant metastatic site. Cancer stem cells such as NSCs and MSCs have demonstrated 
better candidates for packaging the OV because for their abilities such as intrinsic 
tumour-homing ability, supporting viral replication and protecting it from peripheral 
antiviral immunity, ability to migration towards tumour based on various 
chemoattractants produced in the tumour microenvironment like hypoxia-inducible 
factor (HIF), stromal cell-derived factor-1 (SDF-1), VEGF and urokinase plasminogen 
activator (uPA) in glioma cells (67). Above mentioned approaches have explained the 
strategies of enhancing the efficiency of OV-mediated cancer therapy in various types 
of cancers and viruses. 
 
1.8. NDV as an oncolytic virus 
1.8.1. Introduction to NDV  
Newcastle disease virus (NDV) is an economically important poultry pathogen causing 
Newcastle disease (ND), which is prevalent in many countries. NDV is an avian 
pathogen and known to infect over 250 bird species (68). Doyle named NDV in 1926 as 
a highly pathogenic disease in chickens at a farm near Newcastle-upon-Tyne in England 
(69). NDV was previously known as avian paramyxovirus type-1 serotype (APMV-1). 
Now it is classified as a member of genus Orthoavulavirus in the order Mononegavirales, 
family Paramyxoviridae, subfamily Avulavirinae (70). NDV, like other paramyxoviruses, 
has a non-segmented, single-stranded, negatively-charged, 15.186 kb long RNA 
genome encoding six essential genes expressing nucleocapsid protein (NP), 
phosphoprotein (P), matrix protein (M), fusion protein (F), haemagglutinin-
neuraminidase protein (HN), and large RNA-dependent RNA polymerase (L) (71) 
(Figure 1.4). 
Virions of paramyxoviruses range from 150 to 250 nm in diameter and are pleomorphic, 
often filamentous in shape (72). Virions are enveloped within a lipid membrane derived 
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from the host cell plasma membrane. Two transmembrane glycoproteins are expressed 
on the viral envelope; the HN and F proteins. A non-glycosylated membrane M protein 
lies underneath the envelope. The ribonucleotide protein (RNP) replication complex 
comprises viral nucleocapsid that includes the NP, P and L proteins encapsidating the 
(-) ssRNA genome. Each gene in NDV genome is tagged by conserved gene start (GS), 
and gene end (GE) sequences and two genes split by a conserved intergenic sequence 
(IGS), which regulates mRNA transcription (73).  
NDV has been classified into three pathotypes based on the clinical signs of the disease 
in chickens: avirulent or non-pathogenic (lentogenic), moderately pathogenic 
(mesogenic), and highly pathogenic or virulent (velogenic) (74). The velogenic strains of 
NDV have polybasic amino acids (R-X-K/R-R↓F) in the F protein cleavage site, which is 
a preferred recognition site for furin and furin-like proteases. Cleavage of F0 protein into 
F1 and F2 subunits, by the ubiquitous intracellular host cell proteases, and is is an 
essential event in NDV replication to facilitate the virus replication in the tumour 
microenvironment (75). 
 
Figure 1.4. Schematic diagram of NDV structure and its genomic make-up, 
adapted from Ganar et al., 2014 (73). The viral envelope contains two transmembrane 
glycoproteins; the haemagglutinin-neuraminidase (HN) and the fusion (F) proteins. 
Beneath the envelope lies a non-glycosylated membrane protein called matrix (M) 
protein. The viral nucleocapsid consists of viral RNA and the replication complex 
proteins that include the nucleocapsid (N), phosphoprotein (P) and large RNA-
dependent RNA polymerase protein (L). NDV genome comprises different 
transcriptional units encoding six essential proteins; NP, P, M, F, HN and L proteins. The 
RNA genome contains flanking  55 nucleotides long leader at 3 prime and  114 
nucleotides long 5 prime trailer extragenic regions. Two accessory proteins  V and W 
are derived from mRNA editing at 484th position of the P mRNA by adding non-template 
G residues. 
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1.8.2. NDV genotypes 
There are two classifiaction systems are used worldwide: first one is suggested by 
Aldous, where he groups NDV into 6 lineages and 13 sublineages and later addition of 
3 more sublineages (76). Second classifiaction system divides NDV into two clades: 
class I and class II. Class I clade is further is divided into 9 genotypes (1-9). Class II 
clade is divided into 11 genotypes (I-XI), and genotypes I, II, VI, and VII sub-divided Ia 
and Ib, II and IIa, VIa through VIf, and VIIa through VIIh (77). There is no consensus on 
classification of NDV and both systems are used for classification and generates 
confusion (77). All NDV strains are classified into genotypes/lineages based on NDV 
genome size and sequences of F and L gene sequences (78). 
 
1.8.3. NDV life cycle 
NDV infects cells and replicates in the host cell cytoplasm, where NDV genome 
completes replication and transcription. NDV proteins and genomic RNA are packaged 
into virion particles and egress from cells by a budding mechanism, and upon release, 
NDV virions infect neighbouring cells. NDV shares common lifecycle with other 
paramyxoviruses such as sendai virus, measles, mumps, canine distemper virus etc. 
(79). 
NDV entry into host cells: NDV enters inside host cells with the help of two 
glycoproteins, HN and F, are expressed on NDV envelope. NDV-HN proteins bind to 
sialyl glycoconjugate receptors on the host cells (80, 81). NDV-HN protein interacts 
efficiently with α-2, 3 and α-2, 6 N-linked sialic acid conjugates (82, 83). The HN protein 
and cell receptor tethering activate the F protein, which facilitates fusion activity for viral 
entry into host cells (84). NDV also is known to exploit alternate caveolae-mediated 
endocytic pathways (85) and clathrin-mediated micropinocytosis routes (86) to enter 
host cells through pH-dependent mechanisms. Once NDV attached to host cells, RNP 
complex is released into the host cell cytoplasm and negative-sense RNA gets 
transcribed into positive-sense mRNA, which translates all viral proteins utilising the host 
cell machinery.  
NDV transcription and replication: The RNP complex is required for NDV 
transcription and replication, which consists of three different stages of viral RNA 
synthesis by viral RNA polymerase. First, in the early infection stage, transcription 
results in the synthesis of 3 prime leader untranslated region followed by transcription 
of the NP gene. The NP mRNA translated into protein, NP accumulation switches from 
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transcription to the replication. Secondly, viral RNA polymerase recruits NP proteins to 
encapsidate nascent genomic RNA (-vRNA). Viral RNA polymerase aborts transcription 
of encapsidated -vRNA, and synthesise antigenomic RNA (+vRNA), which serves as a 
template for replication viral RNA (87). Finally, secondary transcription of progeny 
genome results in abundant mRNA transcription of viral genes (88). Viral RNA 
polymerase modifies all six mRNAs to have a 5 prime methyl cap and 3 prime polyA tail 
(89). Viral RNA polymerase uses conserved GS sequence to start translation of  5 prime 
capped RNA and terminates at conserved GE sequence of 3 prime polyadenylated site 
of all viral mRNAs encoding proteins (89). The viral RNA polymerase uses start and stop 
mechanism to transcribe all NDV genes and maintain the abundance of all mRNA in a 
gradient manner from 3 prime NP gene to last 5 prime L gene (90). Both genomic (-
vRNA) and antigenomic (+vRNA) viral RNA contains cis-acting regulatory untranslated 
3 prime leader (55 nucleotides) and 5 prime trailer (114 nucleotides) sequences, which 
are involved in transcription, replication, and packaging of genomic and antigenomic 
RNA (90). The NDV replication briefly illustrated in Figure 1.5. 
 
Figure 1.5. Schematic representation of NDV replication, adapted from Ganar et 
al., 2014 (73). NDV enters the host cell via sialic acid receptors tethering to NDV HN 
protein and fusion facilitated by F protein. The ribonucleotide complex of N, P, and L 
proteins with negatively charged RNA released inside the cell cytoplasm, where viral 
RNA genome gets transcribed and replicated by viral RNA-dependent RNA polymerase 
(L) protein, where exploiting host cellular machinery all viral genes get translated. Once 
NP protein transcribed, it activates the anti-genome gets transcribed in the negatively 
charged RNA genome followed by RNP complex formation and virion packaging 
resulting in the NDV virion egress from host cells.  
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mRNA editing of the NDV P gene: NDV expresses two non-structural 
accessory proteins by mRNA editing of the P gene at nucleotide position 484 in the 
preserved editing site (3 prime-UUUUUCC-5 prime).  P gene uses non-template guanine 
residues (G) viz. V (+G) and W (+GG) during transcription, resulting in a shift of the 
respective open reading frame, where  P, V, and W  proteins share the amino-terminal 
but have a distinctive carboxy-terminal end. Mebatsion et al. (2001) have reported the 
proportions of P and edited P mRNAs in NDV-infected chicken cells: 68% of P-encoding 
mRNA, 29% of V-encoding mRNA, and 2% of W-encoding mRNA (91). Sometimes more 
than two G residues insertions leading to the supplementary amino acid insertion 
reported in chicken cells (60, 61).  The V protein plays roles in NDV virulence as it 
antagonises IFN responses (62, 63). The carboxy-terminal of V protein inhibits type-I 
IFNs (IFN-α/β) signalling by targeting signal transducer and activator transcription factor 
1 (STAT-1). The C-terminal domain of V protein interacts with melanoma differentiation-
associated protein 5 (MDA5) to impede IFN-β response (64). However, the function of 
the W protein remains unclear. 
Egress of NDV from infected cells: Transcribed viral mRNAs translate to 
the proteins; NP, P, L proteins and genomic RNA forms RNP complex and translocate 
to the site of packaging in the host cells. M proteins bind to the host cell membrane and 
promote cell membrane deformation. M proteins serve as an adapter link between viral 
proteins and assembly in the host cell. NDV glycoproteins HN and F translocate through 
host cell plasma membrane using their transmembrane domains and promotes 
complete viral packaging. NDV virions egress from the site of packaging by a budding 
mechanism and use neuraminidase activity of HN protein to cleave virion particles from 
the host cell receptors (Figure 1.5) (88, 92).  
 
1.9. Oncolytic NDV strains 
In 1957, J. Sinkovics first time reported the oncolytic potential of NDV, where NDV 
coated ascitic cancer cells inoculated in the abdominal cavity of mice lost their viability 
(93), stating the non-pathogenicity and oncolytic possibility of naturally occurring NDV. 
Soon after in 1965, Cassel and Garrett used mesogenic strain 73T of NDV. The 73T 
had been attenuated by 73 passages in vitro and 13 passages in vivo in murine Ehrlich 
ascites tumour cells. The antineoplastic nature of 73T was confirmed in Ehrlich ascites 
carcinoma of the mouse and HeLa, human cervical cancer cells (94). In 1980, Hungary 
licensed attenuated NDV-H (referred to as MTH-68/H-more than hope/Hungarian strain) 
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to treat cancer patients for the very first time (21). Many other lentogenic (non-
pathogenic) strains such as Hitchner B1, LaSota, Ulster, V4UPM, MTH-68/H, and NDV-
HUJ (Hebrew University Jerusalem) and mesogenic (moderately pathogenic) strains 
suh as PV701, and 73T and velogenic (highly pathogenic) AF2240 have been used in 
various preclinical and clinical studies. 
 
1.10.  Important oncolytic properties of NDV  
1.10.1. Tumour selective replication 
Tumours provide a favourable environment for NDV and other virus replication and 
spread due to the crippled antiviral responses, weaker IFN sensitivity, weaker 
expression of IFN receptors, and resistance to cell death pathways (95). Tumour 
selective replication and cell death induction by various strains of NDV conclusively 
demonstrated in many human and murine cancer cells (96, 97). NDV-HN protein 
interacts efficiently with α-2, 3 and α-2, 6 N-linked sialic acids conjugates (82, 83) 
expressed by most of the cells to infect and replicate, which make it easy to target all 
types of cancer cells. Fusion activation occurs after F protein interaction with the stalk 
region of HN protein of NDV while egressing new virions resulting in syncytium formation 
in infected cells, which helps viral spread within the tumour. Enhanced NDV-mediated 
cell lysis and up to two-log fold improved virus replication was reported in anti-apoptotic 
Bcl-xL protein-expressing A549 and 293T cells. Overexpression of Bcl-xL protein 
strikingly increased NDV-induced apoptosis as an outcome of better NDV replication 
with the induction of type-I IFN in A549 cells, proving selective tumour replication in 
apoptosis-resistant cells (98). 
 
Similarly, Lazar et al. confirmed that Livin, an inhibitor of apoptosis (IAP) family protein-
expressing chemo-resistant primary melanoma cells overcame the resistance by non-
lytic NDV-HUJ virus replication. NDV-induced apoptosis in melanoma cells was 
associated with the cleavage of anti-apoptotic Livin to pro-apoptotic tLivin protein 
independent of type-I IFN pathways (99). 
 
Type-I IFNs are known to diminish viral replication, and their antiviral action lead to 
activation of a complex array of cellular processes. Cellular response to IFN launches 
antiviral eminence through the expression of IFN-stimulated genes (ISGs) against 
numerous family of viruses (100, 101). Like many other viruses, NDV evades the 
immune system using its accessory V protein in its natural hosts, where V protein 
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interferes with JAK-STAT mediated type-I IFN signalling pathways (102, 103). However, 
in mammalian and rodent cells, the escape mechanism does not work. The expression 
of ssRNA and dsRNA intermediates of NDV is recognised (as PAMPs) by TLR3 and 
also by RIG-I like receptor (RLR), and activates IRF-3, IRF-7, and IFN-β antiviral 
products to diminish viral replication in healthy cells (104-106).  Most cancer cells lack 
strong antiviral signalling responses and have resistance to the IFN-stimulated 
apoptosis. Krishnamurthy et al. investigated the differential response of NDV in primary 
human fibroblast cells and HT1080 fibrosarcoma cells. NDV replicated better in HT1080 
cells than human skin fibroblast cells regardless of the IFN-β pre-treatment confirming 
the role of unresponsive antiviral system, where the decrease in phosphorylation of 
STAT-1 and STAT-2 proteins along with downregulation of ISG3 gene was reported 
(104). NDV showed improved susceptibility to IRF-3, and IRF-7 genes deleted murine 
macrophages. However, IRF-3 knockout (KO) cells supported better viral replication 
than in IRF-7 KO and normal macrophages. IRF-3 KO cells expressed lower levels of 
basal NDV-induced RIG-I expression than IRF-7 KO and normal murine macrophages 
(107). 
 
NDV-73T had shown thousand-fold increased susceptibility to HT1080 cells 
overexpressing N-Ras and H-Ras oncogenes (108). The elevated expression of these 
oncogenes potentially related to sialyl glycoconjugate expression, and hence the 
sensitivity to NDV can be explained (109, 110). The investigation of NDV sensitivity in  
HaCaT multistage skin carcinogenesis model revealed the requirement of oncogenic 
Rho GTPase Rac1  protein expression to sustain viral replication (111). The dynamic 
relationship between the actin cytoskeleton and Rho GTPases, including Rac1, Cdc42, 
and Rho, have been associated within the establishment of cell-cell contacts and cell-
matrix interactions (112), which is known to be exploited by different DNA and RNA 
viruses including paramyxoviruses such as SeV and NDV to promote virus replication, 
assembly and egress (113). 
 
1.10.2. Safety profile 
The high levels of safety profile is explained in NDV-infected patients by various factors 
NDV being avian pathogen: e.g. an absence of pre-existing antibodies against NDV in 
human, absence of recombination for gene exchange, cytoplasmic viral replication, lack 
of viral RNA integration into host cell genome, non-pathogenic nature in humans, higher 
tolerable doses tested in phase I/II clinical trials, and mild side effects observed in 
immunocompromised patients. 
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Recombination has not been detected in NDV. In last 50 years, study has revealed the 
difference in the NDV strains are typically results of point mutations in the F, HN, and M 
genes (114). NDV replicates in the cell cytoplasm (Figure 1.5), the viral genome does 
not integrate into the host genome, and it replicates regardless of host genome 
replication. Unlike conventional chemotherapy and radiotherapy, NDV can replicate in 
non-dividing, resting, radiation and drug-resistant, hypoxic cancer cells. Pecora et al. 
demonstrated tolerance of intravenously administered PV701 attenuated mesogenic 
strain of NDV up to 1.2 x 1010 PFU/m2 in advanced solid tumours in phase I clinical study, 
where patients displayed mild flu-like symptoms developed only after first injection (115). 
 
Further, the PV701 intravenous dose optimised for administration, where maximum 
tolerable dose (MTD) is reported up to 12 x 1010 PFU/m2 of solid tumours in advanced 
cancers and dose as high as 4 x 1012 PFU/m2 tolerated via the intratumoral route (115-
117). NDV being an avian pathogen cause only mild flu-like disease symptoms such as 
eye infections, usually consisting of unilateral or bilateral reddening, excessive 
lachrymation, and oedema of the eyelids, conjunctivitis and sub-conjunctival 
haemorrhage in high risk and immunocompromised individuals only. Most of the human 
population are reported to be NDV seronegative (116, 118). 
 
1.10.3. Immuno-stimulatory properties 
NDV infection and replication in favourable tumour microenvironment forms syncytium 
due to the expression of viral HN and F glycoproteins and have domino effects, inducing 
cell death in tumour cells. For instance, NDV causes immunogenic cell death which 
leads to translocation of danger signals like HSPs, calreticulin, and viral glycoproteins 
HN/F to the plasma membrane. Damage-associated molecular patterns( (DAMPs) and 
pathogen associated molecular patterns (PAMPs) then activate the antiviral responses 
post oncolytsis by triggering the innate immune system, cytokines, and adaptive immune 
responses. NDV activates innate immune responses as 5 prime phosphate of viral ss 
RNA and ds RNA intermediates recognised by RIG-I (105, 119) and TLR3 (120). NDV-
HN proteins are known to have immunostimulatory properties such as induction of IFN-
α and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human blood 
mononuclear cells (121) as well as increase the adherence of cancer cells to leukocytes 
and induce adaptive immune response participation by T-cell co-stimulation  (122-124).   
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1.11. Mechanisms of NDV-induced oncolysis 
NDV induces cancer cell death by two mechanisms (direct and indirect), as discussed 
in detail below. The mechanisms of NDV-induced oncolysis are also schematically 
represented in Figure 1.7. 
1.11.1. The direct mechanism of NDV-induced oncolysis 
NDV kills cancer cells as a direct consequence of virus replication followed by the 
hijacking of host cellular machinery, causing stress leading to the ultimate cell death. 
NDV proteins are known to play a crucial role in participating activation of programmed 
cell death in natural host (avian) cells as well as in mammalian cancer cells.  NDV is 
reported to induce cytotoxicity in chicken embryos by activating the apoptotic pathways 
(125), and studies in chicken embryo fibroblast (CEF) cells have confirmed that HN 
protein causes programmed cell death (126). Characterisation of AF2240 NDV strain 
protein sequences revealed the pro-apoptotic Bcl-2 homology-3 (BH-3) domain-like 
homology with M, F, and L proteins. HeLa cells transfected with plasmids expressing 
AF2240-M and AF2240-F proteins showed apoptotic cell death (127). The interaction of 
AF2240-M protein with BH-3 domain of Bax protein was confirmed by co-
immunoprecipitation. Moreover, deletion of BH-3 like region in M protein obliterated the 
M interaction with the Bax protein and revealed that M protein of AF2440 strain played 
a role in triggering cell death in HeLa cells. However, AF2240-F protein have not 
demonstrated any interaction with Bcl-2 family proteins such as Bax, Bad, or Bcl-XL 
(127).  
Furthermore, NDV-induced apoptosis has been reported in several studies of various 
mammalian cell cultures such as Vero, HeLa, and PC12 cells (128-131).  In 2006 
Elankumaran et al. confirmed that human cancer cells originated from ecto, meso, and 
endodermal sites, were prone to NDV-induced oncolysis due to activation of both 
mitochondrial/intrinsic apoptotic pathway and death receptor/extrinsic apoptotic pathway 
(132). Apoptosis is a type of programmed cell death and can be triggered by two 
signalling pathways: extrinsic (death receptor) pathway and intrinsic (mitochondrial) 
pathway, illustrated in Figure 1.6. The extrinsic pathway is initiated by oligomerisation 
of death receptors such as FAS, CD95 ligand (CD95L), or tumor necrosis factor receptor 
(TNFR) by death signals such as CD95, TNF-α, or TRAIL. Death receptor activation lead 
to the recruitment of adaptor proteins (Fas-associated death domain (FADD)/TNFR-1 
associated death domain (TRADD)) and pro-caspase-8/10, which activates initiator 
caspase-8/10. Initiator caspase-8/10 activates executioner caspase-3/7 to execute 
apoptotic cell death (133). 




Figure 1.6. An illustration of apoptotic signalling pathways, adapted from Galluzzi 
et al. (133) and Baig et al. (134). Apoptosis can be induced by two patways: extrinsic 
(death receptor) pathway and intrinsic (mitochondrial) pathway. The extrinsic apoptotic 
pathway is induced by the activation of death receptors of the tumor necrosis factor 
(TNF) receptor (TNFR) superfamily such as CD95 (APO-1/Fas) or TNF-related 
apoptosis-inducing ligand (TRAIL) receptors (TRAILR) by CD95 ligand (CD95L) or 
TRAIL. Activation of death receptors result to recruitment of adaptor proteins e.g. Fas-
associated death domain (FADD)/TNFR-1 associated death domain (TRADD) and pro- 
caspase-8/10, which activates pro-caspase-8/10 to caspase-8/10 to initiate apoptosis. 
In contrast, the intrinsic apoptotic pathway is induced mitochondrial outer membrane 
permeabilization (MOMP) and release of cytochrome-c (Cyt-c), inducing factor (AIF), or 
second mitochondria-derived activator of caspases (SMAC) in the cytoplasm. Release 
of Cyt-c in cytoplasm initiates activation of caspase-3/7 via formation of the apoptosome 
complexcontaining Cyt-c/Apaf-1/caspase-9. The SMAC promotes caspase activation by 
blocking X-linked inhibitor of apoptosis protein (XIAP). Both pathways are 
interconnected by BH3-interacting domain death agonist (BID) BH3-only protein, where 
caspase-8/10 truncate BID to tBID to activate BAX and BAK proteins to induce MOMP 
resulting in apoptotic cell death.  
 
In contrast, the intrinsic (mitochondrial) pathway is induced by various mitochondrial 
stress signals such as reactive oxygen species (ROS), endoplasmic reticulum (ER)-
stress, calcium (Ca2+), DNA damage etc. The intrinsic apoptotic pathway is vastly 
regulated by BCL-2 family proteins and control BH-3 only proteins, which stimulate BAX 
and BAK pro-apoptotic effector potiens. Activated BAX and BAK disrupts mitochondrial 
outer membrane potential (MOMP) to release cytochrome-c (Cyt-c), inducing factor 
(AIF), or second mitochondria-derived activator of caspases (SMAC) in the cytoplasm. 
The release of Cyt-c in cytoplasm, activates executioner caspase-3/7 to form 
apoptosome formation comprising of Cyt-c/Apaf-1/caspase-9. The release of SMAC in 
cytoplasm inhibits apoptosis inhibitor,  X-linked inhibitor of apoptosis protein (XIAP) and 
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promote caspase-3/7 activation to execute apoptosis. Executioner caspase-3/7 and 
BH3-interacting domain death agonist (BID) BH3-only protein connects extrinsic and 
intrinsic apoptotic pathways via initiator caspase-8/10 mediated truncation of BID to tBID 
and activation of BAX and BAK effector pro-apoptotic proteins to disrupt MOMP (134).  
 
Upon NDV infection in human tumour cells, TRAIL and TNF-α were secreted to fight the 
infection activating caspase-8 to trigger the extrinsic apoptotic pathway. However, in all 
human cancer cell lines used in the study, NDV-induced cytotoxicity was found to be 
independent of caspase-8 activation. Consequential cell demise was triggered because 
of caspase-9 activation in response to the loss of mitochondrial membrane potential, 
highlighting the instigation of the intrinsic apoptotic pathway leading to the oncolysis. 
Activation of apoptotic pathways was independent of type-I IFN-α induction, as apoptotic 
cell death upon NDV infection was also confirmed in IFN-α-defective cancer cells (132). 
The NDV MTH-68/H strain was reported to induce apoptotic cell death in infected PC12,  
rat pheochromocytoma cells in a dose-dependent manner independent of mitogen-
activated protein kinases (MAPK) pathway participation (129). Fábián et al. (2007) 
reported activation of caspase-3 and -12 in MTH-68/H infected PC12 cells and 
independent of caspase-8 and -9. In the same study, infection of MTH-68/H in rat PC12 
and human HeLa cells have confirmed the activation of virus-induced endoplasmic 
stress (ER) pathway, where activated caspase 3 and 12 increased the phosphorylation 
of eukaryotic Initiation Factor 2 (eIF2) located on ER through PKR-like endoplasmic 
reticulum kinase (PERK). The increased phosphorylation inactivated eIF2 and inhibited 
protein synthesis and led to cell death (135). 
Bian et al. (2011) reported that mesogenic(moderately pathogenic) strain Beaudette C 
(BC) and velogenic (highly pathogenic) strain FMW induced more apoptotic cell death 
in A549 cells than lentogenic LaSota strain (136). However, all three strains activated 
the MAPK in all three associated pathways; ERKs (extracellular-signal-regulated 
kinases), JNKs (Jun amino-terminal kinases), and p38/SAPKs (stress-activated protein 
kinases) and downregulation of PI3K-Akt pathway in A549 cells. This study revealed 
that NDV induced apoptosis in A549 cells was caspase 8/9 and p38 MAPK dependent 
(136). Nevertheless, the exact mechanism of oncolysis has remained unclear. In this 
same study, Bian et al. could not reproduce phosphorylation of eIF2a and activation of 
caspase 12 in FMW strain of NDV infection in PC12 cells (136).  
In several human cancer cells such as MCF-7, HeLa, and U373, lentogenic (non-
pathogenic) NDV strain MTH-68/H infection triggered p53-independent apoptotic cell 
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death by activating the ER stress-mediated mechanism (135). There are discrepancies 
in the mechanisms described in NDV-induced apoptosis in different studies. For 
example, PC12 cells showed induction of apoptosis independent of the stress-inducible 
JNK pathway and the p38 pathway when infected with MTH-68/H (129, 137). However, 
in A549 cells LaSota, BC, and FMW strains of NDV induced apoptosis by activating 
caspases 8/9 and p38 pathway.  
Recently the role of RNA viruses such as hepatitis C virus (HCV), influenza A virus (IAV), 
and retroviruses HIV-1 and human T-cell lymphotropic virus 1 (HTLV-1) was studied by 
Ryan et al. (2016) in the activation of DNA damage response (DDR) pathways (138).  It 
is reported that RNA viruses irrespective of their diverse tropism and replication site in 
the infected cells induced DDR stimulated apoptosis, instigation of inflammatory 
responses, and promotion of genetic instability leading to the increased risk of 
tumorigenesis (138). For example, the core protein or nonstructural protein 3 (NS3) of 
HCV have been shown to activate the inducible nitrous oxide synthase (iNOS) and 
augmented release of ROS (138, 139). Accumulation of iNOS and ROS are known to 
induce double-stranded breaks (DSBs) in the infected cell DNA and activation of genetic 
abnormalities due to non-homologous end joining (NHEJ) repair involvement, said to be 
associated with HCV-driven oncogenesis in HCV-infected cells (138). Whereas 14 kDa 
viral protein R (Vpr) of HIV-1 is known to induce DNA damage by arresting cell cycle in 
G2 phase, and the activation of the ataxia telangiectasia mutated (ATM)-CHK2 pathway 
induce apoptotic cell death upon infection (138).  Saeed et al. have reported 
ultramicroscopic observation of infected human glioblastoma multiforme (GBM) cells 
with AF2240, a Malaysian velogenic strain of NDV (140). In this study, Saeed et al. 
analysed the cellular DNA content in infected cells and reported the loss of DNA in 
treated cells in G1, S and G2/M phases of the cell cycle. Disruption of the cell cycle was 
reported to induce apoptotic cell death as indicated by typical features such as 
morphological changes of apoptosis, including shrinkage and blebbing of the membrane 
(140). The study of velogenic NDV AF2240 strain infected GBM cells has suggested the 
role of DDR in NDV-induced oncolysis. 
 
Inconsistencies in these findings are explained by the differences between the cell lines, 
NDV strains (summarised in Table 1.4) and experimental designs. It can be postulated 
that NDV induces oncolysis in different transformed cells of various origins/sites and 
mammalian species differently in a completely de novo manner which is yet to be 
explored.  
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Table 1.4: Summary of NDV-induced cell death in different cell lines 
Sr. 
No. 






strain) is reported to induce apoptosis 
independent of mitogen-activated 






Beaudette C (mesogenic/moderately 
pathogenic strain) is reported to induce 
apoptosis dependent of caspase 8/9 




cells from African 
green monkey  
Vero cell-adpted NDV is reported to 
induce apoptosis through extrinsic and 




astrocytoma cells  
Beaudette C (mesogenic/moderately 
pathogenic) is reported to induce 
autophagic cell death. 
(141) 
5 GL261  Murine glioma cells 
Hitchner B1 (lentogenic/non-
pathogenic strain) is reported to induce 
immunogenic cell death (ICD) 







strain) is reported to induce p53-





tumor MCF-7 cell 
line 
AF2240 (velogenic/highly pathogenic 
strain) is reported to induce apoptosis. 
(143) 
8 DT6606PDA Murine pancreatic 
adenocarcinoma cell 
lines 
NDV R75/98  strain isolated from field 
is reported to activate NK cells 
mediated the CD4+ T cell infiltration, 




1.11.2. Indirect mechanism of NDV-induced oncolysis 
Apart from straightforward NDV-induced cell death as a result of virus replication, NDV 
induces oncolysis by activating the innate and adaptive immune system at the site of 
infection and virus spread. In various studies, different non-pathogenic NDV strains 
activated murine macrophages by secreting adenosine deaminase (ADA), iNOS, acid 
phosphatases, and lysozymes leading to the upregulation of nitrous oxide (NO) and 
TNF-α causing cytotoxicity in both in vitro and in vivo models of study (145-148). NDV 
Ulster strain activated human monocytes by triggering TRAIL expression in the 
macrophages regardless of viral replication. NDV-activated macrophages induced 
TRAIL-mediated cytotoxicity in human cancer cells (149). NDV-HN protein alone was 
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capable of activating TRAIL and IFN-α in human peripheral blood mononuclear cells 
(PBMCs) highlighting that viral replication is not necessary to instigate the innate 
immune system (121). Ni et al. have also shown that NDV-HN plasmid DNA-based 
vaccination alone stimulated anti-tumour activity in a prophylactic mammary carcinoma 
DA3 tumour mouse model by inducing IFN-α, diminishing the tumour growth (150). Anti-
tumour events resulted in increased NK cell infiltration and decreased infiltration of 
myeloid-derived suppressor cells (MDSC) inside tumour microenvironment after 
vaccination with HN plasmid DNA  (150).  
Ulster and MTH-68/H NDV lentogenic (non-pathogenic) strains have shown increased 
expression of natural cytotoxicity receptors NKp44 and NKp46, and not NKp30 upon 
infection in melanoma and other carcinoma cells (151). NDV-HN proteins were 
associated with NK cell activation leading to the secretion of IFN-γ and TNF-α, which 
contributed to NDV antineoplastic properties (151). NDV-HN protein is also known to 
modify cell adherence strength and lymphocyte interactions with T-cell co-stimulation 
along with antigenic peptide presentation to CTL (122-124).  
NDV replication in human tumour cells have been shown to induce IFN-β and 
chemokines such as RANTES (regulated on activation, normal T cell expressed and 
secreted, which is also known as CCL5) and IFN-γ-inducible protein-10 (IP-10). Besides 
these chemokines, NDV is also known to upregulate adhesion molecule ICAM-I (CD54) 
and LFA-3 (CD58) in MCF-7 breast carcinoma cells, and to trigger cell death by 
apoptosis (152). 
NDV infection in cancer cells triggers cell death not only by apoptotic pathways but also 
by inducing immunogenic cell death (ICD). NDV Hitchner B1 strain induced ICD in an 
orthotopic, allograft murine glioblastoma cell line GL261 model. NDV infection resulted 
in translocation of danger signals such as calreticulin to the plasma membrane and 
release of HMGB1 along with increased premelanosome protein 17 (PMEL17) cancer 
antigen protein expression prompting necroptotic and autophagic cell death. In an 
animal study, increased infiltration of IFN‑γ+ T-cells was reported at the site of oncolysis 
(153). NDV-induced oncolysis releases various danger signals (dsRNA, IFN-α, viral 
glycoprotein HN, HSPs, calreticulin, HMGB1 etc.) these DAMPs and PAMPs that 
stimulate not only the innate immune system as discussed above, but also play a crucial 
role in activating the adaptive immune response. NDV-mediated cell death activates NK 
cells, DC, and secreted chemokines (IP-10, RANTES, IL), attracts APCs and also 
presents otherwise hindered TAAs-activated DC cells, CD4+, and CD8+ T-cells (154). 
Schwaiger et al. have shown that NDV-mediated rejection of pancreatic tumour cells 
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(DT6606PDA and Panc02) in a syngeneic orthotopic tumour model by activated NK 
cells. Activated NK cells mediated the CD4+ T cell infiltration, and CD8+ T-cell mediated 
cytotoxicity to avoid tumour recurrence (144). NDV Ulster strain-infected autologous 
primary melanoma cell lysates have shown that T-cell penetration was costimulatory 
receptor CD28 dependent and independent of the co-inhibitory receptor CTLA-4 and 
pathways involving shared ligands CD80 (B7-1) and CD86 (B7-2) (155).  
Zamarin et al. reported the localised NDV intratumoural therapy in a B16 melanoma 
murine model to confirm the infiltration of tumour-specific CD4+ and CD8+ T 
lymphocytes and NDV-induced cytokine stimulation at a distant untreated tumour site 
without any sign of virus replication at the remote location (156). 
 
 
Figure 1.7. An illustration of the oncolytic mechanisms of action of NDV, adapted 
from Howells et al. (2017) (157). Cytotoxic activity of NDV in cancer cells channelled 
via direct (A) and indirect (B) mechanisms. The mechanisms involved in the NDV 
infection and replication resulting in the formation of multinucleated syncytia, activation 
of the extrinsic as well as an intrinsic apoptotic pathway, activation of ER stress pathway, 
and participation of MAPK pathways. The indirect mechanisms include secretion of 
proinflammatory cytokines and chemokines, which employ mediators of both innate and 
adaptive immune system such as NK cells, macrophages, and lymphocytes. Anti-tumour 
immune responses are further improved by the enhanced adhesion of leukocytes, 
through binding to the viral glycoproteins HN and F expressed on the surface of infected 
cells, by upregulation of MHC and cell adhesion molecules, which serve to activate 
tumour-specific T lymphocytes, and by activation of macrophages. 
(Note: ROS-reactive oxygen species, TAA-tumour associated antigens, PAMPs- 
Pathogen associated molecular patterns, TLR-toll like receptors, TCR-T-cell receptors, 
MHC-major histocompatibility complex, and APC- Antigen presenting cells) 
 
Different strains of NDV (both lentogenic/non-pathogenic and velogenic/pathogenic 
type) have been shown to induce virus-mediated indirect oncolysis through apoptosis, 
necroptosis, autophagic and immunogenic cell death in various mammal tumour cells 
activating type-I IFN pathways, as well as T-cell-mediated cytotoxic pathways by 
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releasing PAMPs and DAMPs recognised by PRR to activate NK cells, DC cells, 
macrophages, CD4+, and  CD8+ T-cell activation (154). 
1.12. Genetically modified NDV strains used in oncovirotherapy 
The advent of reverse genetic engineering approaches for negative-strand RNA viruses 
has opened up new avenues to modify NDV genetically and allowed to underpin the 
efficacy of oncolytic potential of modified oncolytic modified NDV strains by inserting 
foreign genes (158, 159). 
Hitchner B1 strain of NDV was genetically engineered by modifying the cleavage site of 
the F protein with polybasic F with a green fluorescent protein (GFP) to get NDV (F3aa)-
GFP to improve its oncolytic potential. The oncolytic potential was tested in vivo in a 
peritoneal carcinomatosis gastric tumour mouse model bearing MKN-74 human gastric 
cancer cells, and cancer cells were administered with NDV intraperitoneally (IP). 
Insertion of the GFP made monitoring of virus replication easy. The genetically modified 
NDV showed oncolysis in gastric tumour cells without any sign of toxicity (160). The 
genetically modified NDV vector rNDV/F3aa(L289A), containing the L289A mutation 
within the F gene shown better fusion activity and enhanced cytotoxicity in an in vitro  
model of hepatocellular carcinoma (HCC) cells compared to the NDV (F3aa)-GFP virus 
(161). 
Another genetically modified Hitchner B1 strain of NDV expressing pathogenic F protein 
showed better anti-tumour efficacy than unmodified NDV when injected intratumorally 
and increased survival when injected intravenously in CT26 bearing mouse model (162). 
Similarly, recombinant  NDVs (rNDVs) generated for expressing GM-CSF, IFN-γ, IL-2, 
or TNF-α tested in colon carcinoma tumour models have also shown improved rNDV-
mediated oncolysis (163). rNDV with IL-2 notably revealed the striking outcome of 60% 
improved long-term survival rate compared of 20% induced by the parental virus. Higher 
levels of activation of IFN-γ and presentation of CD4+ and CD8+ T-cells near the site of 
virus infection and lymph nodes adjacent the tumour microenvironment (163). Zamarin 
et al. confirmed the significant improvement in immunomodulation of malignant 
melanoma in a syngeneic mouse model by NDV(F3aa)-IL-2 virus leading to clearance 
of tumour cells in 87% (7/8) of the animals used in the study (164, 165).  
A potential threat of using genetically modified NDV with the pathogenic F protein 
expression comes from the biosafety to the poultry and wild birds. Pathogenic strains 
can cause an economic burden on the poultry industry. Recombinant fusogenic NDV of 
Hitchner B1 strain (NDV/F3aa) had been tested in the chicken and not found pathogenic 
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with strong innate immune response. However, the mean death time (MDT) in 
embryonated hen eggs have confirmed the mesogenic profile. A detailed study 
recombinant fusogenic NDV in chickens essential to be considered to reduce the risks 
to birds in the wild before considering the potential oncovirotherapy (166). 
Elankumaran et al. modified the mesogenic strain of NDV BC with a mutation in the P 
gene resulting in defective V protein expression (rBC-edit virus). The variation in V 
attenuates the pathogenic BC strain into the non-pathogenic strain. This mutated virus 
was reported to show restricted replication in healthy cells specifying the tumour-
selective replication whereas in a human fibrosarcoma-bearing nude mouse model 
regressed the tumour more effectively and stimulated IFN-α via IRF-7 pathway (167).  
Influenza NS1 protein is a multifunctional protein having IFN inhibitory and anti-apoptotic 
properties through binding to the dsRNA, an inhibition of RIG-I and PKR as well as 
TLR3-mediated type-I IFN induction. An rNDV expressing influenza NS1 showed 
enhanced oncolysis in a syngeneic murine melanoma model. rNDV activated type-I IFN 
by inhibiting the RIG-I helicase activity and triggering the CTLs (168). 
NDV modified with a VP3, an apoptin protein from chicken infectious anaemia virus 
(CIAV) to rNDV-rFMW/AP was tested in vitro and in vivo, human tumour models 
revealed increased oncolysis by apoptosis better than unmodified virus when infected 
at high MOI of 10. The apparent shortcoming in vivo model was early apoptotic cell death 
resulting in the monocyclic virus replication and limiting the virus spread before 
achieving the desired effect (169). 
MTH68 is a mesogenic strain of NDV modified by Puhler et al. by inserting two 
transgenes, heavy (50 kDa) and light chain (25 kDa) of IgG antibody against a tumour-
specific vascular marker antigen extradomain B (ED-B) of fibronectin, in the genome 
without compromising the virus stability. Functional antibody expression successfully 
was shown in fibrosarcoma xenograft as well as in vitro models. This modification opens 
new roads to develop cancer vaccines targeting tumours with the delivery of specific 
therapeutic agents (170). 
TAA and IL-2 expressing NDV showed increase in tumour-specific T-cell infiltration after 
intratumoral administration of NDV in mice bearing CT26 tumour (162). rNDV expressing 
lacZ gene encoding model TAA peptide epitope TPHPARIGL presented to MHC class I 
molecules led to complete tumour regression in 60% of animals used in the study 
compared to the 20% of animals treated with unmodified control viruses. When 
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treatment included IL-2 rNDV along with TAA, the results were improved by 90% (162). 
rNDV expressing codon-optimised HIV-gag protein, activated gag-specific CD8+ T-cells 
in mice. The oncolytic property was further enhanced by the addition of a single-chain 
variable fragment (Fv) (scFv) antibody explicit to the DC-restricted antigen uptake 
receptor DEC205 encoded by F protein. This approach improved CD4+ and CD8+ T-
cell responses and protected tumours upon recombinant vaccinia virus expressing HIV-
1 Gag (Vac-gag) infection  (171). Nevertheless, the strategy of expressing TAA was 
limited by the complexity of tumours, vast numbers of families of TAA, continuously 
hyper mutating cancer DNA, and mostly weaker immunostimulation by TAA. 
 
Bian et al. have developed a novel approach to engineering NDV using enhanced green 
fluorescent (EGFP) protein and bispecific F protein connected with IL-2 and HN proteins 
(NDFL-EGFP/aHN-IL-2) especially targeting IL-2 receptor-expressing human leukaemia 
MT-2 tumour cells. Further assessment of NDFL-EGFP/aHN-IL-2 has revealed that 
biodistribution NDV in liver, spleen, kidney, lung and thymus was reduced to 35-100%, 
whereas 98% of the transgene was delivered to IL-2R+ tumours, significantly reducing 
the off-target effect and resulting in better safety (172-174).  
 
Haas et al. further modified the strategy of bispecific scFv (bsscFv) antibody, which 
specifically bind to HN proteins and to either CD3 or CD28 on human T lymphocytes, 
bsHN-CD3 and bsHN-CD28 antibody respectively. Human T-cell activation was 
achieved by using autologous tumor vaccine-NDV (ATV-NDV) modified with bsHN-CD3 
or bsHN-CD28 bsscFv antibody. ATV-NDV vaccine is prepared by isolating tumour cells 
from surgically operated tumour. Isolated tumour cells are infected with Ulster strain of 
NDV for 1h. NDV-infected tumour cells inactivated by 200 Gy-irradiation to inhibit tumour 
cell proliferation without affecting NDV replication. ATV-NDV then mosified by adding 
soluble bsHN-CD3 or bsHN-CD28 bsscFv antibody. A strong and durable antitumour 
activity was demonstrated in human lymphocytes using bsHN-CD3 or bsHN-CD28 
bsscFv antibody modified ATV-NDV (175). Similarly, bispecific scFv bsHN-IL2 or bsHN-
CD28 antibody modified ATV-NDV vaccine co-culturing with PBMCs or T-cells 
demonstrated stimulation of  naive T-cells through CD3 and IL-2 mediated signalling 
cascade with upregulation of PLC-γ1, Grb-2, Vav-1 and PDE-4A. Further on validation, 
this approach was even more effective when aHN-IL-2 fusion protein used for T-cell 
stimulation instead of bsHN-CD28 protein (176). 
 
So far, the development of genetically engineered NDV expressing modified F proteins, 
cytokines such as IL-2/IFN-γ/GM-CSF/TNF-α, TAA, antigen-specific antibodies alone or 
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as in bispecific approaches in cellular as well as in animal models, have demonstrated 
the great potential and a strategic place of NDV in future as an effective oncovirotherapy 
to treat various cancers. Many of these candidates have already been in different phases 
of clinical trials to generate more field data to improve NDV-mediated oncolysis. 
1.13. Clinical NDV trials 
First study was published by Goto et al. in 1959, where the oncolytic possibility of NDV 
strains Sato and Miyadera were tested in the Yoshida sarcoma rat model (177).  
Numerous preclinical studies have now established the substantial anti-cancer activity 
of naturally occurring and recombinant NDV in pre-clinical models. Encouraging results 
were documented in preclinical models of leukaemia, lymphoma, melanoma, 
neuroblastoma, fibrosarcoma, rat pheochromocytoma, colon carcinoma, lung 
carcinoma, prostate carcinoma, breast carcinoma, gastric carcinoma, mesothelioma, 
and head and neck carcinoma (164). 
Wheelock and Dingle (1964) demonstrated for the first time oncolytic potential of 
intravenously injected NDV in a acute human leukaemia patient showed up to 75% 
reduction in peripheral myeloblasts within 18 h of the first injection. The mild fever 
recorded within 3 h of the first injection, was passed after 3 h (178). Soon after this, 
Cassel and Garret (1965) evaluated the oncolytic properties of 73T NDV strain in a 
woman with inoperable cervix carcinoma without previous treatment. Just with a single 
intratumoral injection, a significant tumour regression of lymph node (LN) was observed 
with subjective improvement in the patient for a short time (94). Cassel et al. employed 
NDV 73T strain in 83 patients with stage II malignant melanoma were inoculated with 
autologous or allogeneic NDV oncolysates. A long-term follow-up of these patients 
confirmed over 60% for 10-year survival without any recurrence of the disease (179). A 
15-year survival phase-II study included AJCC stage III malignant melanoma patients 
and was conducted in two groups, group I (32 patients) and group II (51 patients). 
Patients were treated with subcutaneous injection of NDV 73T oncolysates post-
operatively. Independent analysis of both groups demonstrated survival of 59% (18/30) 
in group I and 53% (23/44) in group II with overall 55% survival in 15-years (180). 
Schirrmacher and colleagues employed a different strategy where irradiated entire 
autologous tumour cells were infected with vaccine strain Ulster of NDV and developed 
autologous tumour vaccine with NDV (ATV-NDV), which was administered with 
cytokines. The first successful prevention of the metastatic spread of tumour in ATV-
NDV treated post-operated tumour model (181). The efficacy of ATV-NDV was 
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established first in Esb lymphoma, B16 melanoma, and 3LL Lewis lung carcinoma 
preclinical animal models with improved immune responses (182-184). Several clinical 
studies in phase I and II were carried out based on ATV-NDV tumour vaccines in 
colorectal cancer cells, which has shown augmented immunogenicity by activating 
innate and adaptive immune responses with improved long term survival in various 
phase II clinical trials (185). Patients with advanced colorectal carcinoma were 
vaccinated with ATV-NDV vaccine after potential curative tumour resection, where 
delayed-type hypersensitivity (DTH) was measured in all vaccinated patients. NDV 
vaccination was reported to be well-tolerated amongst all patients, 75% (12/16) of 
patients have shown NDV sensitisation confirmed by the histological examination and 
helper T-cell infiltration (186). A group of 23 colorectal cancer patients were treated with 
ATV-NDV in phase II after post-operative resection of liver metastases. In adjuvant 
vaccination settings, 61% of patients have shown recurrence of cancer compared to the 
87% control group (187). 
Liang et al. conducted the most extensive study of treatment of digestive tract tumours 
with an autologous NDV-modified tumour cell vaccine using non-lytic NDV strain LaSota 
(188). In this phase III study, NDV virotherapy with resection and immunotherapy was 
used in 310 patients in stage I-IV colorectal cancer and compared to 257 patients treated 
with resection alone. There was not enough information on randomisation or allocation, 
as there was a lack of mention of sampling and additional chemotherapy. In this study, 
a statistically significant median of overall survival was reported of 7 years in the vaccine 
group compared to 4.46 years in the resection alone group was recorded (188). 
Additionally, a one-year survival rate was 96% for 25 patients treated with NDV 
immunotherapy with unresectable colorectal, stomach, liver, pancreatic, and gallbladder 
cancers who were all treated with ATV-NDV vaccines. Although this study has presented 
some clinical benefits with encouraging short term survival further rigorous randomised 
clinical trials would be necessary to reach more decisive conclusion (188). 
In a pilot study, 23 patients of glioblastoma were postoperatively vaccinated with ATV-
NDV and compared with 87 non-vaccinated control patients. Vaccination resulted in 
statistically significant median progression-free survival of 40 weeks in treated patients 
(vs 26 weeks in controls), and the median overall survival of vaccinated patients was 
100 weeks (vs 49 weeks in controls), where 91% treated patients survived for one year, 
39% survived for two years, and 4% were long-term survivors (189). 
Later, NDV MTH/68 and HUJ strain-based phase I clinical studies were conducted in 
GBM brain tumour patients. MTH/68 intravenous injection in 4 high-grade glioma 
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patients showed 5 to 9 years of long term survival and the HUJ based vaccination 
achieved a complete response in 9% (1/11) of the patients, only rest showed recurrence 
of progressive disease (190, 191). 
In a PV701 based phase I trial, 79 patients were treated through intravenous injections 
to determine the MTD for the single-dose and multiple-dose schedules. Flu-like 
symptoms were the most common adverse effects, consistent with cytokine induction. 
Most symptoms were associated with the first dose followed with subsequent doses. 
Subsequent doses were bwtter tolerated due to reduced induction of proinflammatory 
cytokines, which occurred before the development of antibodies against PV701 in all 
patients (115).  
Primarily, direct administration of NDV to patients have revealed minimal toxicity with 
the recommendation of clinical benefits in some patients, necessitating further 
assessment. A summary of NDV clinical trials listed in Table 1.5. 
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Allogenic or autologous human melanoma cells 





Patients confirmed over 60%  survival for 
10-year without any recurrence and overall 
survival 55% for NDV-treated melanoma 
patients in 15 years 
1992 (179, 180) 
NDV-MTH-68 
Mesogenic 





1-year survival for 22 out of 33 versus 4 out 
of 26 in the control group; 2-year survival 






Dose intensified up to  
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Objective responses occurred at higher 
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vaccine, 
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64 HA units of the NDV 
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Phase 1/2        
(n = 23) 
1 patient was long term survivor versus 
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Case series     
(n = 14) 
7 out of 14 responses; four major,  








(n = 11) 
1 patient out of 11 achieved a complete 









(n = 16) 
1 patient experienced the near-complete 
response with at least 1-year survival, four 









(n = 18) 
6 out of 18 responses: one complete, three 
partial, and two minor; six patients surviving 
rate of least 2 years 
2007 (117, 194) 
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1.14. Potential for oncolytic NDV to break resistance to therapy  
From the last five decades of study of NDV as an oncolytic virus, NDV disrupted 
tolerance or immune suppression by activating host immune mechanisms and 
destroying tumour cells by ICD. NDV has been demonstrated to be effective for break 
therapy resistance, as discussed below with the examples. 
Breaking resistance to conventional treatments: Conventional 
chemotherapy (CT) and radiotherapy (RT) target the proliferating cells to kill the tumour, 
but non-proliferating tumour cells such as dormant tumour cells or cancer stem cells 
remain unaffected by it. However, NDV replicates in cell cytoplasm regardless of the 
host cell DNA replication and gives the advantage of replicating in non-proliferating cells. 
NDV is known to replicate in γ-irradiated cells (to develop ATV-NDV vaccines) (123). 
Meng et al. have demonstrated that NDV triggers caspase-9-mediated apoptosis in 
cisplatin-resistant A549 lung cancer cells demonstrating its potential to overcome drug 
resistance (195). In another study, NDV FMW strain modulated autophagic cell death in 
drug-resistant A549 cells (196). Bai et al. have shown the enhancement of proapoptotic 
properties of temozolomide (TMZ) in combination with LaSota in GBM cells in vitro as 
well as in in vivo models by down-regulating the AKT–mTOR signalling pathway but also 
by activating AMPK (197). 
Breaking resistance to apoptosis: Oncolytic NDV has been shown to break 
apoptosis resistance in Bcl-xL antiapoptotic protein overexpressing A549 cells. 
Apoptosis-resistant cells favoured better viral replication and paradoxically induced 
apoptosis-resistant cells by activating the type-I IFN pathway (98). In another study, 
melanoma cells overexpressing Livin antiapoptotic protein NDV-HUJ strain broke 
apoptosis resistance by caspase-mediated cleavage of Livin (99). Both studies 
confirmed better viral replication in apoptosis-resistant cells, proving potential of NDV to 
break therapy resistance properties of NDV. 
Breaking resistance to hypoxia: Solid tumour microenvironments comprise 
of dominant hypoxic areas with activated hypoxia-inducible factor-alpha (HIF-α) a 
transcription factor. It impacts gene expression and contributes to the resistance of 
tumours to CT and RT. Wei-Choong Ch'ng et al. have investigated the oncolytic efficacy 
of velogenic NDV strains with or without of HIF-2α expression in renal cell carcinoma 
(RCC) cell lines with defective or reconstituted wild type (wt) von Hippel-Lindau (VHL) 
activity. NDV stimulated IFN-β. Stimulation IFN-β was associated with increased STAT-
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1 phosphorylation in RCC cells. Hypoxia augmented NDV-induced oncolysis 
irrespective of the HIF-2α status in the cells (198). 
Breaking resistance to antiviral immunity: Antiviral immunity was 
measured as a significant obstacle for the productive therapeutic activity of oncolytic 
viruses. In a recent study from Ricca et al., it was reported that pre-existing immunity to 
oncolytic NDV LaSota enhances rather than constrains its immunotherapeutic efficacy, 
suggesting at least NDV LaSota has potential to break resistance to anti-viral immunity 
in a tumour model (66). 
Breaking resistance to immune checkpoint blockade: Zamarin et al. 
(2014) demonstrated that oncolytic NDV broke down the resistance developed against 
CTLA-4 checkpoint blockade immunotherapy at the distant untreated tumour site when 
injected intratumorally in localised B16 mouse melanoma tumour model (156). The 
promising therapeutic effect was associated with infiltration with activated CD8+ and 
CD4+ effector cells but not with regulatory T-cells at distant tumour site. The result was 
dependent on CD8+ T-cells, NK cells, and type-I IFN (156).  Later, the same group 
studied the immunogenic potential of NDV in bladder cancer, where the application of 
immune checkpoint inhibitory antibodies revealed only suboptimal response rates (199). 
NDV infection in human and mouse bladder cancer cells have induced ICD. Induction 
of ICD was found to be associated with upregulation of MHC and PD-L1 regardless of 
sensitivity to NDV-induced oncolysis. It has been reported that NDV-mediated localised 
activation of checkpoint PD-1 or CTLA-4 blockade therapy in both treated and distant 
tumours and even when administered in lysis-resistant tumour cells, in a bilateral flank 
test animal model (a mouse model where tumour cell transplantation is introduced at 
two opposite sides) (199). 
1.15. Projections for NDV as oncolytic viruses 
Since NDV was first recognised as an oncolytic virus, the understanding of NDV biology, 
oncotropism, and cancer cell biology has come a long way.  
Numerous studies demonstrated tumour-specific NDV replication and 
immunomodulation of tumour microenvironment. NDV demonstrated various 
advantages over other OV candidates, such as lack pre-existing immunity in humans 
because NDV is an avian pathogen. Serological data suggests almost 96% of the human 
population is seronegative for NDV (200, 201). NDV is non-pathogenic to humans, and 
adverse effects like mild conjunctivitis, laryngitis, and mild flu-like symptoms are 
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observed only in high-risk personnel such as farmers and immunosuppressed or 
immunocompromised patients (118). NDV has demonstrated to have 
immunostimulatory properties by inducing type-I IFNs, activating NK cells, 
macrophages, dendritic cells, CD4+, and CD8+ T-cells. Anti-tumour immune responses 
were found to remain longer in vaccinated tumours to clear remaining virus replication 
and governs the safety profile. The large size of the NDV genome has allowed 
successful engineering to insert foreign genes without (any associated toxicity) 
hampering virus replication. As NDV is a negative-strand RNA virus that replicates in 
the cytoplasm there is no genetic integration with host cell genome (202). Considering 
all the discussed advantages of NDV as OV, there is scope to improve its potential. It 
can be achieved with some of the following approaches. 
1.15.1. Improving tumour-specific targeting and systemic 
delivery 
Conventional NDV vaccines are mass-produced using embryonated hen's eggs. 
However, to enhance tumour specificity of NDV vaccines requires modification of HN, 
and processing of NDV with modified HN poses constraints for production in eggs. 
Hence the development of a tissue culture-based system is required for NDV rescue, 
viral growth and production. Nonetheless, bispecific adapter F protein was successfully 
used for targeting tumours by Schirrmacher and colleagues, and similar approaches 
have been used for retargeting adenovirus (203). Alternatively, modification of the F 
protein cleavage site with tumour-specific proteases can be used in NDV to improve 
virus replication of non-lytic strains, already demonstrated for measles, Sendai, and 
retroviruses (204, 205). 
RNA viruses are naturally limited from exploiting tissue-specific promoters, which is used 
with HSV-1 and adenoviruses to restrict their replication in tumour cells (206). Utilising 
RNA destabilising elements like AU-rich elements (ARE) encoded by viral proteins 
enhance the tumour-specific replication. Oncogenic pathways lead to activation of ARE-
binding proteins like tristetraprolin (TTP) and human antigen R (HuR), which then 
stabilise mRNA of multiple tumour-promoting genes such as cytokines, chemokines, 
growth factors, and transcription factors. Viral mRNA destruction strategy by application 
of ARE in healthy cells will promote tumour-specific virus replication and overexpression 
of chemokines and cytokines in tumour microenvironment can be achieved (207). 
In preclinical and clinical NDV trials, administration of NDV vaccine vectors via 
intravenous and intratumoural routes presented promising results by activating type-I 
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IFN responses upon NDV sensitisation, although the intravenous route of administration 
demonstrated better than intratumoural doses (154). Inefficient dose administration of 
viral vector vaccines, poor systemic delivery to the target, rapid clearance of virus, and 
off-target effects have resulted in reduced oncolysis (208). Overcoming this challenge 
requires attempting different approaches such as using mesenchymal stem cells (MSC) 
as carriers for measles virotherapy. Different types of cells such as MSCs and neural 
stem cells (NSC), immune cells, and cancer cells have demonstrated to have tumour-
homing characteristics, which was used in measles virotherapy and shown to protect 
the virus from neutralising antibodies and to efficiently transfer the virus to tumours in 
an orthotopic xenograft ovarian cancer model (209, 210).  Consideration of similar 
methods for delivery of NDV to target tissues will undoubtedly be essential and useful 
further development as a systemic agent. 
One such strategy of combining ATV-NDV with DCs used to improve the de novo 
synthesis of TAA-specific cells from naïve T-cells. The Immunological and Oncological 
Center (IOZK) in Cologne (Germany) have developed a protocol for the generation of 
viral oncolysate-pulsed DCs (VOL-DCs), which has received an official permit for an 
individual application of this product to cancer patients in 2015 (202). Combination 
therapy of local hyperthermia (LHT) with ATV-NDV in VOL-DC induced a long-lasting 
antitumor memory T-cell response and achieved complete remission of prostate cancer 
with widespread bone metastases in a patient who had failed standard therapy (211). 
IOZK is running multimodal two-stem immunotherapy in situ vaccination first followed by 
second active-specific vaccination (154). Cancer patients were intravenously injected 
with NDV MTH-68 in combination with several ICD inducers such as moderate local 
electrohyperthermia (mEHT), ionising radiations, hydrostatic pressures etc. to trigger the 
immune system and to induce ICD in tumour cells; this is referred as in situ vaccination 
stage; the process is repeated 5 times in 5 days. In the second step of active vaccination, 
cancer patients were treated with VOL-DCs in combination with in situ vaccination 
intradermally. The dendritic cells were isolated from cancer patients to prepare VOL-
DCs preparation. This multimodal two-step study is ongoing. So far, a significant 
increase in CD8+ T-cells infiltration with long-lasting memory T cells response has 
observed in various trials in GBM patients (154). 
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1.15.2. Enhancement of NDV-mediated immunomodulation 
and bypassing NDV neutralising immune responses 
With recent advancement in the understanding of cancer biology, a lot is known about 
the T-cell co-stimulatory, and co-inhibitory receptors molecules, which have provided 
valid new targets for immune therapies for improvement in the stimulation of anti-tumour 
immune responses and to inverse the immunosuppressive mechanisms to the 
widespread tumour resistance to immune destruction. Substantial anti-tumour activity 
has been demonstrated using stimulatory antibodies to 4–1BB, OX40, and GITR, as well 
as inhibitory antibodies to PD-1 and CTLA-4. Identification of these immune checkpoint 
inhibitors opened new avenues for combinational therapies targeting cancer with even 
more precision (212). In phase III clinical trial of advanced melanoma patients, a 
significant improvement in median overall survival was demonstrated by treating 
patients with CTLA-4 antibody Ipilimumab, which led to the FDA approval for cancer 
treatment (213, 214). Simultaneously a therapeutic autologous antigen-presenting cell 
vaccine (Sipuleucel-T) got FDA approval for prostate cancer treatment after 
demonstrating the prolonged overall survival in compared to a placebo control group 
(215). 
The potential synergy between oncovirotherapy and immunotherapy was studied in a 
preclinical and clinical trial, including NDV, HSV-1, adenoviruses, and other OVs. 
Recombinant oncolytic viruses demonstrated superior anti-tumour properties. 
Oseledchyk et al. have shown that a combination of intratumoral NDV with systemic PD-
1 or CTLA-4 blockade led to improved local and abscopal tumour control and overall 
survival in a human and murine bladder model. These findings have encouraged 
upcoming clinical trials to combine intratumoral NDV therapy with systemic 
immunomodulatory agents (199). Likewise Vijayakumar et al. have also demonstrated 
benefits of six different recombinant NDV (rNDV-anti-CD28-mIL12, rNDV-anti-PD-1-
mIL12 and rNDV-anti-PD-L-1-mIL12) targeting immune checkpoint blockades showed a 
survival benefit both in a highly aggressive unilateral and bilateral B16-F10 murine 
melanoma models (216). 
As NDV is known for immunostimulatory properties, it elicits strong neutralising antibody 
responses. A premature anti-NDV antibody response would restrict oncolysis even after 
repeated administrations of multiple doses of NDV.  In the face of the limited clinical data 
representation of sustained benefits in patients treated with multiple prescriptions, the 
problem of virus deactivation and clearance will be expected to limit its therapeutic 
effectiveness in majority of the patients. Impending solutions to this problem would 
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depend on the utilisation of different NDV strains, the use of viral carriers such as MSCs 
or NSCs, and modification of different viral surface proteins using reverse genetic 
engineering. Surprisingly, the oncolytic LaSota strain of NDV demonstrated to be 
unaffected by pre-existing antiviral immunity when injected intratumorally; in contrast, it 
potentiated the immunotherapeutic efficacy both in vivo and in vitro models (66). 
Abrogation of secondary response to adenovirus vector from pre-existing immunity has 
been studied in immunised bilirubin-UDP-glucuronosyltransferase (BUGT)-deficient 
jaundiced Gunn rats upon infection with recombinant adenovirus (5 x 109 PFU/rat). This 
recombinant adenovirus expressed a human UDP-glucuronosyltransferase (BUGT1) 
gene (Ad-hBUGT). This study has demonstrated that well-tolerated doses for repeated 
adenovirus-directed gene transfer despite the presence of a residual antibody titre from 
previous adenoviral exposure (65). A similar strategy could be developed to overcome 
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1.16. Aims and objectives of the thesis 
The mechanisms of NDV-induced oncolysis using lentogenic/avirulent non-reporter and 
reporter strains of NDV such as Hitchner B1, B1-GFP, LaSota, and LaSota-GFP are not 
clearly understood; therefore, the aims and objectives of the thesis are as follows: 
 
Aim 1: Establish a model system to study oncolysis  
Objective 1: Identify an NDV-sensitive cell line/s for lentogenic strains of NDV 
Objective 2: Identify an effective lentogenic strain of NDV used for oncolysis in 
susceptible cells 
Objective 3: Isolate persistently infected cells from the most susceptible cells upon NDV 
infection 
Objective 4: Investigate the impact of persistent NDV infection in isolated cells in 
comparison with parental cells with or without NDV infection 
 
Aim 2: Explore the differences between persistent and acute 
NDV infection in susceptible cells 
 
Objective 1: RNA-seq analysis of persistently and acutely infected cells in comparison 
with uninfected cells 
Objective 2: Analysis of differentially expressed genes (DEGs) in pair-wise comparisons 
of persistently and acutely infected cells in comparison with uninfected cells 
Objective 3: Comparative analysis of RNA seq-analysis from this project with similar 
already published data  
 
Aim 3: Investigate the mechanism of NDV-mediated induction of 
mitophagy in susceptible cells 
 
Objective 1: Investigate the role of NDV in susceptible cells for the induction of 









2 Materials and Methods 
2.1. Materials 
2.1.1.  Cells 
 
Different human cancer and non-cancer cell lines along with chicken embryo fibroblast 
cells used in this PhD project, are listed in Table 2.1. 
 
Table 2.1: List of cells/cell lines used in this study 
Sr. 
No. 
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Note: A549, PC3, MRC5, Caco-2 and VR Caco-2 cells (VR Caco-2 cells are discussed in chapter 




Different avirulent strains of NDV, AIV (avian influenza virus), and VSV (vesicular 
stomatitis virus) used in this PhD project, are listed in Table 2.2. 
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2.1.3.1. Amplification primers 
 






Forward Primer 5 prime  to 3 
prime 













2.1.3.2. Cloning primers 
 




Forward Primer 5 prime  
to 3 prime 
Reverse Primer 5 prime  







CGTATTTGATGAG    
TTACTAGTTCAATAC
CCCCAGTCGGTG 

















F- Eco RI,  
(1.187 kb) R-SpeI 
3 
M AACCATGGCAATGGAC




(1.09 kb) R-SpeI 
4 
F AACCATGGCAATGGG
CTCCAGACCTTCTAC       
GGACTAGTTCACATT
TTTGTAGTGGCTCTC   
F-NcoI, 
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Figure 2.1. The schematic representation of the NDV genome fragmentation for 
Sanger sequencing. The strategy of Sanger sequencing by fragmenting 15,192 





Table 2.5: List of primers used for NDV cDNA synthesis and PCR amplification  
Sr. 
No. 
NDV Fragment  
(Sanger sequencing) 
Forward Primer 5 prime  to 
3 prime 







 (38-2689 bp) 
AGGAGCAATTGAAGTC
GCAC (38 to 57 bp) 
GGCTTCCATGACTGCAAC




(2104 to 4760 bp) 
ACAAACAACCATCCACA
CCC (2104 to 2123 bp) 
TATCCTTGGGCAGATTCG




(3397 to 7919 bp) 
AATCGCCCCGCAATATA
GGA (3397 to 3416 bp) 
GACGCAGGGTTAAGTCTT




(6130 to 10291 bp) 
AAAGGCGCAACAAAAG
ACCT (6130 to 6149 bp) 
GAAGGTTGCAACTCTCCG
AC (10272 to 10291 bp) 
4161 
5 
Fragment 4  
(8834 to 13486 bp) 
GAGGAGTTCAGCAGCA
TTCG (8834 to 8853 bp) 
AGGTTGTCGGGTGAATGG




(12088 to 15172 bp) 
GACTGCTGCTCTCACGA
TTG (12088 to 12107 bp) 
TGGTGAATGACGAGACTA





Table 2.6: List of sequencing primers used to sequence NDV fragment 
Fragments Sequencing primers 
5 prime  to 
3 prime 
Orientation 
Fragment 1 A-Y:             
38 to 2689 bp 
AGGAGCAATTGAAGTCGCAC (38 to 57 bp) 
Forward 
ATTGGCCGTGCTTGAGATTG (415 to 434 bp) 
CTCAAGTACGGAATCAACACCA (932 to 953 bp) 
CCTACAAGGCGGATCGAATAG (1399 to 1419 bp) 
ACAAACAACCATCCACACCC (2104 to 2123 bp) 







GGCTTCCATGACTGCAACAA (2689 to 2708 bp) 
Fragment 1 B-V:          
2104 to 4741 bp 
ACAAACAACCATCCACACCC (2104 to 2123 bp) 
Forward 
CAACCAGTGCCACATCCATC (2871 to 2890 bp) 
AGCAACCTGTTAGCATTTCCG (3341 to 3361 bp) 
ACAAGATCCCAGCTGCAGTA (3849 to 3868 bp) 
TTACCTGTCCATCAAGTTAG (4471 bp to 4490 bp) 
TATCCTTGGGCAGATTCGGG (4741 to 4760 bp) 
Fragment 2= 4523 bp 
(3397 to 7919 bp)  
AATCGCCCCGCAATATAGGA (3397 to 3416 bp) 
Forward 
GAAAGCGCCAGAGAAGATCC (3760 to 3779 bp) 
CCAAAAGCTTAGTCCGTGCA (4141 bp to 4160 bp) Reverse 
CCAAGCAGGTACCCAACG (4276 to 4293 bp) 
Forward 
CCCGAATCTGCCCAAGGATA (4741 to 4760 bp) 
TCTAGCTGGTGGGAATATGGA (5263 to 5283 bp) 
GCAATGTTTTATCCTTAGGCGG (5814 to 5835 bp) 
GTGGCCCTTGAGTCTCCATT (6673 to 6692 bp) 
CCACGGAGACAGAGGAAGAA (7172 to 7191 bp) 
GACGCAGGGTTAAGTCTTGC (7900 to 7919 bp) Reverse 
Fragment 3= 4162 bp 
(6130 to 10291 bp) 
AAAGGCGCAACAAAAGACCT (6130 to 6149 bp) 
Forward 
CTTGGTGTGCTCCGGACAT (7033 to 7051 bp) 
AGTAGGCGCCGGGATAAAAT (6893 bp to 6912 bp) Reverse 
TTGGTGGGAAACGCATACAG (7502 to 7521 bp) 
Forward 
ACCTCATTCTCAGCCGACAA (8523 to 8542 bp) 
GGAGGGCAGAGATATGGTCA (9103 to 9122 bp) 
AAATGTGCGCACCGAAAATG (9510 to 9529 bp) 
GAAGGTTGCAACTCTCCGAC (10272 to 10291 bp) Reverse 
 Fragment 4= 4653 bp 
(8834 to 13486 bp) 
GAGGAGTTCAGCAGCATTCG (8834 to 8853 bp) 
Forward 
TCTGCACTTGAATTTGAGCCA (9722 to 9742 bp) 
GCCACACACCTGCATTCTTC (9598 to 9617 bp) Reverse 
GTATCTTCAAACCGCAATCATGA (10232 to 10254 bp) 
Forward 
CCGTAATGTCCTGTGCCAAC (10905 to 10924 bp) 
GGCAGAAGAGAAGGCATTGG (11431 to 11450 bp) 
ACCAGCAAGAATCCTCCGAT (11924 to 11943 bp) 
TTTGAATATGCAGCACTTGAAGT (12770 to 12792 bp) 
CCCCGATCAAGTGAGCTCTA (13276 to 13295 bp) 
AGGTTGTCGGGTGAATGGAT (13467 to 13486 bp) Reverse 
Fragment 5= 3100 bp 
(12088 to 15172 bp) 
GACTGCTGCTCTCACGATTG (12088 to 12107 bp) 
Forward 
TCAAGGTTACATGCAGTGGG (12938 to 12957 bp) 
TGGTAAGAACGGTGGAGGAG (12794 bp to 12813 bp) Reverse 
 GGTGCTCGAGTGAAAGATCC (13451 to 13470 bp) 
Forward 
GTTATTCACCTCACAGCGGC (14374 to 14393 bp) 
 TGGTGAATGACGAGACTACACT (15151 to 15172 bp) Reverse 
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2.1.3.4. SYBR Green qRT-PCR primers 
 






Forward Primer 5 prime  to 3 
prime 





1 GAPDH CTCTGCTCCTCCTGTTCGAC GTTAAAAGCAGCCCTGGTGA 237 
2 IFN-B AGGACAGGATGAACTTTGAC TGATAGACATTAGCCAGGAG 181 








2.1.3.5. TaqMan qRT-PCR primers and probes 
 








































2.1.4.1. Primary antibodies 




Antibody Type  


























Abcam, ab 34402 
IF, WB, and plaque 
assay 
 
2.1.4.2. Secondary antibodies 




Antibody Host Reactivity Source Use 
1 
Goat anti-Rabbit IgG (H+L), 








Goat anti-Rabbit IgG (H+L), 





Goat anti-Mouse IgG (H+L), 





Goat anti-Mouse IgG (H+L), 





Goat anti-Chicken IgY 








Goat anti-Chicken IgY 

















blot detection 8 
IRDye® 800CW Goat anti-





IRDye® 680RD Goat anti-
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2.1.5. Media and Buffers 
 
2.1.5.1. Media and solutions 
 









MEM-Minimum essential medium 
eagle with Earle's salts and sodium 
bicarbonate without L-Glutamine  
(Sigma-Aldrich, D5796) 
1% Penicillin-Streptomycin (10,000 U/ml) (Gibco™-15140122), 1x NEAA 
(Gibco™-11140050), 4 mM L-Glutamine (Gibco™-25030081), 1 µg/ml 
Amphotericin B (Gibco™-15290026), 20% foetal bovine serum (FBS) 
(Gibco™-10099141) 
Caco-2, Ox Caco-2, 
and VR Caco-2 cells 
culturing 
2 
MEM-Minimum essential medium 
eagle with Earle's salts and sodium 
bicarbonate without L-Glutamine  
(Sigma-Aldrich, D5796) 
1% Penicillin-Streptomycin (10,000 U/ml) (Gibco™-15140122), 
4 mM L-Glutamine (Gibco™-25030081), 1 µg/ml Amphotericin B 
(Gibco™-15290026), 10% FBS (Gibco™-10099141) 




eagle's medium (with high 
glucose 4.5 µg/ml), L-Glutamine 
and sodium bicarbonate without 
sodium pyruvate (Sigma-Aldrich, 
D5796) 
1% Penicillin-Streptomycin (10,000 U/ml) (Gibco™™-15140122), 1 mM 
Sodium Pyruvate (Gibco™-11360070), 1 µg/ml Amphotericin B (Gibco™-
15290026), 10% FBS (Gibco™-10099141) 
DF-1, HEK-293, and 
A549 cells culturing 
4 
RPMI (Roswell Park Memorial 
Institute), -1640 medium with L-
Glutamine and sodium 
bicarbonate (Sigma-Aldrich, 
R8758) 
1% Penicillin-Streptomycin (10,000 U/ml) (Gibco™-15140122),1 µg/ml 
Amphotericin B (Gibco™-15290026), 10% FBS (Gibco™-10099141) 
HeLa cells culturing 
5 
Ham's F-12K (Kaighn's) Medium 
(Gibco™, 21127022) 
1% Penicillin-Streptomycin (10,000 U/ml) (Gibco™-15140122),1 µg/ml 
Amphotericin B (Gibco™-15290026), 10% FBS (Gibco™-10099141) 
PC3 cells culturing 











VERSENE, (0.53 mM) aqueous 
solution of the tetrasodium salt of 
ethylenediaminetetraacetic acid 
Na4EDTA (prepared in house) 
0.25% Trypsin and 0.53 mM Versene mixed in 1:1 ratio  Cell trypsinisation 
8 
Opti-MEM™ I Reduced Serum 
Medium (Gibco™-31985070) 
NA Cell transfection 
9 
DMEM-Dulbecco’s modified 
EAGLE'S medium-high glucose 
with 4.5 µg/ml glucose, L-
Glutamine and sodium 
bicarbonate without sodium 
pyruvate (Sigma-Aldrich, R8758) 
5% FBS (Gibco™-10099141) Cell transfection 
10 
Luria Broth (LB) (Gibco™™, 
10855021) 




LB Agar plate (Pirbright Institute 
cell services unit) 











Plaque assay 0.8% Methyl 
cellulose overlay media 
1x DMEM (Sigma-Aldrich, R8758), pre-sterile 0.8% Methyl cellulose 
(Sigma-Aldrich, M0512), 2% FBS (Gibco™-10099141),10% freshly 
collected from 10 days old SPF chicken embryonic eggs (Valo Biomedia 
GmbH), 1% Penicillin-Streptomycin (10,000 U/ml) (Gibco™-15140122), 1 
µg/ml Amphotericin B (Gibco™-15290026) 
Virus plaque assay 
Note: Foetal bovine serum (FBS) (Gibco™-10099141) heat-inactivated at 56OC in a water bath for 30 minutes before adding to the cell 
culture media. 









Buffer Composition Use 
1 PBSa 
Ca+2- Mg+2 free phosphate-buffered saline 
(PBS), pH 7.4 (Pirbright Institute cell 
services unit) 
Cell wash 
2 4% PFA 
4% Paraformaldehyde (PFA) solution in 
PBS (Chem Cruz SC-281692)  





(IF) blocking buffer 
0.5% Bovine serum albumin (BSA) 
(Sigma-Aldrich, 810533) in PBSa solution 
Blocking of cells before 
IF staining and antibody 
dilution 
4 Cell lysis buffer 
RIPA (Radio-Immuno precipitation assay) 
cell lysis buffer  
(Thermo Scientific™, 89900) 
Cell lysate preparation 
5 PBST 
0.01% v/v Tween 20 (Sigma, P2287) in 
PBSa 
Western blot washing 
6 WB blocking buffer 
10% Skim Milk Powder (Millipore, 70166) 
in PBST 
Blocking of western blot 
before staining 
7 WB blocking buffer 
5% Skim Milk Powder (Millipore, 70166) in 
PBST 





20x TruPAGE™ TEA-Tricine SDS Running 
Buffer (Sigma-Aldrich, PCG3001)-1:5 
dilution in deionised water 





0.1% v/v NuPAGE™ Sample Reducing 
Agent (10X) (Invitrogen™, NP0004) in 
NuPAGE™ LDS Sample Buffer (4X) 
(Invitrogen™, NP0008) 
Protein samples (cell 
lysates) loading on 4-




1x Agarose gel 
preparation and 
running buffer 
 UltraPure™ TBE Buffer, 10X 









0.01% v/v Triton™ X-100 (Sigma-Aldrich, 
X100) in PBSa 
Cells treatment in IF 




5 mg/ml BSA (Sigma-Aldrich, 810533), 
and 0.01% v/v Tween 20 (Sigma-Aldrich, 
P2287) in PBSa  
IF plaque assay- 
blocking of cells before 
immunostaining and 
antibody dilution  
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2.5.1.3. Commonly used reagents 
 





2.2.1. Cell culture techniques 
2.2.1.1. Culturing, passaging, and storage of adherent cells 
Cell lines listed in table 2.1 (section 2.1.1.) were revived from the frozen state by flash 
thawing in 37OC water bath and resuspended in a cell line-specific complete growth media 
listed in Table 2.11 (section 2.1.5.1.) and centrifuged at 325 x g. The supernatant was 
discarded, and the cell pellet resuspended in complete growth media. The cells were 
cultured in 25 cm3 tissue culture flasks, incubated at 37OC inside 5% CO2 incubator until 80 
to 90% confluence attained. Once cells were 80 to 90% confluent, cells were washed with 
sterile PBSa (Table 2.12) solution and covered with 0.25% (w/v) Trypsin - 0.53 mM 
Versene solution (Table 2.11) until cells were detached from the flask surface (detachment 
of cells was confirmed under a bright-field microscope). The trypsinisation was stopped by 
inactivation of Trypsin-Versene solution with the addition of FBS-containing growth media 
and centrifuged at 325 x g before passaging into new culture flasks. All cells used in the 
Sr. 
No. 
Reagent Name Use 
1 
No SDS Gel Loading Dye, Purple 
(6X), (NEB, B7025S) 
1x PCR Samples prepared in a loading 
dye (Agarose gel electrophoresis) 
2 
GelRed™ Nucleic Acid Gel Stain, 
10,000X in Water,  
(Biotium, BT41003) 
Nucleic acid visualisation on agarose gel 
using Bio-Rad Gel Doc™ EZ System 
3 
1 kb Plus DNA Ladder 
(NEB, N3200) 
DNA marker for western blotting 
4 
Precision Plus Protein™ All Blue 
Prestained Protein Standards 
(Bio-Rad, #1610373) 
Protein marker for western blotting 
5 
NuPAGE™ LDS Sample Buffer 
(4X) (Invitrogen™, NP0008) 
Loading buffer of protein samples 
6 
NuPAGE™ Sample Reducing 
Agent (10X)  
(Invitrogen™, NP0004) 
Dithiothreitol (DTT) used to reduce the 
disulphide bonds of proteins and peptides 
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study were frequently tested before cell freezing and after frozen cell revival for 
mycoplasma contamination using MycoAlertTM Mycoplasma Detection Kit (Lonza, LT07-
118) according to the manufacturer’s instructions. 
Every after ten passages, cells were stored in liquid nitrogen tanks. Cells were cultured to 
attain 80 to 90% confluence, trypsinised, and pelleted in sterile 50 ml Falcon tubes. The 
cell pellet was resuspended in freezing media consisting of 90% FBS and 10% dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, DM8418). The cell suspension containing 1 to 3 × 106 
cells/ml aliquoted in cryovials and stored overnight at -80OC in isopropanol filled Mr 
Frosty™ Freezing container (Thermo Scientific™, 5100-0001). Next day, frozen cryovials 
were transferred to the liquid nitrogen tank until further use. 
 
2.2.1.2. Cell counting and cell seeding in culture vessels 
The number of viable cells was counted using a Neubauer Hemocytometer based on dye 
exclusion principle utilising 0.4% trypan blue solution (Gibco™-15250061). Cells were 
diluted ten fold using 0.4% trypan blue solution (10 µl cell suspension with 90 µl 0.4% trypan 
blue solution) before loading 10 µl on the grid of the haemocytometer. Trypan blue dye is 
absorbed only by dying cells due to permeable cell membranes and stains the cell 
cytoplasm blue which differentiate viable cells from dead cells. Viable cells per ml of the 
suspension were counted using the following formula. 
Cells per ml = 
Average no. cells X Dilution factor (10) X Neubauer chamber volume (104) 
Number of Neubauer chambers (4 Big squares) 
 
Viable cell count was used for seeding the cells in various types of culture vessels (plates 
and flasks) for 24 h based on the experimental requirement. 
 
2.2.1.3. Transfection 
Viable cells were seeded in 24- or 12-well plates 24 h before the transfection of plasmid 
DNA to attain 60 to 75% confluence. Plasmid DNA was transfected in cells using Opti-MEM 
I reduced serum media (Table 2.11) and Lipofectamine® 2000 transfection reagent 
(Invitrogen™, 11668019). Plasmid DNA and Lipofectamine® 2000 dilutions were prepared 
using Opti-MEM I media according to the manufacturer’s instructions. Transfection mixture 
(plasmid DNA+ Lipofectamine + Opti-MEM I) was incubated for 30 minutes at room 
temperature to facilitate DNA uptake and condensation inside the micelle (Lipofectamine). 
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Cells to be transfected were washed with sterile PBS and replenished with 5% FBS 
containing antibiotic-free transfection media (Table 2.11), the transfection mixture was 
added onto cells drop by drop covering the culture plate surface area. Cells were incubated 
at 37OC inside 5% CO2 incubator. The media replaced with complete growth media (Table 
2.11) 6 to 8 hpi. The list of plasmids used in this PhD project are presented in Table 2.14. 





Plasmid Name Gene expression 
1 pEFplink.2-V5 Empty (Steve Goodbourn's Lab) Empty 
2 pEFplink.2-V5/NP (Cloned in this PhD) NDV-NP 
3 pEFplink.2-V5/P (Cloned in this PhD) NDV-P 
4 pEFplink.2-V5/M (Cloned in this PhD) NDV-M 
5 
pEFplink.2-V5/V (Cloned by Manoja Rasamanikkam, 
PhD, Pirbright Institute) 
NDV-V 
6 pEFplink.2-V5/F (Cloned in this PhD) NDV-F 
7 pEFplink.2-V5/HN (Cloned in this PhD) NDV-HN 
8 pcDNA3.1(+) EGFP (AVO Group, Pirbright Institute) EGFP only 
9 pcDNA3.1(+) EGFP/HN (Cloned in this PhD) NDV-HN and EGFP 
10 
pAT016 (mito-mRFP-EGFP) (provided by PD Dr Andreas 
Till, University of Bonn, Germany) 
In frame expression of RFP and 
EGFP 
11 pBABEpuro-HA-p62 (Addgene, 71305) p62/SQSTM1 
12 
pLV01 (All in one lentiviral vector from Sigma-Aldrich), 
three plasmids expressing different gRNA targeting 
p62/SQSTM1 pLV01-p62-18, pLV01-p62-19, and pLV01-
p62-20 
Guide RNA (gRNA) targeting 
SQSTM1, Puromycin N-
acetyltransferase (PAC), Cas9, 
and GFP) 
13 
pGEM-T SV40 Renilla PolyA MfeI 
(AVO Group, Pirbright Institute) 
Renilla luciferase from sea 
pansy (Renilla reniformis) 
14 pNiFty-Luc (Dalan Bailey lab, Pirbright Institute) 
ELAM proximal promoter, five 
NF-κB repeated transcription 
factor binding sites (TFBS) and 
a Luc reporter gene.  
(Firefly luciferase from beetles 
Photinus pyralis)  
15  
SQSTM1 1 nanomole siRNA (siRNA ID s16962, Ambion) 
Sense strand: 5’CUUCCGAAUCUACAUUAAAtt 3’ (21) 
Antisense: 3’UUUAAUGUAGAUUCGGAAat 5’ (21) 
siRNA transfection to 
knockdown p62/SQSTM1 in 
Caco-2 cells 
16 
Silencer™ Negative Control No. 1 siRNA 
(Invitrogen™, AM4611) 
Negative control for siRNA 
silencing 
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2.2.1.4. Cell viability and cell toxicity assay 
For both the cell viability and cell cytotoxicity assays, 1 x 105 cells were plated per well of a 
96-well plate for all the treatments 24 h before the virus infection studies. Promega 
GloMax® Explorer multimode microplate reader was used to read the plate. 
A) Cell Viability Assay  
Viability of NDV-infected cells was measured using CellTiter-Blue® Cell Viability Assay 
(Promega, G8080) comparative to the mock-infected control cells. The cell viability assay 
was performed according to the manufacturer’s instructions. The principle of the assay was 
based on the metabolic conversion of resazurin in fluorescent resorufin by viable cells 
(Figure 2.2). The fluorescence was measured at 590 nm. The fluorescence was directly 
proportional to the number of viable cells.  
Human cancer cells ( Table 2.1) were plated at 1x 105 cells per well in 96-well plates and 
cultured at 37OC inside 5% CO2 incubator. Once cells were 90% confluent they were 
infected with ten-fold dilutions of NDV strains mentioned (Table 2.2) and incubated until 
different time points (0 to 6 dpi and 9 dpi) post-infection. Cell viabilities were measured by 
adding 20 µl of CellTiter-Blue® reagent to 100 µl growth medium in each well of a 96-well 
plate. The plates were incubated 4 to 6 h at 37OC inside 5% CO2 incubator, before 
measuring the fluorescence in the plate reader. 
Measured cell viabilities were converted in viability fraction; the viability fraction was 
calculated using the following formula.  
 
 
Note: fluorescence readings were normalised with blank reagent controls. 
Viability Fraction = 
Normalised fluorescence reading of infected cells at (560Ex/590Em) 
Normalised fluorescence reading of uninfected cells at (560Ex/590Em) 




Figure 2.2. Viable cells metabolically convert resazurin to resorufin (Taken from 
Promega protocol). Metabolically active cells reduce resazurin substrate into a fluorescent 
product resorufin in up to 4 to 6 h incubation at 37OC inside 5% CO2 incubator. The 
fluorescent resorufin measured at 590 nm using Promega GloMax® Explorer Multimode 
Microplate Reader. The fluorescence produced is proportional to the number of viable cells. 
 
 
B) Cell death assay 
Cell death induced by NDV infection was measured using CellTox™ Green Cytotoxicity 
Assay (Promega, G8741). The principle involved in cytotoxicity assay was based on the 
changes in the membrane integrity of dying cells. A proprietary asymmetric CellTox™ 
Green DNA binding cyanine dye was taken up by dead cells, excluding the living cells as a 
result of a disruption in membrane integrity. The dye binding to the dead cell DNA resulted 
in the enhanced and robust fluorescent signal, which was measured at 520–530 nm. The 
fluorescent signal produced by the dye-bound dead-cell DNA was directly proportional to 
cytotoxicity in the cells. Caco-2 and VR Caco-2 cells were infected with NDV strains (Table 
2.2) at 0.1 MOI for 4 days. End-point cytotoxicity assay was performed using the 
manufacturer’s instructions in NDV-infected cells. The fold change in cytotoxicity was 




Fold change cytotoxicity = 
Cytotoxicity of NDV-infected cells normalised with blank reagent 
Cytotoxicity of mock-infected cells normalised with blank reagent 
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2.2.1.5. Caspase-3/7 activity assay 
The NDV-induced apoptotic activity was measured in NDV-infected Caco-2 and VR Caco-
2 cells by using Caspase-Glo® 3/7 assay (Promega, G8090). Both cells were plated at 1 x 
105 cells per well in a 96-well plate for 48 h before infection to ensure 90% confluence. Cells 
were infected with NDV strains (Table 2.2) at MOI (discussed in section 2.2.2.6)  of 1 for 
24 h. Both cells were treated with 10 µM Staurosporine (Sigma-Aldrich, S5921) as a 
positive control for 8 h before the addition of Caspase-Glo® 3/7 reagent. The assay was 
performed as per manufacturer’s instructions; plates were incubated for 30 minutes in the 
dark before reading the luminescence (in relative light units (RLU)) on Promega GloMax® 
Explorer multimode microplate reader.  
The luminescence produced was directly proportional to the caspase 3 and 7 activity in the 
cells.  
2.2.1.6. Luciferase assay 
The pNiFty-Luc is an NF-ΚB-inducible luciferase reporter plasmid, which expresses 
transcription factor binding sites (TFBS) regulated by NF-kB-specific endothelial cell-
leukocyte adhesion molecule (ELAM-1) promoter. Nuclear factor NF-kB gets activated by 
various PRRs stimulated by PAMPs. The NF-kB transcription factor is composed of p65 
and p60 subunits, which bind to TFBS and induce firefly luciferase activity. The luciferase 
activity is directly proportional to induction of NF-kB in the cells. Renilla luciferase was used 
as a control for firefly luciferase mediated NF-kB induction. 
The NF-kB activity was measured in the uninfected Caco-2 cells, NDV-infected Caco-2 and 
VR Caco-2 cells using Dual-Glo® Luciferase assay system (Promega, E2940). All cells 
were transiently co-transfected with pGEM-T SV40 Renilla and pNiFty-Luc plasmids (Table 
2.14) in 1:2 ratio using Lipofectamine® 2000 transfection reagent (section 2.2.1.2.) for 48 
h. Caco-2 cells were infected with B1-GFP NDV strain at MOI of 5 for 18 h. All the cells 
were lysed using Dual-Glo® Luciferase reagents, and the dual-luciferase assay was 
performed according to the manufacturer’s instructions. The luminescence of firefly and 
renilla luciferases sequentially measured (in RLU) using the Promega GloMax® Explorer, 
multimode microplate reader.  
 The NF-kB activity was calculated using the following formula. 
 




Firefly luciferase of sample - Firefly luciferase of blank 
Renilla luciferase of sample – (Firefly + Renilla) luciferase of 
blank 
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2.2.1.7. Cell proliferation assay 
Cell proliferation assay in Caco-2 and VR Caco-2 cells was measured based on CFSE dye 
dilution principle in dividing cells using the CellTrace™ CFSE cell proliferation Kit, 
(Invitrogen™, C34570) and flow cytometry analysis of CFSE labelled cells at 488 nm.  
Both cell lines were cultured in T-25 tissue culture flasks, incubated at 37OC inside 5% CO2 
incubator until 80 to 90% confluence attained. Cells were trypsinised and centrifuged at 
325 x g, and cell pellets were washed with serum-free MEM media. Cell pellets were 
resuspended in serum-free MEM media. Suspended cells were mixed with 5 µM CFSE 
buffer (5 µl of 10 mM CFSE stock in 10 ml of serum-free MEM media) to maintain 1 x 106 
cells/ml in 2.5 µM CFSE buffer. Cells in CFSE buffer were in incubated in 37OC water bath 
for 15 minutes to label DNA. CFSE labelled cells were washed with serum-free MEM media 
and resuspended in complete growth media (Table 2.11) at 37OC water bath for 1 h. Cells 
were washed again and resuspended in complete media. Cells were plated in 24 well plates 
at 5 x 105 cells/well and incubated at 37OC inside 5% CO2 incubator. Cells were collected 
at five different time points 0, 12, 24, 48, and 72 h of post CFSE labelling. The fluorescence 
of CFSE cells was measured at each time point using MACSQuant Analyzer (Miltenyi 
Biotec).  
Cell proliferation of Caco-2 and VR Caco-2 cells was also monitored using the IncuCyte 
Live-cell Analysis system (Sartorius) in real-time. Both types of cells were seeded in 96-
well plates at different seeding densities (5k/well, 10k/well, and 15k/well) and cell 
proliferation was observed by taking an account of cell confluence at different time points. 
 
2.2.1.8. Indirect immunofluorescence (IF) assay 
Indirect immunofluorescence staining approach was used to detect the expressions of NDV 
proteins (NP, P, M, V, F, and HN) and endogenous expression of p62/SQSTM1 protein in 
Caco-2 and VR Caco- 2 cells. Cells were either transiently transfected  with p62/SQSTM1 
expressing plasmidsor were infected with NDV.  
For IF staining, cells were cultured on coverslips (13 mm diameter) in a 24-well plate to 
attain 50 to 60% confluence before transfection or infection. Cells with or without virus 
infection and with or without plasmid transfection were fixed using cold 4% PFA (Table 
2.12) for 1 h at room temperature. Fixed cells were permeabilised by treating cells with 
0.1% Triton X100 PBSa buffer (Table 2.12) for 15 minutes. Cells were blocked with 0.5% 
BSA blocking buffer (Table 2.12) for 1 h at room temperature and stained with respective 
primary antibody (1:1000) listed in Table 2.9 for 1 h at room temperature on a rocking 
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platform. Primary antibody-treated cells were washed three times with PBSa and then 
treated with respective Alexa Flour 488/568 secondary antibodies (1:500) (Table 2.10) for 
45 minutes at room temperature on a rocking platform in the dark and finally washed again 
with PBSa three times. Coverslips were then mounted carefully on grease-free glass slides 
using VECTASHIELD® (Vectorlabs, H-1200), the mounting medium containing nucleic 
acid stain DAPI. Treated cells were imaged using the confocal microscope with a Leica 
application suite (LAS) software for imaging (Leica, UK). 
2.2.1.9. siRNA mediated to knockdown  
The RNA interference (RNAi) approach was used in silencing sqstm1 mRNA transcript, 
which encodes p62/SQSTM1 adapter protein involved in the selective mitophagy and 
tumorigenesis.  
Caco-2 cells were plated at 5 x 105 cells in a 24-well plate, 24 to 36 h before transfection 
to ensure 60 to 70% cell confluence. A 21-nucleotide long small interfering RNA (siRNA) 
targeting sqstm1 mRNA and negative control siRNA were transfected in Caco-2 cells using 
Lipofectamine® 2000 transfection reagent (Table 2.14). Three different concentrations 25 
nM, 50 nM, and 100 nM prepared from 20 µM siRNA stocks in Opti-MEM I media; 0.5 % 
Lipofectamine® 2000 transfection reagent prepared in used Opti-MEM I media as 
mentioned in Table 2.15. The mixture of siRNA, Lipofectamine® 2000, and Opti-MEM I 
media incubated at room temperature for 30 minutes. Cells were washed with PBSa and 
replenished with 200 µl of antibiotic-free 5% FBS supplemented DMEM media. The 
transfection mixture was added drop by drop on the top cells and incubated at 37OC inside 
5% CO2 incubator. The media replaced with complete growth media (Table 2.11) 6 to 8 hpi 
and incubated for 24 to 48 h at 37OC. 
 
Table 2.15: siRNA transfection mixture preparation 
Sr. 
No. 
Reagent Mixture A in µl     
per well 
Mixture B in µl per 
well Final siRNA concentration 
for 300 µl (100 µl 
transfection mixture + 200 µl 
antibiotic-free 5% FBS 
transfection media) 
1 Opti-MEM 50 50 
2 Lipofectamine 
2000 




20 µM siRNA 
 
1.5 - 100 nM 
0.75 - 50 nM 
0.375 - 25 nM 
4 Incubate mixture A and B at room temperature for 5 minutes 




2.2.1.10.  CRISPR/Cas9 KO 
CRISPR/Cas9 uses RNA guided target-specific editing of the gene of interest through Cas9 
(DNA endonuclease) enzyme upstream to PAM (protospacer adjacent motif) associated 
with the target DNA sequence. 
CRISPR/Cas9 based KO of sqstm1 gene encoding p62/SQSTM1 protein in human cells 
was accomplished by using an all-in-one lentiviral vector pLV01 (Sigma-Aldrich). The 
pLV01 encoded guide RNA (gRNA) targeting sqstm1under mammalian U6 promoter and 
puromycin N-acetyltransferase (PAC), Cas9, and GFP under EF1a promoter (vector map 
shown in Figure 2.4B). Three pLV01 vectors expressing different gRNAs were ordered to 
KO the sqstm1 gene (list of gRNAs ordered shown in Figure 2.4A) in HEK-293 and Caco-
2 cells. All three sqstm1 targeting plasmids were transformed in high-efficiency NEB® 
stable, competent E. coli cells (section 2.2.3.5.3.)  and then plasmids purified using 
QIAGEN plasmid purification kit (section 2.2.3.6.). 
Caco-2 and HEK-293 cells were plated at 1 x 106 cells/ml in a 6-well plate and incubated 
at 37OC inside 5% CO2 incubator. Cells were washed with PBSa after 70 to 80% confluence 
was attained and transfected with a lentiviral vector pLV01using Lipofectamine® 2000 
transfection reagent and Opti-MEM I media (section 2.2.1.3.). Transfected cells were 
incubated at 37OC for 48 to 72 h before puromycin (Sigma-Aldrich, P8833) selection in 
Caco-2 and HEK-293 cells. Puromycin concentrations was optimised by kill curve in both 
the cell lines, 2.5 µg/ml and 5 µg/ml puromycin concentrations to select transfected HEK-
293 and Caco-2 cells, respectively. Puromycin selection and GFP expression qualitatively 
confirmed the expression of gRNA and Cas9 genes in transfected cells. Puromycin 
selected GFP positive cells were serially diluted to get 1 cell/ml in complete growth media 
and plated in 24 well plate to grow single-cell clones of gRNA and Cas9 expression system. 
Single cells were incubated at 37OC in 5% CO2 incubator until cells were grown as colonies, 
which were then trypsinised and cultured in a new 24-well plate with fresh complete growth 
medium. Single-cell clones were tested for sqstm1 KO by IF staining and confocal imaging, 
western blotting and PCR amplification methods. 
5 Mixture B was added to the mixture A (siRNA + Lipofectamine® 2000 + Opti-MEM I 
media), incubate the mixture at room temperature for 30 minutes. 




Figure 2.3. The strategy of lentiviral vector-based CRISPR/Cas9 KO of p62/SQSTM1. 
(A) Sequences of guide RNAs (gRNA) to knockout human p62/SQSTM1 transcripts. (B) 
Lentiviral pLV01 vector map showing all-in-one custom gRNA expression plasmid provided 
by Sigma-Merck expresses gRNA under mammalian U6 promoter and Cas9, GFP, and a 
puromycin N-acetyltransferase (PAC) under EF-1a promoter. 
 
2.2.2.  Virology techniques 
2.2.2.1. Propagation of virus 
A)  NDV propagation 
NDV strains listed in Table 2.2, were propagated in 10-day-old specific pathogen-free 
(SPF) embryonated eggs (Valo Biomedia GmbH). Eggs were candled to check the viability 
of the embryo and to mark the air sac before virus inoculation. Viable eggs were disinfected 
with 70% ethanol, and a hole was punctured on the top of the air sac. Then 100 µl of virus 
dilution (1:1000 virus dilution in sterile PBSa) inoculated in the allantoic cavity through 1 ml 
syringe using 22 G needle passing through the chorioallantoic membrane in 45O angle. 
Inoculated eggs were incubated in 60% humidified incubator at 37OC on the egg turner for 
72 h. After incubation, eggs were euthanised by chilling in the refrigerator for at least for 4 
h to overnight. The allantoic fluid and amniotic fluid was harvested and pooled together 
from the eggs. The combined virus was centrifuged at 3000 x g for 20 to 30 minutes at 4OC; 
the cleared virus was aliquoted in 1ml volume into cryovials and stored in -80OC. 
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B) Vesicular stomatitis virus (VSV) propagation 
VSV tagged with EGFP was grown in the cell culture. Caco-2 cells were cultured in 75 cm3 
tissue culture flask and at 37OC inside 5% CO2 incubator to attain 90% confluence. Then 
cells were infected by adding 1 ml of virus dilution (1:1000 virus dilution in sterile PBSa) 
into culture flask, and infected cells were incubated at 37OC inside 5% CO2 incubator for 
24 h. Cell supernatant was harvested and centrifuged at 3000 x g for 20-30 minutes at 4OC; 
the cleared virus was aliquoted in 1ml volume into cryovials and stored at -80OC. 
 
2.2.2.2. Confirmation of virus by haemagglutination assay (HA) 
Haemagglutination assay (HA assay) was used to confirm NDV propagation in the viable 
embryonated eggs. A two-fold serial dilution of the virus in PBSa was achieved in a V-
bottom 96-well plate (Greiner Bio-One) using a multichannel pipette. In a V-bottom 96-well 
plate, each well contained 50 µl of each two-fold dilution of virus (from neat virus, 1:2, 1:4, 
up to 1:1024) in triplicates. Similarly, 50 µl of PBSa and allantoic fluid from PBS-inoculated 
eggs were used as controls for the assay. Then 50 µl of 1% chicken red blood cells (cRBCs) 
(from Pirbright animal facility) prepared in PBS was added to the V-bottom 96 well plate 
followed by 1 h incubation at 4OC or on ice. Haemagglutination was observed as a result 
of NDV-HN protein binding to the sialic acid receptors on cRBCs in the form of the immobile 
lattice at the bottom of the plate, whereas in case of PBS and allantoic fluid cRBCs settled 
at the bottom were mobile. HA assay was also used to calculate HAU (haemagglutinating 
units) based on last virus dilution showing hemagglutination in the V-bottom 96-well plate. 
 
2.2.2.3. Receptor binding avidity assay 
Receptor binding avidity assay was used to determine the affinity of the NDV-HN protein 
to the host cell sialic acid receptors by using the α2-3,6,8 neuraminidase (NEB, P0720S) 
enzyme. The α2-3,6,8 neuraminidase enzyme isolated from Clostridium perferingens 
cleaves α2-3, α2-6 and α2-8 linked N-acetyl-neuraminic acid (sialic acid residues) from 
glycoproteins and oligosaccharides. cRBCs were treated using different enzyme units of 
α2-3,6,8 Neuraminidase. Initially, two-fold dilutions of α2-3,6,8 neuraminidase enzyme 
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Table 2.16: Two-fold dilutions α2-3,6,8 neuraminidase enzyme in PBSa 
Dilution 
α2-3,6,8 neuraminidase 
(50,000 U/ml) in μl 
PBS in μl 
Final conc. 
of in U/ μl 
1:2 2.5 2.5 25 
1:4 2.5 of (1:2) 2.5 12.5 
1:8 2.5 of (1:4) 2.5 6.25 
1:16 2.5 of (1:8) 2.5 3.125 
1:32 2.5 of (1:16) 2.5 1.5625 
1:64 2.5 of (1:32) 2.5 0.78125 
1:128 2.5 of (1:64) 2.5 0.390625 
 
1 ml of 10% cRBCs were treated with different α2-3,6,8 Neuraminidase units, as shown in 
Table 2.17. 
Table 2.17: α2-3,6,8 Neuraminidase enzyme in units used for cRBCs treatment 
α2-3,6,8 neuraminidase 
(50,000 U/ml) stock added 
Estimated final concentration of α2-3,6,8 
neuraminidase (in U) in 1 ml of 10% cRBCs 
10 μl (from stock) 500 U 
5 μl (from stock) 250 U 
2.5 μl (from stock) 125 U 
2.5 μl (from 1:2) 62.5 U 
2.5 μl (from 1:4) 31.25 U 
2.5 μl (from 1:8) 15.6 U 
2.5 μl (from 1:16) 8 U 
2.5 μl (from 1:32) 4 U 
2.5 μl (from 1:64) 2 U 
2.5 μl (from 1:128) 1 U 
 
α2-3,6,8 Neuraminidase treated 10% cRBCs were incubated in 37OC water bath for 2 h 
with intermittent mixing every 15 minutes to ensure homogenous enzyme treatment of 
cRBCs. In the meantime, viruses to be tested for NDV-HN receptor binding avidity assay 
for sialic receptors expressed on cRBCs were titrated using HA assay (section 2.2.2.2.), 
for each virus, HAU was maintained at 4 HAU per 50 µl volume. Two hours later, treated 
cRBCs were washed with PBSa and resuspended to 10 ml to get 1% cRBCs. All treated 
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cRBCs at α2-3,6,8 neuraminidase mentioned in Table 2.17 were used for HA assay in 
triplicate using 4 HAU per 50 µl of the virus. The negative control with PBSa for each treated 
cRBCs was used. The highest α2-3,6,8 neuraminidase unit treated cRBCs showing 
haemagglutination was recorded as an indication of affinity to partially desialylated cRBCs. 
 
2.2.2.4. Virus infection 
Cells were plated in desired cell culture plates (96-well, 24-well, 12-well or 6-well plates) at 
a required seeding density of cells to attain >90% confluence on the day of infection. For 
cell infections, virus stock was diluted in cold serum-free media. Cells were washed with 
PBSa before infection, and then the volume of virus dilution was added to each well on top 
of the cells depending upon the culture vessel (0.05 ml for 96-well plate, 0.25 ml for 24-well 
plate, 0.5 ml for 12-well plate or 1 ml for 6-well plate) to cover the surface area and uniform 
distribution of virus throughout the plate. Infected cells were incubated at 37OC inside 5% 
CO2 incubator for 1 h. Cells were washed with PBSa after 1 h of incubation to remove the 
unattached virus particles and replaced with either 1 ml of complete growth media or plaque 
assay 0.8% methylcellulose overlay media (Table 2.11). 
Cells infected with the reporter viruses (Table 2.2) were imaged in real-time using the 
IncuCyte Live-cell Analysis system (Sartorius) to monitor the virus replication as indicated 
by the expression of the reporter protein (GFP). 
 
2.2.2.5. Virus titration using plaque assay 
Plaque assay methods for NDV and VSV in chicken DF-1 and human Caco-2 cells are 
discribed below. Plaque forming units per ml (PFU/ml) of both the viruses were calculated 
using the below formula. 
PFU/ml = Average no. of plaques / (D x V) 
D = Dilution factor of virus used to count the number of plaques 
V = Volume of virus dilution used in the infection 
A) NDV plaque assay 
NDV plaque assays were carried in chicken DF-1 cells and human Caco-2 cells (Table 2.1) 
in a 24 well plate. Ten-fold virus dilutions were used in the infection, and cells were infected 
as described in section 2.2.2.4. For the plaque assay, 0.8% methylcellulose overlay media 
was used (Table 2.11). Infected plates were incubated for 7 days at 37OC inside 5% CO2 
incubator. The infected cells were fixed by adding 1 ml of cold 4% PFA (Table 2.12) 
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overnight and plates were kept at room temperature in a closed container inside the fume 
hood. The plaque assay overlay media with 4% PFA was discarded, and cells were washed 
with PBSa four times to remove contents of media and cell debris. Fixed cells were 
permeabilised with 0.1% Triton X100 PBSa solution (Table 2.12) for 15 minutes and then 
blocked with blocking buffer (5 mg/ml BSA and v/v 0.01% Tween 20 in PBSa, Table 2.12) 
for 1 h at room temperature. Cells were treated with the anti-NDV chicken sera (Table 2.9) 
(1:2000 dilution prepared in the blocking buffer) for 1 h at room temperature on the rocking 
plate. Cells probed with anti-NDV chicken sera, were washed for three times with PBSa 
five minutes each. Then cells were incubated with secondary fluorescent donkey IRDye® 
800CW anti-Chicken antibody (Table 2.10) for 45 to 60 minutes in the dark on the rocking 
plate. Finally, cells were washed with PBSa three times for five minutes each in the dark. 
Stained plates were read using the Odyssey® CLx Imaging System (LI-COR) and analysed 
using Image Studio Lite software (LI-COR) for the detection of plaque-forming units. 
 
B) VSV-GFP plaque assay 
VSV-GFP plaque assays were carried in chicken DF-1 cells and human Caco-2 cells (Table 
2.1) in a 12 well plate. Ten-fold virus dilutions were used to infect the cells (section 2.2.2.4). 
For the plaque assay, 0.8% methylcellulose overlay media was used. Infected plates were 
incubated for 3 days at 37OC inside 5% CO2 incubator in an upright position. The cells in 
infected plates were fixed by adding 1 ml of cold 4% PFA (Table 2.12) for overnight and 
plates were kept at room temperature in a container inside the fume hood. The plaque 
assay overlay media with 4% PFA was discarded, and cells were washed with PBSa four 
times to remove contents of media and cell debris. Fixed cells were stained with 0.1% 
crystal violet (Sigma-Aldrich, C0775) solution prepared in 20% methanol for 1 to 2 h. 
Stained cells were washed under running tap water to visualise the plaques. 
 
2.2.2.6. Multiplicity of infection (MOI) calculation 
The multiplicity of infection (MOI) is a critical aspect to control and estimate the number of 
virus particles entering the host cell in virus-infection studies. The plaque-forming unit 
(PFU) is a measure of the number of an infectious virus particle, which used in the 
calculation of MOI.  
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For virus-infection studies in this PhD project, the volume of virus dilution or stock was 
calculated to achieve infection at required MOI by using the following formula. 
 
2.2.2.7. Use of flow cytometry to quantify virus infection 
Caco-2 and VR Caco-2 cells were infected with different reporter viruses listed in Table 
2.2. The cells were infected (section 2.2.2.4.) with NDV reporter viruses (B1-GFP and 
LaSota-GFP), avian influenza reporter virus (H9N2-GFP), and VSV-GFP at MOI of 0.1 
(calculated as mentioned in section 2.2.2.6.). Cells were trypsinised after 48 hpi and fixed 
with 4% PFA for 1 h at room temperature. After fixation cells were washed and resuspended 
in cold PBSa to measure GFP intensity at 488 nm using MACSQuant Analyzer. The 
fluorescence intensity of GFP was directly proportional to the % of reporter virus replication 
in the cells. 
 
2.2.3. Molecular techniques 
2.2.3.1. DNA Extraction 
DNA was extracted from sqstm1 KO HEK-293 cell clones and HEK-293 cells using DNeasy 
Blood & Tissue Kit (Qiagen, 69504) according to the manufacturer’s protocol. Genomic 
DNA was eluted using 100 µl of AE buffer. 
 
2.2.3.2. Polymerase chain reaction (PCR) amplification 
Polymerase chain reactions were used to amplify genes of interest with gene-specific 
primers using Q5® High-Fidelity 2X Master Mix (NEB, M0492). Gene-specific forward and 
reverse primers (section 2.1.3.) 1.25 µl each, and 10-100 ng DNA was added to 12.5 µl of 
Multiplicity of infection (MOI) = 
PFU/ml of virus used in the infection 
Number of cells to be infected 
Volume of virus 
dilution or stock 
= 
MOI to be achieved X Number of cells to be infected  
PFU/ml count of the virus 
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2X master mix. The reaction volume was made up to 25 µl using nuclease-free water. 
Thermal cycling conditions were set according to the manufacturer’s instructions, and 
annealing temperatures were calculated using the NEB Tm calculator. All PCR products 
were separated by agarose gel electrophoresis (section 2.2.3.3.). 
 
2.2.3.3. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA; 0.5% to 2% agarose gels were 
prepared in 1x Tris/borate/EDTA (TBE) (Table 2.12) buffer depending upon the size of DNA 
fragments. DNA samples were prepared in 6x purple gel loading dye and 1 kb Plus DNA 
ladder (Table 2.13) was loaded on the gel with samples for identification of separated DNA 
fragments. A DNA binding dye GelRed™ was added in the gel for DNA visualisation. DNA 
gel was run at between 80-100V using 1x TBE buffer (Table 2.12). A Gel Doc™ EZ Imager 
(Bio-Rad) was used for DNA gels using the ‘GelRed’ setting. 
 
2.2.3.4. PCR product purification and Gel extraction 
All PCR products used for sequencing and cloning preparations were cleaned up by using 
QIAquick PCR Purification Kit (Qiagen, 28104) and DNA fragments of interest were 
extracted from agarose gel by using QIAquick Gel Extraction Kit (Qiagen, 28704).  
Manufacturer’s protocols were used for PCR product clean up, and DNA extraction from 
agarose gel, DNA was eluted in 25-50 µl volume using elution buffer. Eluted DNA samples 
were quantified using NanoDrop Lite Spectrophotometer (Thermo Scientific). 
 
2.2.3.5. Gene cloning 
NDV genes were cloned using conventional restriction digestion of insert DNA and vector 
DNA, followed by ligation of complementary ends of the insert with self-replicating vector 
DNA before transformation in competent E. coli cells. NDV genes (NP, P, M, F, and HN) 
were PCR amplified using cloning primers mentioned in Table 2.4 as described earlier in 
section 2.2.3.2, and gel extracted and purified as specified in 2.2.3.4. 
 
2.2.3.5.1. Restriction digestion 
All PCR amplified and gel purified NDV genes and expression vectors pEFplink2.V5 and 
pcDNA3.1(+) EGFP were used for restriction digestion. NDV genes NP, P, M, F, and HN 
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were cloned into pEFplink.2-V5 and NDV-HN gene was also cloned into pcDNA3.1(+) 
EGFP vector. Both the vectors were double digested with restriction enzymes based on the 
insert restriction sites, mentioned in Table 2.4. High-fidelity restriction enzymes (RE) were 
purchased from NEB. Double-digestion of 1 µg vector DNA and 500 ng of PCR products 
were performed overnight at 37OC using manufacturer’s protocol. RE digested vector DNAs 
were gel electrophoresed to confirm the complete digestion. All RE treated products were 
purified using either PCR clean-up kit (PCR products) or gel extraction purification kit 
(vector DNAs) as (section 2.2.3.4.). Restriction digestion used here generated sticky-end 
products. 
 
2.2.3.5.2. T4-DNA ligation 
Respective NDV inserts and vector DNA pairs were ligated using T4 DNA ligase (NEB, 
M0202). DNA inserts and vector DNA were mixed in 3:1 molar ratio, calculated using 
NEBioCalculator. A 10 µl ligation reaction was set according to the manufacturer’s 
instructions at 4OC for overnight. 
 
2.2.3.5.3. E. coli transformation 
Ligated recombinant plasmids and plasmids used in this PhD project were propagated 
using bacterial transformation. Highly efficient chemically competent E. coli cells (NEB® 
Stable Competent E. coli, C3040) were used. Briefly, 50 µl of E. coli cells were thawed 
carefully on ice, and 1 to 5 µl of ligation mixture or 100 pg to 100 ng of plasmid DNA was 
added to the cells. Cells and plasmid DNA mix were incubated on ice for 30 minutes, and 
heat-shock treated at 42OC for precisely 45 seconds and chilled on ice for 2 minutes. 
Transformed cells were incubated at 37OC for 1 h on bacterial shaker after addition 250 µl 
pre-warmed of S.O.C. media. Pre-warmed selection L.B. agar plates (Table 2.11) were 
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2.2.3.5.4. Plasmid DNA screening 
Transformed plasmids were screened to detect DNA insert in the expression vector by 
using colony PCR, mini preparation of plasmid DNA, and RE digestion of isolated plasmid 
DNA. 
A) Colony PCR 
Randomly, 10 to 25 colonies were selected from bacterial transformation plates for colony 
PCR to amplify inserted DNA.  Bacterial colonies were used as a source of plasmid DNA; 
colonies were transferred on the new pre-warmed L.B. agar selection plates using sterile 
10 µl tip and with the same tip was used to transfer colony remnants in PCR tube to maintain 
the same source of plasmid DNA in the screening. Cloning primers mentioned in Table 2.4 
were used in colony PCR with GoTaq® Green Master Mix (Promega, M7122). Master mix 
and primers were added to the colony containing a PCR tube and amplified at temperature 
programme as per the manufacturer’s instructions. Final PCR products were separated 
using agarose gel electrophoresis (section 2.2.3.3). 
B) Small-scale plasmid DNA preparation  
Positive screens from colony PCR grown on the screening L.B. selection agar plate was 
selected for plasmid DNA isolation on a smaller scale using the QIAGEN Plasmid Mini Kit 
(Qiagen, 12123). Positive colonies were inoculated in 5 ml of selection L.B. media (Table 
2.11), and cultures were incubated overnight at 37OC in a bacterial incubator. Plasmid DNA 
was isolated according to the manufacturer’s instructions. Plasmid DNA was eluted in 30 
µl volume of elution buffer. 
C) Restriction digestion 
Plasmid DNA isolated from the mini preparations were used to detect DNA insert in the 
vector DNA by restriction digestion. Plasmids were double-digested, as described in 
section 2.2.3.5.1. at 37OC overnight and gel electrophoresed to identify the cut DNA insert 
and linear vector DNA compared to cut and uncut vector DNA. 
 
2.2.3.6. Large-scale plasmid DNA preparation  
Once cloned plasmids were confirmed for the DNA insertion in the vector DNA (section 
2.2.3.5.4.), then confirmed clones were inoculated in 250 ml antibiotic containing L.B. 
media (Table 2.11) and incubated at 37OC on a bacterial shaker overnight for large scale 
isolation of the plasmid DNA. Plasmid DNA was isolated on a large scale by using the 
QIAGEN Plasmid Maxi Kit (Qiagen, 12162). The plasmid DNA was isolated as per the 
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manufacturer’s instructions. The plasmid DNA pellet was dissolved in 0.5 ml nuclease-free 
water and quantified using NanoDrop Lite Spectrophotometer (Thermo Scientific). 
 
2.2.3.7. Plasmid DNA and PCR product sequencing 
Plasmids and PCR products of interest were sequenced using Sanger sequencing services 
provided by Eurofins Genomics (UK). The DNA and primers were prepared as per the 
company’s requirement for sequencing. 
NDV genes cloned in pEFplink.2-V5 vectors were sequenced using pEFplink.2-V5 vector 
primers (forward and reverse) (Table 2.4) and NDV-HN gene cloned in pcDNA3.1(+) EGFP 
vector sequenced using M13 primers (forward and reverse).  
DNA chromatograms were visualised using Flinch TV 1.4.0 (Geospiza), and DNA 
sequences were analysed by using Vector NTI® Express Designer software (Thermo 
Scientific). 
 
2.2.3.8. RNA Extraction 
 
2.2.3.8.1. Total RNA Extraction  
Total RNA was extracted from virus-infected and non-infected Caco-2 cells, Ox-Caco-2, 
A549 cells, and VR Caco-2 cells using the TRIzol™ reagent (Invitrogen™, 15596018).  To 
extract RNA from cells, 0.25 ml of TRIzol™ reagent was added to each well of 12-well plate 
and collected in 1.5 ml microtube. The cells were lysed, pipetted up and down several times 
and incubated for 5 minutes to ensure dissociation of the nucleoprotein complexes. Then 
0.05 ml of chloroform was added to the tube and vortexed vigorously for 10 seconds and 
incubated for 2-3 minutes. The tubes were centrifuged at 12,000 x g at 4OC for 15 minutes. 
The mixture got separated into three layers: top aqueous phase (RNA), interphase, and 
bottom phenol-chloroform organic phase (DNA and proteins). The aqueous phase was 
carefully transferred to RNase-free 1.5 ml microtube and RNA was precipitated by the 
addition of 0.125 ml of isopropanol and incubation for 10 minutes at room temperature. 
Total RNA was pelleted down by centrifugation at 12,000 x g at 4OC for 10 minutes. The 
supernatant was carefully discarded using a micropipette and the pellet was washed with 
0.5 ml of 75% ethanol prepared in RNase-free water at 7500 x g at 4OC for 5 minutes. Then 
the RNA pellet was air-dried after careful discarding of 0.75% ethanol. The air-dried RNA 
pellet was resuspended in 15 to 30 µl of RNase-free water, and RNA was quantified using 
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NanoDrop Lite Spectrophotometer (Thermo Scientific). A ratio of A260/280 of ~2 was 
considered pure enough for SYBR-Green qRT-PCR analysis. 
 
2.2.3.8.2. MicroRNA extraction 
MicroRNA was isolated from NDV-infected, uninfected Caco-2 cells and VR Caco-2 cells 
using miRNeasy Mini Kit (Qiagen, 217004) and QIAzol® Lysis Reagent (Qiagen, 79306). 
The total RNA, including small RNAs, were isolated from the cells according to the 
manufacturer’s instructions. The elution volume 30 to 50 µl RNase free water was used to 
collect the RNA and quantified using NanoDrop Lite Spectrophotometer (Thermo 
Scientific). The total RNA with small RNAs from all three cell types were used to quantify 
miR-155 using TaqMan RT-PCR. 
 
2.2.3.8.3. RNA Quantification 
Isolated total RNA was selectively and accurately measured at the lower concentration for 
sensitive assays using the Qubit™ RNA HS Assay Kit (Invitrogen™, Q32852). RNA 
samples and RNA standards were diluted in Qubit® assay tubes (Invitrogen™, Q32856) 
using Qubit® working solution (Qubit® RNA HS Reagent diluted 1:200 using Qubit® RNA 
HS Buffer) according to the manufacturer’s recommendations. All samples and standards 
were incubated for 2 minutes at room temperature. RNA standards were used to calibrate 
Qubit® Fluorometer (Thermo Scientific). RNA concentrations were calculated using the 
following formula.  
           RNA concentration = QF value × (200 / A) x DF 
Where, QF value = the value given by the Qubit® 2.0 Fluorometer 
             A = the number of microliters of sample added to the assay tube 
                                        DF = dilution factor of RNA  
 
2.2.3.8.4. DNase Treatment 
Isolated total RNA from cells was treated with RNase-free DNase I recombinant enzyme 
(Roche, 04716728001). The reaction mixture was prepared by adding 2U of DNase I per 1 
µg of RNA and 1 µl of 10x reaction buffer (supplied by the manufacturer), made up to 10 µl 
reaction volume with RNase-free water. The reaction mixture was incubated at room 
temperature for 30 minutes. DNase I was heat-inactivated at 75OC for 5 minutes. DNase I 
treated samples were stored at -80OC and used for qRT-PCR or cDNA synthesis. 
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2.2.3.8.5. cDNA synthesis 
Total RNA was isolated from NDV-infected Caco-2 and VR Caco-2 cells (section 
2.2.3.8.1.) and treated with DNase I (section 2.2.3.8.4.). Total RNA was used for cDNA 
preparation, which was used for Sanger sequencing of the NDV genome strategy (section 
2.1.3.3.). Hence NDV fragments were reverse transcribed to generate cDNA from isolated 
total RNA using SuperScript™ III First-Strand Synthesis System (Invitrogen™, 18080051). 
NDV genome was divided into six overlapping fragments; all six fragments were reverse 
transcribed using fragment-specific primers (Table 2.5). Manufacturer’s instructions were 
followed to synthesise all cDNA fragments.  
cDNA fragments were PCR amplified (section 2.2.3.2.) and purified using a gel extraction 
method (section 2.2.3.4.). Purified PCR fragments were sent for Sanger sequencing using 
sequencing primers listed in Table 2.6 and sequences were analysed (section 2.2.3.7.). 
 
2.2.3.9. Quantitative real-time (qRT)-PCR 
 
2.2.3.9.1. One-step SYBR Green qRT-PCR 
One-step SYBR Green qRT-PCR analysis was used to quantify log2 fold changes in IFN-
β, ISG-15 and NDV-M mRNAs in virus-infected Caco-2, Ox Caco-2, A549, and VR Caco-2 
cells. All cells were infected with NDV strains (Hitchner B1 and B1-GFP) at MOI of 5 for 12 
h, with VSV-GFP at MOI of 0.1. All cells were transfected with dsRNA mimic polyinosinic-
polycytidylic acid [poly(I:C)] high molecular weight (HMW) (Invivogen, tlrl-pic) at 0.2 µg/ml 
concentration for 12 h in A549 cells and 24 h in Caco-2 cells. Total RNA was isolated from 
all cells using the TRIzol method (section 2.2.3.8.1.), and total RNA was treated with 
DNase I enzyme (section 2.2.3.8.4.). SuperScript™ III Platinum™ SYBR™ Green One-
Step qRT-PCR Kit (Invitrogen™, 11736051) was used for GAPDH, IFN-β, ISG-15 and 
NDV-M mRNA quantification using the primers listed in Table 2.7. The reaction mixtures 
were prepared according to the manufacturer’s protocol. The thermal cycling programme 
used for cDNA synthesis was 50OC for 3 minutes, hold at 95OC for 5 minutes, followed by 
40 PCR cycles at 15 seconds at 95OC, annealing and elongation at 58 OC and final hold at 
40OC for 1 minute. Melt curve programme was used to ensure primer-specific amplification.  
SYBR Green qRT-PCR data were acquired and analysed using ABI 7500 Fast RT-PCR 
software (Applied Biosystems™). 
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2.2.3.9.2. TaqMan qRT-PCR 
The number of copies of miR-155 was quantified using TaqMan qRT-PCR in Caco-2 cells 
with or without NDV infection and VR Caco-2 cells. MicroRNA isolated from all cells 
(section 2.2.3.8.2.) was used in this assay. The microRNA mimic miR-223-3p was used to 
prepare the standard curve to quantify miR-155 copies. Where 2 µM of miR-223-3p was 
diluted to get 6 x 108 copies/µl. Micro RNAs from all samples along with 6 x 108 copies/µl 
stock of miR-223-3p MicroRNA mimic were reverse transcribed to synthesise cDNA as 
described in following Table 2.18 using TaqMan™ MicroRNA Reverse Transcription Kit 
(Applied Biosystems™, 4366596). The cDNA synthesis was completed using a 
temperature programme of 16OC for 30 minutes and 42OC for 30 minutes and the reaction 
was stopped at 85OC for 5 minutes. Once cDNA synthesis was finished, all cDNAs samples 
were diluted up to 150 µl (135 µl nuclease-free water added); dilution of miR-223-3p mimic 
diluted to give 1 x 108 copies/ µl which then serially diluted ten-times in nuclease-free water 
to prepare dilutions for standard curve 1 x 108 copies/µl up to 1 x 101 copies/µl. The reaction 
mixtures for PCR were prepared in 20 µl volume (for all samples including all the standard 
dilutions) by adding 5 µl cDNA from stocks, 10 µl of 2x PCR master mix, 0.5 µl of TaqMan 
probe specific to miR-155 and miR-223-3p mimic microRNAs (Table 2.8), and 4.5 µl of 
nuclease-free water. The plate was centrifuged at 1000 x g for 2 minutes before loading 
plate into RT-PCR machine. Temperature programme was 50OC for 2 minutes for uracil-N-
glycosylase (UNG) activation (UNG was used for degrading many contaminating carryover 
amplicons), 95OC for 10 minutes for enzyme activation and 40 cycles were set using 95OC 
for 2 minutes (denaturation) and 60OC for 1 minute (annealing and primer extension). 
TaqMan qRT-PCR data were acquired and analysed using ABI 7500 Fast RT-PCR 
software (Applied Biosystems™). The copies of miR-155 were calculated using the 
following formulae. 
 
Y= Slope X + Constant (from standard curve) 
X = (average Ct - Constant) / slope 
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2.2.3.10. Protein analysis 
 
A) Cell lysis of protein sample preparation 
Caco-2 cells were transfected with different plasmids (section 2.2.1.2.), and Caco-2 cells 
were infected with NDV (section 2.2.2.4.), before lysing the cells. Cells were washed with 
ice-cold PBSa and then lysed using 100-150 µl of radioimmunoprecipitation assay buffer 
(RIPA) buffer (Table 2.12) containing 1x Protease Inhibitor Cocktail (Promega, G6521).  
The cells were incubated with RIPA buffer on ice for 30 minutes. Lysed cells were collected 
in 1.5 ml microfuge tube and passed through 25 G needle probed in 1 ml syringe 5-6 times 
to break all the cell debris. To the cell lysates, protein loading buffer (Table 2.13) containing 
1x reducing agent was added before protein reduction. The protein reduction was carried 
out by heating the samples at 98OC for 5 to 10 minutes. Reduced protein samples were 
either stored at -20OC or loaded on a protein gel. 
 
B) Sodium dodecyl sulfate (SDS)- polyacrylamide gel electrophoresis (PAGE) and 
western blotting. 
Denatured protein samples were loaded on 4 to 20% TruPAGE™ Precast Gels (Sigma-
Aldrich, PCG2004) for protein separation along with precision plus all blue protein marker 
(Table 2.13). The SDS-PAGE gel was run at 100 to 120V using 1x TruPAGE buffer (Table 
2.12) for 1 to 2 h until the complete separation of protein markers in the 4% resolving gel. 
The SDS-PAGE gel was then used to transfer separated protein samples from gel to on 
PVDF membrane iBlot™ 2 Transfer Stacks (Invitrogen™, IB24002) using the iBlot 2 Gel 
Transfer Device (Invitrogen™) according to the manufacturer’s instructions. Transferred 
western blot was moved in 10% skimmed milk blocking buffer without any delay (Table 
2.12) for 1 h at room temperature on the rocking plate. Western blot was probed with a 
1:1000 to 1:5000 dilution of primary antibody (Table 2.9) in 5% blocking buffer (Table 2.12) 
targeting separated proteins of interest for overnight at 4OC on a rocking platform. Western 
blot was washed with PBST buffer (Table 2.12.) three times 10 minutes each before 
treating with secondary antibody. Either 1:15000 dilution of secondary IRDye® 680RD or 
IRDye 800CW antibodies (Table 2.10) in 5% blocking buffer was incubated at room 
temperature in the dark on the rocking plate. Finally, western blot was washed in the dark 
with PBST three times for 10 minutes and a last wash in PBS. The membrane was scanned 
using the Odyssey® CLx Imaging System (LI-COR) and analysed using Image Studio Lite 
software (LI-COR). 
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2.2.4. Sample preparation for RNA-seq analysis 
Caco-2 cells were infected with B1-GFP strain at MOI of 0.1 for two-time points 18 h and 
36 h in a 6-well plate (section 2.2.2.4.). Total RNA was extracted from NDV-infected Caco-
2 cells (18 h and 36 h), uninfected Caco-2 cells (3 technical replicates), and VR Caco-2 
cells (3 technical replicates, late passage P-25) using TRIzol method (section 2.2.3.8.1.). 
Total RNA was quantified using Qubit™ RNA HS Assay (section 2.2.3.8.4.), and quality 
was checked using a Bioanalyser 2100 RNA Pico kit (Agilent, San Diego, CA). Amounts of 
RNA were normalised for approximately 200 ng input. Total RNA was enriched for mRNA 
using a polyA enrichment kit (NEB, Ipswich, MA) before sequencing library preparation 
using a NEBNext directional Ultra RNA-Seq kit (NEB, Ipswich, MA). Library QC was 
performed using the Bioanalyser 2100 DNA 1000 kit and Qubit, before pooling.  For NDV 
inocula, the library pools were quantified using a NEBNEXT Illumina library quantitation kit 
(NEB) with APMV-1 universal primers for M gene M+4100 /M-4220, before being diluted 
and loaded onto a High output 150 cycle NextSeq reagent cartridge v2.5 and flow cell for 
(a) 2x75 paired-end sequencing run (b) 1x150 cycle sequencing run. The RNA-Seq 
samples preparation, quality checks, and runs were conducted by the High Throughput 
Sequencing Unit, The Pirbright Institute, UK. 
 
2.2.5. Sample preparation for Mass spectrometry analysis 
Caco-2 cells and VR Caco-2 (late passage P-25) were cultured (three technical replicates 
each) (section 2.2.1.1.) to get 1x107 cells for both the cell types and for all the replicates. 
All cells were washed with PBSa and trypsinised using Versene-Trypsin buffer. The cell 
pellets were rewashed with PBSa and pelleted at 325 x g. All cell pellets were stored in -
80OC and submitted to Dr Stuart Armstrong’s group, at The University of Liverpool for Mass 
spectrometry sample preparation and analysis. Dr Stuart Armstrong provided the protocol 
for Mass spectrometry sample preparation and analysis. 
Caco-2 cell pellets (persistently infected and mock) were lysed in 100 mM TEAB buffer, 
0.1% (w/v) Rapigest detergent (Waters), with complete mini EDTA free protease inhibitor 
(Roche) and Benzonase (25 U/ml, Merck) for 1 h on ice.  Then was followed by 3 cycles of 
sonication on ice (Vibra-cell 130PB sonicator, 20Hz, with microprobe, 10 seconds 
sonication alternating with 30 seconds incubation on ice). The samples were centrifuged at 
13,000 x g for 10 minutes at 4°C and supernatant was removed and retained. Protein 
concentrations of the samples were determined using a Bradford protein assay (Thermo 
Scientific). All samples were normalised to 100 µg total protein with 100 mM TEAB. Proteins 
were reduced with 4 mM DTT (Sigma) at 60°C for 10 miutes and cooled. Then alkylated 
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with 14 mM iodoacetamide (Sigma) at RT for 30 minutes in the dark. All steps were 
performed with intermittent vortex-mixing. Proteomic-grade trypsin (Sigma) was added at 
a protein to trypsin in a ratio of 50:1 and incubated at 37OC overnight. A small aliquot (5 µl), 
was used to check that protein digestion was complete (by SDS PAGE). Rapigest was 
removed by adding TFA to a final concentration of 0.5% (v/v). Peptide samples were 
centrifuged at 13,000 x g for 30 minutes to remove precipitated Rapigest. Peptide samples 
were desalted using Pierce peptide desalting spin columns (ThermoFisher) and evaporated 
to dryness with a centrifugal evaporator (Eppendorf). Each sample was reconstituted in 100 
µl 100 mM TEAB ready for TMT labelling. 
Desalted peptides were labelled with TMT (10 plex) reagents according to the 
manufacturer’s instructions (Thermo). Each 0.8 mg vial of TMT reagent was reconstituted 
in 41 µl of acetonitrile and added to the sample for 1 h at RT. The labelling reaction was 
quenched with 8 µl of 5% hydroxylamine for 15 minutes at RT. An aliquot (5 µl) of each 
sample was pooled for label QC checking. The remaining labelled samples were stored at 
-80°C until analysis. 
The QC samples were acidified with TFA, desalted using Pierce peptide desalting spin 
columns (ThermoFisher), and dried down before reconstitution in 0.1% TFA, 3% methanol. 
The samples were run on the Q-Exactive mass spectrometer to check label incorporation. 
The analysis was performed using PEAKs platform as described below but using 
TMT10plex as a variable modification. TMT label incorporation was >98%.  
Remaining samples were mixed in 1:1:1:1:1:1 ratio and dried down before reconstitution in 
bRPC buffer A (20mM ammonium hydroxide pH 10, 3% acetonitrile). The peptides were 
fractionated (10 fractions) using high pH reverse-phase liquid chromatography (RPLC) 
(column: Agilent Zorbax 80A extend C18, 3.5 µm, 3 x 150mm). 
                                 Table 2.19: Sample TMT Labels 
Sample Name Tag 
1 P51 R1 TMT10_126 
2 P51 R2 TMT10_127N 
3 P51 R3 TMT10_128C 
4 P25 R1 TMT10_129N 
5 P25 R2 TMT10_130C 
6 P25 R3 TMT10_131 
 
LC-MS/MS analysis 
The peptides were analysed by on-line nanoflow LC using the Thermo EASY-nLC 1000 LC 
system (Thermo Fisher Scientific) coupled with Q-Exactive HF mass spectrometer (Thermo 
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Fisher Scientific). The samples were loaded on a trap column (Acclaim PepMap 100, 2 cm 
× 75 μm inner diameter, C18, 3 μm, 100 Å) at 5 μl per minute with an aqueous solution 
containing 0.1% (v/v) TFA and 2% (v/v) acetonitrile. After 3 minutes, the trap column was 
set in-line an analytical column (Easy-Spray PepMap® RSLC 50 cm × 75 μm inner 
diameter, C18, 2 μm, 100 Å) was fused to a silica nano-electrospray emitter (Dionex).  The 
column was operated at a constant temperature of 30°C. The liquid chromatography was 
performed with a buffer system consisting of 0.1 % formic acid (buffer A) and 80 % 
acetonitrile in 0.1% formic acid (buffer B). The peptides were separated using a linear 
gradient of 3.8 to 50% buffer B over 90 minutes at 300 nl/minute flow rate. The Q-Exactive 
HF was operated in data-dependent mode with survey scans acquired at a resolution of 
120,000 at m/z (mass to charge ratio). From the top 10 most abundant isotope patterns 
with charge states +2 to +5 of the survey scan were designated with an isolation window 
of 1.2Th and fragmented by higher-energy collisional dissociation with normalised collision 
energies of 32. MS2 resolution was set at 60,000. The maximum ion injection times for the 
survey scan and the MS/MS scans were 100 and 110 ms, respectively, and the ion target 
value was set to 3E6 for survey scans and 1E5 for the MS/MS scans. Repetitive sequencing 
of peptides was minimised through the dynamic exclusion of the sequenced peptides for 
90 seconds. 
Analysis of MS data 
Spectral data were analysed using the PEAKS studio 10 software (Bioinformatics Solutions 
Inc., Waterloo, ON, Canada) and analysis was based on the method developed by Cox and 
Mann (2008) (217). Tandem MS data were searched against the predicted protein set of 
the human reference genome sequence (Uniprot, 2018), Newcastle disease virus (strain 
Chicken/United States/B1/48) (Uniprot, 2019) and an additional contaminants database 
(cRAP protein sequences, GPM, https://www.thegpm.org/crap/). Search parameters were 
as follows; precursor mass tolerance set to 10ppm and fragment mass tolerance set to 0.02 
Da. Two missed tryptic cleavages were permitted. Carbamidomethylation (cysteine) and 
TMT10plex (Lys, Nterm) were set as fixed modifications and oxidation (methionine) set as 
a variable modification. The false discovery rate was set at 1%. Quantification was 
performed using PEAKS Q. Results were filtered to include only proteins with greater than 
2 unique peptides and a fold change of greater than two-fold (compared to cells group). 
Significant differences were tested by the PEAKSQ method (like Significance B method, 1) 
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2.2.6. RNA-seq data analysis 
Dr Luca Ferretti from Big Data Institute (University of Oxford, UK) analysed the RNA-seq 
data. Briefly, RNA was sequenced from uninfected Caco-2 cells (3 technical replicates), 
NDV-infected Caco-2 cells (18 hpi and 36 hpi at MOI of 0.1), and persistently NDV-infected 
VR Caco-2 cells (3 technical replicates, late passage P-27). For each sample, sequenced 
reads were trimmed using TrimGalore version 0.5 (218) with default parameters to remove 
adapter sequences and low-quality bases before reading (219). Reads shorter than 50 
bases were filtered out (if sequenced using a paired-end (PE) protocol) or 75 bases (if 
single-end (SE)). The remaining reads were then aligned to the concatenation of the human 
genome (GRCH38 release 25) and the NDV B1 genome (AF375823) using the RNA-seq 
pipeline implemented in GEM with default parameters (220). The counts for all transcripts 
in the human and NDV transcriptomes were extracted for each sample using the same 
pipeline with default filtering parameters. The resulting transcriptomic counts were analysed 
for differentially expressed genes (DEGs) using the R package DESeq2 (221) with standard 
parameters and ape-GLM shrinkage for the log2 fold changes (LFCs) (222). Genes 
covered by less than 20 reads across all conditions were excluded from the analysis. All 
other analyses were implemented in R (223). The same pipeline was applied to the analysis 
of the datasets already published from CEF and Caco-2 cells. Statistical over-
representation and enrichment analyses for GO biological processes and Reactome 
pathways were performed using PantherDB (224) and IPA (QIAGEN Inc) (225). 
 
2.2.7. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 8 software. Data obtained from 
NDV-infected Caco-2 and VR Caco-2 cells were analysed with Shapiro-Wilk normality test 
and Two-way ANOVA with Sidak’s multiple comparison test. Paired t-test was used to 
compare receptor binding avidity assay in egg harvested B1-GFP and NDV released in VR 
Caco-2 cells supernatant. Data obtained from qRT-PCR assays were analysed using Two-
way ANOVA with Tukey’s multiple comparison test. The standard error bars were obtained 
from calculated means of three independent readings (mean ±SD), p-value <0.05 was 
considered statistically significant. The symbols represented levels of p-values significance: 
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3 Establishment of a model system to study oncolytic 




NDV is a well-known naturally occurring oncolytic virus; various lentogenic (non-
pathogenic), mesogenic (moderately pathogenic) and velogenic (highly pathogenic) strains 
of NDV have been reported to be oncolytic in a diverse type of cancer cells (94, 132, 146, 
202, 226). The haemagglutinin-neuraminidase (HN) and fusion (F) proteins are the 
glycoproteins embedded in the viral envelope, are responsible for virus attachment and 
fusion activity to facilitate entry into host cells (84).  The HN glycoprotein of NDV tethers to 
sialyl glycoconjugate receptors on the host cell (80, 81). Human cancer cells are known to 
express sialylated glycoconjugates in an unregulated manner (227, 228). NDV interacts 
efficiently with α-2, 3 and α-2, 6 N-linked sialic acids (82, 83) consequently, cancer cells 
derived from various tissues can be targeted to study NDV-induced oncolysis. 
 
NDV is an economically important poultry pathogen known worldwide. More than 250 
species of birds, including poultry, are susceptible to NDV infection. The use of virulent 
strains as oncolytic virus poses some threat to domestic poultry and wild birds and risks 
the environment biosafety (68). Hence in this study, lentogenic (non-pathogenic) strains of 
NDV were used for model establishment. 
 
In this chapter, in vitro model system was established using different lentogenic strains of 
NDV in the most susceptible cancer cell line selected from the panel representing 
neoplastic cells derived from diverse tissue origins. Firstly we focused on using the green 
fluorescent protein (GFP) expressing lentogenic strains of NDV: Hitchner B1-GFP 
(obtained from Peter Palese, Department of Microbiology, Mount Sinai School of Medicine, 
New York (103) and LaSota-GFP (rescued by Manoja Rasamanikkam, The Pirbright 
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3.1.1.  Chapter objectives 
• Identify NDV susceptible human cancer cell line 
• Assess NDV strain-specific oncolysis in susceptible cancer cells 
• Isolate and characterise persistently NDV-infected VR Caco-2 cells 
• Validate persistence of NDV-infection in VR Caco-2 cells  
• Investigate VR Caco-2 cells response to virus infections in comparison with the parental 
Caco-2 cells 






3.2.1. Cell line screening for in vitro NDV-induced oncolysis study 
 
To establish the NDV susceptible cancer cell system, reporter viruses were employed in a 
dose-dependent manner into five different human cancer cell lines derived from different 
tissues such as colon (Caco-2), prostate adenocarcinoma cells derived from metastatic site 
in bone (PC3), lung (A549), liver (Hep G2), cervix (HeLa), and a non-cancerous fibroblast 
continuous cell line derived from healthy human lung (MRC5).  Initially, reporter lentogenic 
strains of NDV: Hitchner B1-GFP and LaSota-GFP were used, which assured easy 
monitoring of viral infection and spread. Neat virus and ten-fold dilutions of both the strains 
were used to infect all the cell lines (section 2.2.2.4.). NDV-induced cell death was 
measured using CellTiter-Blue® Cell Viability Assay (section 2.2.1.4.)  in comparison with 
mock infection to each day in nine day virus killing curve study. The study was carried out 
for three independent times for each virus and each cell line. 
 
In this study, Caco-2 cells, a heterogeneous colorectal cancer cell line derived from the 
large intestine, was identified as a most susceptible to NDV infection, as presented in 
Figure 3.1. The decrease in the cell viabilities of B1-GFP (Figure 3.1.A) and LaSota-GFP 
(Figure 3.1 B) infected Caco-2 cells were demonstrated in a time- and dose-dependent 
manner. The B1-GFP virus infection reduced Caco-2 cell viability >90% within 48 h of neat 
virus infection and a gradual decrease in cell viability was observed in successive ten-fold 
dilutions of B1-GFP infected Caco-2 cells after 48 h of infection (hpi) (Figure 3.1.A).  
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However, LaSota-GFP infection in Caco-2 cells demonstrated a >90% reduction in cell 
viability in all viral doses 9 days post-infection (dpi) (Figure 3.1 B). 
 
PC3 and A549 cells were found to be moderately susceptible to the B1-GFP infection only 
at higher viral doses (neat virus, 10-1, and 10-2 dilutions for PC3 cells and Neat virus, and 
10-1 dilution for A549 cells) (Figure 3.1.A) compared to the LaSota-GFP infection. 
Whereas, HeLa cells remained unaffected by B1-GFP and LaSota-GFP infection 
regardless of viral dose or duration of the infection. Liver cancer Hep G2 cells were 
susceptible only to the B1-GFP neat virus infection within 72 hpi (Figure 3.1 A) and Hep 
G2 cells were unaffected by the successive ten-fold virus dilutions and all the doses of 
LaSota-GFP irrespective of the duration of the infection (Figure 3.1 B).  
 
A decrease in cell viability of non-cancerous human lung fibroblast MRC5 cells was 
observed upon B1-GFP and LaSota-GFP infection (neat virus and 1:10 dilution) within 48 
h. However, increase in the cell viability of MRC5 cells was observed after 5 dpi with 1:10 
dilution of B1-GFP (Figure 3.1 A). A similar trend was found in the LaSota-GFP neat virus 
and its 1:10 dilution infected MRC5 cells (Figure 3.1 B).  Here the decrease in the cell 
viability of virus-infected MRC5 cells with the higher doses (neat virus and its 1:10 dilution) 
of B1-GFP and LaSota-GFP suggested that higher viral doses induced stress for 5 dpi 
(resulting in the decrease in the cell viability) and later cells recovered from viral stress, 
which led to increase in the cell viability measured at 9 dpi, as demonstrated by Figure 3.1.  
 





Figure 3.1. Time and NDV dose-dependent CellTiter-Blue® Cell Viability Assay in different human cancer cells. Cell lines derived from 
different cancerous tissues such as the colon (Caco-2), prostate adenocarcinoma cells derived from the metastatic site in bone (PC3), lung 
(A549), liver (Hep G2), cervix (HeLa) and non-cancerous human lung fibroblast cells (MRC5) were used for the study. These cell lines were 
infected with a neat virus, and its ten-fold dilutions of lentogenic reporter strains of NDV B1-GFP (A) and LaSota-GFP (B) and cell viability was 
measured throughout nine days of infection study. Data (mean ± SD) represented here is the combination of three repeats for each virus and 
each cell line. (Viability fraction is a ratio of normalised fluorescence reading of infected cells to uninfected cells at 560Ex/590Em. Fluorescence 
readings are normalised with blank reagent controls.) 
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3.2.2. Caco-2 cells response to different lentogenic strains of NDV 
 
After establishing the predisposition of Caco-2 cells to B1-GFP and LaSota-GFP viruses, 
further study was focussed on the Caco-2 cells, reporter (B1-GFP and LaSota-GFP), and 
non-reporter (LaSota, and Ulster 2C) lentogenic strains of the NDV. Neat virus and ten-fold 
dilutions of each strain were used to infect Caco-2 cells for 5 days to examine the effect of 
different avirulent NDV strains. Cell death was measured in comparison with the mock 
infection each day for 5 days of infection study. The cell death measurements of virus-
infected Caco-2 cells with all four strains of NDV (B1-GFP, LaSota-GFP, LaSota, and Ulster 
2C) demonstrated the susceptibility of Caco-2 cells to all NDV strains in a dose-dependent 
manner (Figure 3.2). However, the LaSota-GFP virus had delayed response in Caco-2 
cells compared to LaSota strain, as shown in Figure 3.2. Differential response of LaSota 
and LaSota-GFP could be explained by the position of GFP in NDV genome. GFP gene is 
placed at 3 prime end of NP gene in the LaSota-GFP.  Nonetheless, all lentogenic strains 
were oncolytic in Caco-2 cells showing different oncolysis trends. The reporter B1-GFP 
virus was chosen for further studies as it has shown effective oncolysis at all the employed 
doses in a dose-dependent manner and expression of GFP provides easy monitoring of 
the virus replication in infected Caco-2 cells. 
 
Figure 3.2. Time and NDV dose-dependent CellTiter-Blue® Cell Viability Assay in 
Caco-2 cells infected with different avirulent NDV strains. Caco-2 cells infected with a 
neat virus and its ten-fold dilutions of lentogenic reporter strains B1-GFP, LaSota-GFP and 
non-reporter strains LaSota, and Ulster 2C of NDV for five days. Cell death was measured 
for each virus each day separately. Data (mean ± SD) represented here is the combination 
of three independent repeats. (Viability fraction is a ratio of normalised fluorescence 
reading of infected cells to uninfected cells at 560Ex/590Em. Fluorescence readings are 
normalised with blank reagent controls.) 
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Tumour-selective replication of the NDV in Caco-2 cells was confirmed using a low 
multiplicity of infection (MOI) of 0.1 infection assay for four different strains of NDV: Hitchner 
B1, B1-GFP, LaSota, and LaSota-GFP. For this assay, MRC5, Caco-2, and A549 cells 
were infected with each strain at 0.1 MOI (calculated as discribed in section 2.2.2.6.), and 
cell death was measured using CellTiter-Blue® Cell Viability Assay (section 2.2.1.3.). The 
comparison of NDV-infected MRC5 and Caco-2 cells at 5 dpi revealed that non-cancerous 
MRC5 remained unaffected by NDV infection (Figure 3.3 A). The cell viability of MRC5 
cells compared to the Caco-2 cells upon NDV infection has remained significantly higher 
for all NDV strains 5 dpi. NDV-infected MRC5 cells were found stressed under brightfield 
microscope showing poor cell health within 24 h of infection and also decrease in cell 
viability was observed in B1-GFP infected MRC5 cells in a time and dose-dependent study 
(as shown in Figure 3.1 A). The stress of virus infection in healthy MRC5 cells was seen 
as a result of the antiviral response to NDV. Whereas, cancerous Caco-2 cells promoted a 
favourable condition for NDV replication and shown significant oncolysis as a result of virus 
replication indicated by significantly reduced cell viabilities (Figure 3.3).  
 
NDV-induced oncolysis was confirmed to be a cancer cell line-specific characteristic 
demonstrated comparative Caco-2 and A549 NDV infection for 6 days at MOI of 0.1 (Figure 
3.3 B). The relative cell viability assay of A549 and Caco-2 cells with all four NDV strain 
infections have shown significantly higher cell viabilities in the infected A549 cells (**** p< 
0.0001, by two-way ANOVA with Sidak's multiple comparisons test) regardless of the strain.  
 
The Caco-2 cells upon infection with all four NDV strains have confirmed significant 
oncolysis in comparison with A549 and MRC5 cells. These has validated cancer line-
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Figure 3.3. Tumour selective NDV replication in Caco-2 cells. Caco-2, MRC5, A549 
cells infected with lentogenic non-reporter strains Hitchner B1, LaSota, and reporter strains 
B1-GFP, LaSota-GFP at MOI of 0.1. The comparative cell CellTiter-Blue® Cell Viability 
Assay between (A) Caco-2 and MRC5 5 dpi (B) Caco-2 and A549 6 dpi. Data (mean ± SD) 
represented here is the combination of three independent experiments for each virus-
infected cells. Statistical analysis was performed using a Shapiro-Wilk normality test, and 
Two-way ANOVA with Sidak's multiple comparisons test (*** p<0.001 and **** p< 0.0001). 
(Viability fraction is a ratio of normalised fluorescence reading of infected cells to uninfected 
cells at 560Ex/590Em. Fluorescence readings are normalised with blank reagent controls.) 
 
 
3.2.3. Isolation of NDV-resistant VR Caco-2 cells 
In previous experiments, Caco-2 cells were shown to be susceptible to NDV infection 
regardless of the strains. Initial NDV virus killing curve assays were set up for12 days. 
When Caco-2 cells were infected with the B1-GFP virus at higher MOI (neat virus resulting 
in an estimated MOI of 100), the majority of cells were infected and consequently most died 
after 48 hpi. Despite the high levels of oncolysis in Caco-2 cells, a small population of 
surviving cells was identified at 12 dpi and named virus-resistant Caco-2 (VR Caco-2) cells 
for easy identification from the parental Caco-2 cells. Isolation of VR Caco-2 cells was 
accidental observation, it is  an outcome, where few colonies of Caco-2 cells observed 
microscopically 12 dpi. The strategy of the isolation of VR Caco-2 cells from B1-GFP 
infected Caco-2 cells explained in Figure 3.4. All NDV strains were able to produce VR 
Caco-2 cells. The VR Caco-2 cells were isolated from Hitchner B1 infected Caco-2 cells, 
explained later in Figure 3.7 C, where supernatants from VR Caco-2 cells (isolated from 
both Hitchner B1 and B1-GFP) used for virus-titration by plaque assay. VR Caco-2 cells 
were cultured in complete growth media (Table 2.11 and section 2.1.5.1.). VR Caco-2 cells 
isolated from B1-GFP infected Caco-2 cells were used in further studies unless mentioned 
otherwise. 
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Figure 3.4. Schematic representation of Virus Resistant Caco-2 cells isolation from 
B1-GFP infected Caco-2 cells. Caco-2 cells were infected with B1-GFP (a neat virus). 
About >98% cells were infected within 24 h and >95% of infected cells were dead within 48 
hpi. Few cells survived the infection 12 dpi. The surviving cells were cultured in a complete 
growth medium and isolated from B1-GFP superinfected Caco-2 cells. Isolated cells were 
named virus-resistant Caco-2 cells (VR Caco-2 cells). 
 
 
Initially, surviving VR Caco-2 cells took almost 4 to 6 weeks to form colonies and about 4 
months to attain 80 to 90% confluence. Microscopic observations confirmed a slower 
proliferation of VR Caco-2 cells than uninfected Caco-2 cells. The VR Caco-2 cells isolated 
from B1-GFP infected Caco-2 cells had shown GFP expression of lower intensity than 
acutely B1-GFP-infected Caco-2 cells under a fluorescence microscope in early passages 
(P). Flow cytometric analysis of early passages of VR Caco-2 cells (P1 and P4) along with 
acute B1-GFP-infected Caco-2 cells, and B1-GFP re-infected VR Caco-2 cells confirmed 
the complete reduction of GFP expression from P1 to P4 of VR Caco-2 cells (Figure 3.5 A 
and B). Surprisingly, VR Caco-2 cells remained unaffected by GFP virus re-infection 
demonstrated in Figure 3.5 A and B. Further microscopic analysis was done in VR Caco-
2 cells infected with B1-GFP virus at MOI 5 alongside the parental Caco-2 cells. No 
cytopathic effects (CPE) were observed in VR Caco-2 cells, whereas acutely infected Caco-
2 cells have shown CPE within 24 h of infection as shown in Figure 3.5 C.  
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Figure 3.5. Loss of GFP expression in VR Caco-2 cells. (A) An overlay of histograms 
showing the GFP positive population of VR Caco-2 cells in passage 1 (P1) and passage 4 
(P4) by fow cytometry analysis. In the histogram overlay % maximum represents the 
maximum count  for events of GFP expressing cells. (B) A comparative GFP MFI (mean 
fluorescence intensity) of P1 and P4 in B1-GFP infected Caco-2 and VR Caco-2 cells. (C) 
Bright-field microscopic images of mock or B1-GFP (MOI 5, 24 hpi) infected Caco-2 and 





3.2.4. Characterisation of VR Caco-2 cells 
Previously, the GFP expression in earlier passages of VR Caco-2 cells radically reduced 
in subsequent passages (Figure 3.5 A and B). In addition, CPE was not detected in B1-
GFP (MOI=5) infected VR Caco-2 cells. With this unpredicted outcome, VR Caco-2 cells 
were characterised further. Indirect immunofluorescence (IF) staining assay was used to 
assess the presence of NDV proteins. Uninfected VR Caco-2 cells, mock or NDV infected 
Caco-2 cells were stained with anti-NDV chicken sera and Goat Alexa Fluor 568 anti-
Chicken IgY (H+L) secondary antibody (discussed in section 2.2.1.7.). The IF assay in VR 
Caco-2 cells confirmed the expression of NDV proteins. The syncytium formation was not 
observed in LaSota infected Caco-2 cells 18 hpi, whereas VR Caco-2 cells showed the 
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syncytium formation represented in Figure 3.6 A as multinucleated bodies encapsulated 
by NDV proteins. 
 
Figure 3.6. Confirmation of persistent NDV infection in VR Caco-2 cells using IF and 
qRT-PCR assays. (A) Immunofluorescence analysis of NDV proteins expression in 
uninfected, LaSota infected Caco-2 cells (MOI 1, 18 hpi) and VR Caco-2 cells. 4% PFA 
fixed cells were probed with NDV-specific chicken serum and incubated with Alexa Fluor® 
568 goat anti-chicken antibody. Cell nuclei stained with DAPI (scalebar 75 µm). (B) NDV-
M gene expression profile in NDV infected Caco-2 and VR Caco-2 cells using SYBR Green 
qRT-PCR analysis. Data (mean ± SD) represented here is a combination of three 
independent experiments. (C) The melting curve analysis confirmed primer specific 
amplification of NDV-M gene.  
 
 
The percentage of NDV expressing population varied from passage to passage; not all the 
cells were positive for NDV in VR Caco-2 cells. To obtain further details of the virus-host 
interactions in these cells, we examined the expression of NDV-M gene. NDV-M is one of 
the abundantly expressed genes during NDV replication and also used as a universal 
marker to detect NDV replication. A markedly lower NDV-M gene copy number was 
detected in VR Caco-2 cells compared to the acutely infected Caco-2 cells (Figure 3.6 B 
and C).  In conclusion, based on the NDV gene and protein expression, NDV established 
persistent infection in VR Caco-2 cells (Figure 3.6).  
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Once the persistent infection was established in VR Caco-2 cells, the infectivity of the virus 
was tested by plaque assay using immunofluorescence staining with anti-NDV chicken sera 
(discussed in section 2.2.2.5.). The supernatant from VR Caco-2 cells and virus stocks of 
Hitchner B1 and B1-GFP were used for the virus quantification. All the plaque assays were 
performed in Caco-2 cells. The methodology of virus titration briefly described in Figure 
3.7 A.  
 
The plaque assay of VR Caco-2 cells supernatant has demonstrated the production of 
infectious viral particles in VR Caco-2 cells (Figure 3.7 C). The haemagglutination assay 
(HA) was used to titre NDV in VR Caco-2 cell supernatant (discussed in section 2.2.2.2.). 
Two-fold virus dilutions and 1% chicken red blood cells (cRBCs) were used to assess NDV. 
HA assays were the straightforward approach for the quick estimation of NDV titre in cell 
supernatant and virus stock. The cell supernatant from VR Caco-2 cells was checked 
regularly using HA titration and plaque assays. The HA titration confirmed a significantly 
lower viral load produced in VR Caco-2 cells as compared to the egg propagated NDV 
strains (Figure 3.7 D).  
 
VR Caco-2 cells produced low levels of virus and the titre fluctuated from passage to 
passage and never increased beyond 105 PFU/ml compared to the high titres of Hitchner 
B1 and B1-GFP in Caco-2 cells (Figure 3.7 B and Table 3.1). Virus quantification by plaque 
assay and HA titration revealed that virus titres were significantly lower in VR Caco-2 cells 
(Figure 3.7 E). 
 
Table 3.1: PFU/ml count in different passages of VR Caco-2 cell supernatant. 












Figure 3.7. Confirmation of persistent NDV infection in VR Caco-2 cells using HA and plaque assays. (A) Flow chart explaining the 
methodology of plaque assay. (B) B1-GFP and Hitchner B1 IF plaque assay in Caco-2 cells. (C) VR Caco-2 cells (generated from B1-GFP and 
Hitchner B1 superinfected Caco-2 cells) supernatant used for infection in Caco-2 cells and IF plaque assay plate. (D) HA assay confirming the 
hemagglutination characteristic of NDV or supernatant of VR Caco-2 cells. (E) A graphical representation of significantly differential viral titres of 
NDV strains (Hitchner B1 and B1-GFP) to VR Caco-2 supernatant (late passage P-25, P-29, and P-31) in Caco-2 cells. Data (mean ± SD) shown 
here are from three independent experiments. Statistical analysis was performed using a Shapiro-Wilk normality test, and one-way ANOVA with 
Tukey’s multiple comparisons test (*** p< 0.001, and **** p< 0.0001). 
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Results from the qRT-PCR assays have demonstrated the expression of viral NDV-M 
gene in VR Caco-2 cells at a markedly lower level than acute B1-GFP infected Caco-2 
cells (Figure 3.6). Virus titration of VR Caco-2 cell supernatant using HA assays and 
plaque assays have also demonstrated the production of infectious replication-
competent NDV particles in VR Caco-2 cells at a significantly lower titre (Figure 3.7). 
Therefore, confirmed that NDV established persistent infection in isolated VR Caco-2 
cells (Figure 3.4) by maintaining virus replication at low titers. VR Caco-2 cells 
maintained continuous production of reproducible infectious virus at varying titres at 
every passage (Table 3.1) . The NDV produced in VR Caco-2 cells named VR NDV (VR 





Figure 3.8. Analysis of NDV-HN protein. (A) Receptor avidity assay using 4 HAU of 
B1-GFP virus and NDV from VR Caco-2 supernatant demonstrated higher affinity of VR 
NDV to the desialylated chicken RBCs. Data (mean ± SD) shown here are from four 
independent experiments. Paired t-test was used to analyse data (***p<0.0001). (B) 
Mutation sites located in HN protein of VR NDV compared to the B1-GFP HN protein. 
Protein structures predicted using Phyre2 and aligned using PyMOL. (C) VR NDV from 
VR Caco-2 supernatant and B1-GFP virus used to study replication kinetics of NDV in 
Caco-2 cells. Data (mean ± SD) shown here are from three independent experiments 
and analysed using One-way ANOVA with Sidak’s multiple comparisons test (*** p= 
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Once the viral persistence was confirmed in VR Caco-2 cells, the NDV HN and F 
sequences were analysed. Thirteen different mutations in the HN protein of VR NDV 
were discovered. The receptor binding avidity assays were carried out to investigate the 
functional differences in VR NDV and B1-GFP virus (section 2.2.2.3.).  The receptor 
binding avidity assay measured the avidity of binding of HN protein to sialic acid depleted 
cRBCs. Partially sialic acid depleted cRBCs were obtained by α2-3,6,8 neuraminidase 
enzyme treatment. The optimised VR NDV and B1-GFP virus stocks (4 HAU) were 
tested with sialic acid depleted cRBCs to determine the virus avidity. This assay has 
demonstrated 6x higher avidity of VR NDV to partially depleted cRBCs than B1-GFP 
virus (Figure 3.8 A). The increased receptor binding avidity of VR NDV to partially 
depleted cRBCs suggested mutations in HN protein, which were identified by HN protein 
sequence analysis.  
 
The HN sequence analysis of VR NDV and B1-GFP viruses confirmed 13 amino acid 
mutations in VR NDV compared to the B1-GFP virus shown in Figure 3.8 B. None of 
the amino acid mutation sites was found in HA, NA and antigenic sites in globular head 
of HN protein of VR NDV. Out of 13 mutations, 10 mutations (G134E, Y203H, P226S, 
V254A, K259E, S324T, W363R, P464S, V495E, and T522I) were located in the globular 
head in closest proximity of shared antigenic site 23 (F193, S194, S200, H201, and 
H203) (229), receptor binding (R174, I175, E258, Y299, Y317, E401, R416, R498, Y526, 
and E547) (80), and NA (R174, I175, D198, K236, R416, Y526 and E547) (80) active 
sites. However, Y203H mutation is in the linear amino acid sequence of antigenic site 
23. The other three mutation sites K98N, E118A, and S121R) are in the tail domain of 
HN protein. The tail domain is responsible for F-protein interaction, neuraminidase 
activity, and protein oligomerisation. The increased avidity to desialylated cRBCs could 
be the outcome of these mutations, to pinpoint the exact site needs further investigation. 
 
The replication pattern of VR NDV in Caco-2 cells was compared with the B1-GFP strain 
of NDV. VR NDV has shown a similar trend of infectivity to that of B1-GFP virus in growth 
curve studies shown in Figure 3.8 C. The difference can be seen at earlier time points 
because of the differences in the inoculum at the time of infection. For this study, 100 
PFU of B1-GFP infected Caco-2 cells compared with the unknown titres of VR Caco-2 
supernatant-infected Caco-2 cells. Irrespective of the differences at initial time points of 
the replication study of VR NDV confirmed similarity in the infectivity. 
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Figure 3.9. Cell proliferation assays. (A and B) Caco-2 and VR Caco-2 cell confluence 
monitored in real-time using the IncuCyte imaging system at different seeding densities, 
respectively. Phase object confluence (%) represents the surface area covered by cell 
monolayer in the culture plate. (C) Flow cytometry analysis showing the overlapped 
histograms of Caco-2 and VR Caco-2 cells 72 h post CFSE staining (CFSE is a 
fluorescent cell staining dye). CFSE dilution is significant at 72 h in Caco-2 cells 
indicating more number of cell divisions than VR Caco-2 cells. (D) MFI of CFSE stained 
Caco-2 and VR Caco-2 cells at different proliferation time points.  Data (mean ± SD) 
shown here are from three independent experiments and analysed using multiple 
nonparametric t-tests (p = 0.005).   
 
 
The real-time monitoring of cell confluence using IncuCyte Live-cell Analysis system at 
different cell seeding densities (5000 cells/well, 10000 cells/well, and 15000 cells/well) 
in a 96 well plate has revealed slower growth of VR Caco-2 cells than Caco-2 cells. 
Caco-2 cells spent less than 12 h in lag phase and entered in log phase to attain more 
than 90% confluence in 1.5 days after seeding at 10K and 15K cells/well and 
consequently went into a stationary phase. A similar trend was also observed in 5K 
cells/well 70% confluence and started stationary development (Figure 3.9 A). On the 
other hand, VR Caco-2 cells spent around three days in the lag phase in all three 
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densities regardless of the confluence before entering the exponential phase (Figure 
3.9 B). VR Caco-2 cells certainly had different growth phase curve from the Caco-2 cells 
irrespective of cell density. VR Caco-2 cells at 10K and 15K cells/well seeding took 5.5 
days to attain >90% cell confluence. The CFSE cell proliferation assay (section 2.2.1.6.) 
verified the 2x times slower cell proliferation of VR Caco-2 cells than Caco-2 cells at 48 
and 72 h post CFSE staining (Figure 3.9 C). The trend of decreasing CFSE intensity 
was demonstrated by measuring the mean fluorescent intensities (MFI) of CFSE 
labelled Caco-2 and VR Caco-2 cells at 0-72 h Figure 3.9 D. The microscopic 




Figure 3.10. Microscopic observation of Caco-2 and VR Caco-2 cells. Bright-field 




3.2.5. NDV re-infection study in VR Caco-2 cells 
Caco-2 and VR Caco-2 cells were infected with a neat virus, and ten-fold dilutions of 
NDV strains (B1-GFP, LaSota, and Ulster 2C) and the cell viability was measured 
(section 2.2.1.3.A) each day up to 5 dpi. The assay has demonstrated a significant 
difference in the cell viabilities of infected Caco-2 and VR Caco-2 cells. VR Caco-2 cells 
were unaffected with all the NDV strains and virus doses at all the time points, whereas 
Caco-2 cells responded to all strains in a dose-dependent manner resulting in the 
decreased cell viability. No B1-GFP infection and replication were evident in VR Caco-
2 cells as no GFP expression was seen compared to the B1-GFP infected Caco-2 cells 
(Figure 3.12). No cytopathic effects were observed in the NDV infected VR Caco-2 cells 
regardless of the strain and the dose of infection. The cell cytotoxicity was measured 
(2.2.1.3.B) in reporter and non-reporter NDV strains-infected Caco-2 and VR Caco-2 
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cells at low MOI of 0.1; Caco-2 cells showed significantly higher cytotoxicity to the VR 
Caco-2 upon infection illustrated in Figure 3.11 B. Both assays validated the NDV 
resistance in VR Caco-2 cells. The resistance to NDV infection potentially can be 
explained either by receptor modification of VR Caco-2 cells or by the establishment of 
an antiviral state in VR Caco-2 cells; however, this needs further investigation. Virus 
killing curve assay demonstrated resistance to NDV-induced cell death in VR Caco-2 
cells compared to the parental Caco-2 cells (Figure 3.11 A). 
 
 
Figure 3.11. Resistance to NDV re-infection demonstrated in VR Caco-2 cells. (A) 
Cell viability measured in NDV (B1-GFP, LaSota, and Ulster 2C) neat virus and ten-fold 
virus dilutions infected Caco-2 and VR Caco-2 cells in 5 days virus killing curve 
assay. (Viability fraction is a ratio of normalised fluorescence reading of infected cells to 
uninfected cells at 560Ex/590Em. Fluorescence readings are normalised with blank 
reagent controls.) (B) Cell cytotoxicity assay of 0.1 MOI NDV (Hitchner B1, B1-GFP, 
LaSota, and LaSota-GFP) infected Caco-2 and VR Caco-2 cells 4 dpi demonstrated 
reduced cytotoxicity of VR Caco-2 cells.  (C) Caspase3/7 activity measured to assess 
the apoptosis in NDV infected Caco-2 and VR Caco-2 cells at MOI of 1 24 hpi. Data 
(mean ± SD) shown are of three independent experiments. Statistical analysis was 
performed using a Shapiro-Wilk normality test, and one-way ANOVA with Tukey’s 
multiple comparisons test (* p<0.05, ** p<0.001, *** p< 0.001, and **** p< 0.0001).  
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Type of cell death in NDV-infected Caco-2 and VR Caco-2 cells was investigated by 
infecting Caco-2 and VR Caco-2 cells with different strains of NDV at MOI of 1 for 24 h 
(section 2.2.1.4.). Then executioner caspases 3 and 7 activity measured using Cas3/7 
Glo Luciferase assay to confirm the ongoing apoptosis.  There was no significant 
difference in Cas3/7 activity of VR Caco-2 cells with or without infection (Figure 3.11 C). 
However, B1-GFP and LaSota infected Caco-2 cells were significantly positive, showing 
Caspase 3/7 activity at set parameters. These observations demonstrated that NDV-
induced cell death by apoptosis occurs in a strain-specific manner only in Caco-2 cells 
but not in NDV re-infection-resistant VR Caco-2 cells. 
 
 
3.2.6. Confirmation of NDV-specific resistance in VR Caco-2 
cells 
 
The question was whether the established resistance of VR Caco-2 cells was exclusive 
to the NDV or also extended to other viruses, once resistance to the NDV re-infection 
confirmed in VR Caco-2 cells. Therefore, VR Caco-2 cells were infected with reporter 
viruses of avian influenza A strain (AIV) H9N2-GFP and vesicular stomatitis virus (VSV-
GFP) along with parental Caco-2 cells. The GFP-expressing viruses used to their 
advantage to confirm infection and spread of the virus in Caco-2 and VR Caco-2 cells 
observed under a fluorescence microscope. 
 
Figure 3.12. VR Caco-2 cells showed susceptibility to H9N2, and VSV infections only.  
Microscopic observation of NDV (B1-GFP and LaSota-GFP), avian influenza virus H9N2-GFP, 
and vesicular stomatitis virus (VSV-GFP) infected Caco-2 and VR Caco-2 cells at MOI of 0.1 for 
24 h. The expression of GFP confirmed virus replication inside cells (scale bar 250 µm). 
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This study has confirmed the NDV-specific resistance of VR Caco-2 cells. Microscopic 
observations clearly showed H9N2-GFP and VSV-GFP replication in VR Caco-2 cells 
(Figure 3.12). The flow cytometry analysis of NDV- reporter viruses (B1-GFP and 
LaSota-GFP), H9N2-GFP, and VSV-GFP virus also verified the permissibility of VR 
Caco-2 cells to H9N2-GFP and VSV-GFP viruses, but not to the NDV viruses shown in 
Figure 3.13. NDV and AIV use the sialic acid receptor to facilitate virus entry inside the 
cells. The permissibility of VR Caco-2 cells to AIV discuss the possibility of receptor 
modification in VR Caco-2 cells to explain NDV-specific resistance. The establishment 
of an antiviral state is also potentially questionable as VR Caco-2 cells were infected 




Figure 3.13. Validation of NDV-specific resistance in VR Caco-2 cells. Caco-2 and 
VR Caco-2 cells were infected with various reporter strains of NDV, Influenza A virus, 
and VSV at MOI of 0.1. Virus infection was determined at 48 hpi using flow cytometry. 
An overlay of histograms and MFI (mean fluorescence intensity) of GFP representing 
the virus replication in virus-infected cells demonstrated the susceptibility of Caco-2 and 
VR Caco-2 cells. A comparative account of NDV reporter viruses (B1-GFP and LaSota-
GFP) alongside H9N2-GFP (A) and VSV-GFP (B) NDV-specific resistance of VR Caco-
2 cells. In histogram overlays, % maximum represents the maximum count  for events 
of GFP expressing cells. Data (mean ± SD) shown are the representation of three 
independent experiments and analysed using two-way ANOVA with Sidak’s multiple 
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The infection and replication of VSV-GFP, LaSota-GFP, and B1-GFP was examined in 
Caco-2 and VR Caco-2 cells in real-time using the IncuCyte Live-cell Analysis system. 
The intensity of GFP-expressing infected cells was measured throughout the infection 
indicated the real virus infection and replication in real-time shown in Figure 3.14 A. VR 
Caco-2 cells confirmed VSV-GFP replication only. However, the GFP intensity of the 
VSV-GFP in VR Caco-2 cells significantly lower than in Caco-2 cells even though >99% 
population was infected with the VSV (Figure 3.14 B). The possible explanation for it 
may be based on the fact that VR Caco-2 cells persistently producing NDV, and 
therefore the VSV-GFP, grow slower in VR Caco-2 cells, but the virus successfully 
induced cell death in both Caco-2 and VR Caco-2 cells, as depicted in Figure 3.14 B.  
 
 
Figure 3.14. VSV replication and cell death assay in VR Caco-2 cells. (A) Caco-2 
and VR Caco-2 cells were infected with reporter strains of NDV (B1-GFP and LaSota-
GFP) at MOI of 1, and VSV-GFP at MOI of 0.1 respectively. Real-Time monitoring of 
GFP expression under 10x objective of IncuCyte live imaging system affirming the virus 
replication in Caco-2 and VR Caco-2 cells on a timely basis (n=3). Phase object 
confluence (%) represents the surface area covered by cell monolayer in the culture 
plate. (B) Caco-2 and VR Caco-2 cells infected with NDV (B1-GFP at MOI 0.1) and VSV-
GFP (MOI 0.01) validated VSV-induced cell death in VR Caco-2 cells 72 hpi. the 
replication cycle is of VSV is 2-3 h whereas, NDV replication cycle is 8-12 h in Caco-2 
cells. Hence, different MOI of infection used in the assay. Data (mean ± SD) shown are 
the representation of seven independent experiments and analysed using a Shapiro-
Wilk normality test, and Two-way ANOVA with Sidak’s multiple comparisons test 
(*p=0.04 and **** p< 0.0001). 
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3.2.7. IFN-β induction study in Caco-2 cells 
A strong antiviral innate immune response is evoked by virus-infected cells as the first 
line of defence. Antiviral status of infected cells obtained by the induction of type-I 
interferons (IFNs) such as IFN-α and IFN-β which then binds to IFN-α/β receptors 
(IFNAR) activating the JAK/STAT pathways to express IFN stimulated genes (ISGs). 
Several antiviral ISGs have been identified to abort the viral replication cycle like ISG15, 
ISG20, Mx1/2, and OAS1/2/3 etc. Here we investigated the IFN-β and ISG15 mRNA 
induction in NDV infected cells to define the antiviral status.  
 
In order to rule out any clonal bias of the Caco-2 cell populations, two independent 
sources of Caco-2 cells from The Pirbright Institute and Caco-2 cells from Oxford 
University (Ox Caco-2) were used in the study to understand the induction of IFN in 
response to different stimuli such as viruses (NDV-B1/B1-GFP and VSV-GFP) and long 
synthetic analogue of dsRNA poly(I:C) HMW. A549 cells are known to induce strong 
type-I IFN production hence used as a positive control in this study. A549, Caco-2, VR 
Caco-2 and Ox-Caco-2 cells were infected with VSV-GFP at MOI of 0.1 for 12 h, with 
B1 and B1-GFP viruses at MOI of 5 for 12 h. A549 cells were transfected with 0.2 µg/ml 
of Poly(I:C) for 12 h whereas Caco-2 and Ox-Caco-2 cells were transfected for 24 h 
(section 2.2.3.9.1.). Caco-2 cells were found unresponsive to the poly(I:C) transfection, 
whereas Ox Caco-2 cells responded inconsistently (Figure 3.15). As a result, no 
significant induction of IFN-β mRNA was detected, whereas B1-infected Caco-2 and Ox-
Caco-2 cells showed slightly higher induction of IFN-β and ISG15 mRNAs (Figure 3.15). 
IFN-β and ISG15 mRNA expression in poly(I:C) transfected Ox Caco-2 cells was 
considerably higher to the Caco-2 cells (Figure 3.15). The VR Caco-2 cells showed no 
induction of IFN-β and a slight increase in ISG15 in comparison with unstimulated Caco-
2 cells (Figure 3.15). A549 cells expressed high levels of IFN-β and ISG15 mRNA in 
response to all the stimuli. (Simultaneously, infection in all cells was confirmed by 
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One-way ANOVA with Dunnett’s multiple comparisons test (*p=0.01, **p<0.002, *** p< 




3.2.8. Role of miR-155 in VR Caco-2 cells 
MiR-155 is an 18 to 23 nucleotide short small noncoding multifunctional microRNA 
(miRNA), which is confirmed to be involved in post-transcriptional gene regulation by 
interacting with the 3′-untranslated region of target mRNA, leading to either mRNA 
degradation or protein synthesis suppression. MiR-155 regulation is known to affect 
various biological processes such as haematopoiesis, inflammation and immunity (230, 
231). MiR-155 is also an oncomir, where it is thought to function by downregulating 
tumour suppressor genes leading to oncogenesis. MiR-155 is overexpressed in several 
cancers such as oral, breast, pancreatic cancers and also has a role cancer cell 
proliferation, invasion and migration (230). However, Liu et al. (2018) reported that miR-
155 overexpression limited colorectal cancer progression by targeting collagen triple 
helix repeat containing 1 (CTHRC1) in vitro colon cultures (232). 
 
Formerly, VR Caco-2 cells were confirmed for the persistent NDV-infection, NDV-
specific resistance, dysfunctional IFN response, and slower growth, with no evidence of 
apoptosis. A significant (p< 0.0001) upregulation of miR-155 and two-fold increased (p< 
0.001) NF-kB activity was observed in the VR Caco-2 cells (Figure 3.16). There is no 
direct correlation reported so far between miR-155 (discussed in section 2.2.3.9.2.) and 
NF-kB (discussed in section 2.2.1.6.) activity. However, overexpression of miR-155 in 
VR Caco-2 cells could be the indication of imbalance of homeostasis between the 
regulatory function of the immune system and oncogenesis. The increased NF-kB 
activity indicated a substantial increase in cell survival and anti-apoptosis activity in VR 
Caco-2 cells. There was no difference in caspase 3/7 activity with or without NDV 
infection (Figure 3.11 C), and slower but prolific cell proliferation was observed in the 
growth curves of VR Caco-2 cells (Figure 3.9 A and B) indicating the pro-survival and 
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Figure 3.16. miR-155 expression and NF-kB activity in Caco-2 cells. (A) miR-155 
copy number estimation by TaqMan qRT-PCR (n=3) (B) NF-kB luciferase activity was 
measured in Caco-2, acutely B1-GFP infected Caco-2 and VR Caco-2 cells (n=3). Data 
(mean ± SD) was analysed using a Shapiro-Wilk normality test, and two-way ANOVA 





Cassel et al. reported the antineoplastic properties of NDV in human cancer cells for the 
very first time (94), and since then over the last fifty years, many advancements have 
been made with NDV as an oncolytic agent. The promising feature of NDV as an 
antineoplastic agent is because of the productive tumour-specific replication (96, 97) as 
cancer cells are defective of antiviral signalling pathways, defective of type-I IFN 
signalling pathways, defective of apoptotic pathways, activation of tumorigenic Ras 
signalling pathways, and expression Rac1 protein (111). In this chapter, the oncolytic 
potential of NDV avirulent strains was investigated in five different human cancer cell 
lines derived from different tissues. The study demonstrated that colorectal cancer 
Caco-2 cells are most vulnerable to NDV-induced cell death. This study validated the 
tumour-specific NDV replication and subsequent oncolysis in Caco-2 cells sparing the 
healthy normal cells.  
 
Despite apparent susceptibility to NDV-induced cell death, NDV-persistent infection was 
confirmed in Caco-2 cells, and the isolated population was named VR Caco-2 cells. 
Persistent  NDV infection is not a new phenomenon in its natural host, chicken organ 
cultures (233, 234) and non-human cell cultures (235, 236). Similar to other 
Chapter 3 – Establishment of a model system to study oncolytic properties of lentogenic 
strains of Newcastle disease virus (NDV) 
130 
 
paramyxoviruses such as Sendai and measles virus, persistent infection has been 
reported in the colorectal cancer cell line SW480 using velogenic NDV strain (237) and 
in an ovarian cancer cell line OVCAR3 with mesogenic NDV strain (238). In this study, 
it is demonstrated that VR Caco-2 cells acquired persistent NDV infection while 
maintaining the production of recoverable replicating virus at low titres with similar 
infectivity trend as of B1-GFP strain. Avian cells stably expressing NDV-HN (achieved 
by RCAS vector transfection) have shown resistance to the NDV re-infection potentially 
due to the receptor modification by constant HN expression with functional HA and NA 
activities (239). Persistently infected OVCAR3 cells confirmed the hyperfusogenic 
nature of NDV because of reported mutation in the cleavage site of NDV fusion protein 
at F117S and altered receptor binding of HN protein due to mutation in the second sialic 
acid binding site at HN169R (238). Protein sequences of both F and HN proteins 
investigated and did not find the reported mutations in either of the proteins. Evident 
syncytium formation was observed in VR Caco-2 cells compared to the acutely infected 
Caco-2 cells. Syncytium formation suggests fusogenic activity of NDV in VR Caco-2 
cells and it probably helps spreading NDV infection in VR Caco-2 cells. 
 
Nevertheless, there were ten mutation sites out of 13 found in the globular head of HN 
protein in the proximity of antigenic site 23, and the HA, and NA active sites. The other 
three mutation sites were located in the tail region of the HN protein. The tail domain of 
paramyxovirus HN protein is known to have specificity determinants for F-protein 
activation, which affects neuraminidase activity, and contributes significantly to the 
oligomerisation of the protein (240-242). These mutation sites collectively resulted in six-
fold improved receptor binding avidity to the partially sialic acid depleted cRBCs in VR 
NDV compared to the B1-GFP strain.  In future, these mutations could be validated by 
considering the rescue system to generate the mutant viruses to pin down exact 
mutations responsible for differential HA activity of VR NDV to the B1-GFP virus. The 
NA activity of VR NDV could be explored to conclude the role of HN protein acquiring 
persistent NDV infection in VR Caco-2 cells. As the trend of infectivity of VR NDV was 
reported similar to the B1-GFP strain at late time points while maintaining lower HA and 
PFU/ml titres; one can further investigate the production of defective interfering (DI) 
particles in VR Caco-2 cells as reported for Sendai (243) and measles (244) viruses. 
 
The reduced cell cytotoxicity demonstrated upon NDV re-infection in VR Caco-2 cells in 
comparison with infected Caco-2 cells.  A significant increase in miR-155 and two times 
increased NF-kB activity also have confirmed in VR Caco-2 cells. VR Caco-2 cells have 
shown two-times slower proliferation than of parental Caco-2 cells with higher NF-kB 
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activity with no sign of apoptosis so, pro-survival mechanism in VR Caco-2 cells could 
be confirmed further by investigating the NF-kB pathway. 
 
An NDV-specific resistance and not to AIV (H9N2) and VSV was observed in VR Caco-
2 cells. In other NDV persistent infection studies (237, 238), resistance to VSV has been 
reported as a result of the acquired antiviral status in persistently-infected cells. VR 
Caco-2 cells revealed a contrary behaviour showing susceptibility to VSV and AIV 
(H9N2) viruses. The H9N2 invasiveness in VR Caco-2 cells dismiss the possibility of 
receptor modification hypothesis to gain NDV-specific resistance. The limited resistance 
of VR Caco-2 cells to NDV could be expanded against paramyxoviruses other than NDV 
such as other avian paramyxoviruses (APMVs) or a bovine or human respiratory 
syncytial virus (RSV), measles virus, or Sendai virus. The infection of other 
paramyxoviruses in VR Caco-2 cells could explain whether the resistance is exclusive 
to the NDV or APMVs or other paramyxoviruses and could help to validate the 
mechanism of ongoing NDV infection in VR Caco-2 cells.  VSV-induced cell death was 
also demonstrated in persistently infected VR Caco-2 cells. This finding opens up the 
possibility of the use of a combination of oncolytic viruses (OVs) to overcome persistent 
infection in human cancer cells. The combination of OVs could be a way forward to study 
the persistent infection in Caco-2 cells, and other cancer cell lines or recombinant NDV 
strains expressing immunostimulatory or oncolytic genes from other OVs could be 
employed to make NDV as a better and safer vaccine to treat cancer. 
 
Human tumour cells infected with lentogenic (non-pathogenic) NDV strain Ulster 2C 
infected demonstrated the induction of IFN-β, RANTES, and IP-10 mRNAs with 
activation of MHC as well as cell adhesion proteins ICAM-1 and LFA-3 (152, 245). 
Expressions of IFN-β and ISG15 mRNA was examined in Caco-2 and VR Caco-2 cells. 
No evident mRNA induction was found in Caco-2 and VR Caco-2 cells irrespective of 
the stimuli. This confirmed the inefficient antiviral status due to defective type-I IFN 
pathways in Caco-2 cells. Inefficient antiviral response in Caco-2 cells confirms better 
NDV infection and spread, resulting in active NDV-induced cell death in Caco-2 cells. In 
contrast, strong antiviral response in A549 cells regardless of similar NDV replication 
and supported ineffective NDV-induced oncolysis in A549 cells. This result was 
inconsistent with the reported NDV-induced apoptosis in A549 cells (242).  However, 
the NDV-M gene copies at MOI 5 for 12 hpi demonstrated substantial monocyclic NDV 
replication in Hitchner B1, and B1-GFP infected A549 cells similar to infected Caco-2 
cells, so intact type-I IFN pathways recovered the ongoing NDV infection in A549 cells. 
Persistent infection of NDV in A549 cells was not achieved, which is likely due to the 
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active type-I IFN pathways. The ineffective IFN system possibly could be the reason for 
NDV persistent infection in Caco-2 cells with all the non-pathogenic strains used in the 
study. 
 
In summary, Caco-2 cells were most susceptible to NDV-induced oncolysis using 
avirulent NDV strains in a time and dose-dependent manner. Despite effective NDV-
induced cell death in Caco-2 cells, NDV established persistent infection in Caco-2 cells, 
and was named VR Caco-2 cells. VR Caco-2 cells produced recoverable replicating 
virus and maintained virus at low viral titres in upto 34 passages. VR NDV (NDV 
produced in VR Caco-2 cells) showed six-fold higher receptor binding avidity compared 
to the B1-GFP virus. Sequence analysis of HN protein of VR NDV identified 13 mutation 
sites compared to the B1-GFP. Out of 13, 10 sites were found in the globular head in 
close proximity to antigenic site 23 and HA, and NA active sites and the other three were 
in the tail region. VR NDV has also shown similar replication trend in Caco-2 cells as 
B1-GFP virus. VR Caco-2 cells also have demonstrated two times slower cell 
proliferation than Caco-2 cells. However, VR Caco-2 cells have demonstrated NDV-
specific resistance and remained susceptible to AIV and VSV infections and also have 
shown VSV-induced cell death. Ineffective IFN-β and ISG15 mRNAs induction was 
reported in Caco-2 cells, which resulted in productive NDV-induced cell death in Caco-
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4  An integrated analysis of persistently NDV-infected 




NDV established persistent infection in Caco-2 cells despite being the most susceptible 
cell line for NDV-induced oncolysis, as demonstrated in chapter 3. Persistently infected 
cells were named as VR (virus-resistant) Caco-2 cells, which developed different 
behaviour including two-times slower proliferation than uninfected Caco-2 cells, 
continuous production of recoverable replicating NDV viral particles with lower virus 
titres, and NDV-specific resistance upon re-infection in VR Caco-2 cells while permitting 
infections with AIV (avian influenza virus) and VSV (vesicular stomatitis virus). Given all 
the above differences in Caco-2 and VR Caco-2 cells, an integrated approach based on 
comparative methods such as RNA-seq and proteomic analysis was employed to 
understand the implications of persistent NDV infection in Caco-2 cells compared to the 
acute NDV infection and no infection in Caco-2 cells by analysing differential gene 
expression. 
 
The use of RNA-seq approaches enabled an analysis of the transcriptomes of Caco-2 
cells and NDV in parallel with easy monitoring of gene expressions of both host and 
pathogen while maintaining a high level of accuracy (provided that the read depth is 
sufficiently high), and amenable to computational analysis with or without prior 
knowledge of reference DNA sequences (246, 247). The use of proteomics study using 
mass spectrometry (MS) with a tandem mass tag (TMT) labelling assured precise 
identification of proteins, explaining the variable-dependent translation of abundant RNA 
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4.1.1. Chapter objectives 
• RNA-seq data analysis to identify differentially expressed genes (DEGs) 
• Comparative pairwise analysis between persistently NDV-infected VR Caco-2, 
acutely NDV-infected, and uninfected Caco-2 cells analysis 
• Clustering of DEGs and GO/pathway enrichment analysis for identification of 
relevant functions/pathways and their behaviour across the infection  
• Correlation of transcriptomic and proteomic data of VR Caco-2 cells compared with 
uninfected Caco-2 cells 
• Comparative data analysis using publicly available RNA-seq datasets:  
A) Comparison with Coxsackievirus B infected Caco-2 cells and with Caco-2 cells 
grown in 2D/3D cultures. 







4.2.1. RNA-seq datasets 
A report summary statistics for the RNA-seq data generated in this PhD project, as well 
as data already published from NDV-infected CEF cells (248) and Coxsackievirus B 
(CVB) infected Caco-2 cells (249) used for the analysis. The RNA-seq data, protocol, 
and yield are summarised in Table 4.1 and 4.2. Caco-2 cells were infected with B1-GFP 
strain at MOI of 0.1 for two-time points 18 h and 36 h in a 6-well plate. Total RNA was 
extracted from NDV-infected Caco-2 cells (18 h and 36 h), uninfected Caco-2 cells (3 
technical replicates), and VR Caco-2 cells (3 technical replicates, late passage P-25) 
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without significant differences shown in black dots in scatter plots across all the 
comparisons. In acutely NDV-infected Caco-2 cells, 7160 genes were differentially 
expressed in comparison with uninfected Caco-2 cells, versus 11012 genes in 
persistently infected VR Caco-2 cells (Table 4.3). Hence, both acute and persistent NDV 
infection in Caco-2 cells resulted in extensive changes in the transcription level of 
thousands of genes compared to uninfected Caco-2 cells. A total of 10039 genes were 
also differentially expressed in VR Caco-2 cells compared to the acute NDV infection 
(Table 4.3). All NDV genes were expressed in both acutely NDV-infected Caco-2 and 
persistently infected VR Caco-2 cells.  
 




Pair-wise comparison between Caco-2 cells conditions 
Number 
of DEGs 
















Figure 4.1. Scatter plots representing the gene expression profile in Caco-2 cells 
across different conditions.  A comparison made between RPKM values representing 
gene expressions for human and NDV genes in uninfected, acutely NDV-infected Caco-
2 cells, and persistently infected VR Caco-2 cells. Differentially expressed genes (FDR 
<0.01) shown in red dots and genes without significant differences shown in black dots. 
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The pattern of differential gene regulation was examined across all the conditions in 
Caco-2 and VR Caco-2 cells by quantifying log2 fold changes (LFCs) and adjusted p-
values using the DESeq2 tool to determine the number of DEGs in all the conditions. 
LFCs and DEGs between acute and persistent NDV infection and uninfected Caco-2 
cells were compared in three different pairwise comparisons: (1) relative LFCs and 
DEGs in acutely NDV infected Caco-2 cells and persistently infected VR Caco-2 cells 
compared with the uninfected Caco-2 cells (“Acute infection Vs No infection” compared 
to “VR Caco-2 Vs No infection”). (2) relative LFCs and DEGs in acutely NDV infected 
Caco-2 cells to uninfected Caco-2 cells compared with persistent NDV infection 
compared to the acute NDV infection (“Acute infection Vs no infection” compared to 
“Persistent infection of VR Caco-2 Vs acute NDV infection”). (3) relative LFCs and DEGs 
in persistent NDV infection in relation to the acute NDV infection compared with 
persistent NDV infection relative to the uninfected Caco-2 cells (“VR Caco-2 Vs acute 
NDV infection” compared to “VR Caco-2 Vs no infection”). A schematic representation 
of all the comparisons is shown in Figure 4.2, where DEGs expressed in both conditions 
are shown in red, whereas DEGs expressed in only one condition are shown in orange 
colour and genes without significant differences are shown in black. In all three pairwise 
comparisons, thousands of genes were differentially expressed, where DEGs are 
specific to one condition (orange genes) as well as DEGs showed in both the conditions 
(red genes). Genes under or overexpressed in all three pairwise comparisons are listed 
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Figure 4.2. Relative account of differential genes expression in pairwise 
comparisons across all conditions in Caco-2 cells (acute or persistent NDV 
infection and no infection). Scatter plots demonstrating apeGLM-shrinked log2-fold 
changes in Caco-2 cells across multiple conditions. Genes are shown in red if they were 
expressed in both comparisons and genes shown in orange if they were expressed in 
only one comparison. 
 
The patterns of significantly upregulated and downregulated genes are illustrated 
through the Venn diagrams (Figure 4.3). Total number of DEGs overlapped across all 
pairwise comparisons explained by Venn diagram are shown in Figure 4.3 A, where all 
three comparisons share 1755 DEGs. VR Caco-2 cells showed expression of a 
significantly higher number of DEG in comparison with no infection (2698) and acute 
infection (1266) confirming the broader impact of persistent NDV-infection in VR Caco-
2 cells (Figure 4.3 A). 
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Table 4.4: Genes under or overexpressed in acutely NDV-infected Caco-2 cells in comparison with uninfected Caco-2 cells 
Sr. 
No. 
Gene ID Gene Name LFCs padj Function 
1 NP NP 18.33680872 4.93E-44 
The NDV-Nucleocapsid protein binds to viral RNA and forms RNP 
complex 
2 F F 18.25506865 2.37E-81 NDV-Fusion protein involved in viral entry and egress 
3 P P 18.0208011 9.24E-32 NDV-Phosphoprotein, forms RNP complex  
4 L L 17.36765684 6.41E-33 NDV-Large RNA polymerase, viral RNA synthesis 
5 M M 17.34340765 3.78E-56 NDV-Matrix protein responsible for viral assembly 
6 HN HN 16.9842281 5.21E-49 
NDV-HN protein possess haemagglutinin (HA) and neuraminidase 
(NA) activities and receptor binding 
7 ENSG00000228736.9 RGL2 14.92565371 1.24E-26 
Ral Guanine Nucleotide Dissociation Stimulator Like 2 protein is 
probable guanine nucleotide exchange factor and putative effector of 
Ras and/or Rap. Associates with the GTP-bound form of Rap 1A and 
H-Ras in vitro  
8 ENSG00000204435.13 CSNK2B 13.01124313 9.90E-20 
Casein Kinase 2 Beta protein, a ubiquitous protein kinase which 
regulates metabolic pathways, signal transduction, transcription, 
translation, and replication 
9 ENSG00000204220.10 PFDN6 11.5807309 1.25E-20 
Prefoldin Subunit 6 protein binds specifically to cytosolic chaperonin (c-
CPN) and transfers target proteins to it. Binds to nascent polypeptide 
chain and promotes folding in an environment in which there are many 
competing pathways for non-native proteins 
10 ENSG00000237441.9 RGL2 11.40088636 5.02E-26 
Ral Guanine Nucleotide Dissociation Stimulator Like 2 protein is 
probable guanine nucleotide exchange factor and putative effector of 
Ras and/or Rap. Associates with the GTP-bound form of Rap 1A and 
H-Ras in vitro  
11 ENSG00000206406.9 CSNK2B -5.594047023 0.000361263 
Casein Kinase 2 Beta protein, a ubiquitous protein kinase which 
regulates metabolic pathways, signal transduction, transcription, 
translation, and replication 
12 ENSG00000241146.1 RPL7P41 -5.840970274 0.000304711 Ribosomal Protein L7 Pseudogene 41 
13 ENSG00000122877.14 EGR2 -5.952234653 1.11E-85 
Early Growth Response 2 protein, Sequence-specific DNA-binding 
transcription factor. Binds to two specific DNA sites located in the 
promoter region of HOXA4. 
14 ENSG00000232992.2 AHCYP4 -6.625595612 6.94E-05 Adenosylhomocysteinase Pseudogene 4 
15 ENSG00000120738.7 EGR1 -6.745860281 1.64E-230 
Early Growth Response-1 protein binds double-stranded target DNA, 
irrespective of the cytosine methylation status and Plays a role in the 
regulation of cell survival, proliferation and cell death. Activates 
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expression of p53/TP53 and TGFB1, and thereby helps prevent tumour 
formation. 
16 ENSG00000170345.9 FOS -6.947062206 1.33E-254 
FOS Proto-Oncogene encodes leucine zipper proteins that can 
dimerise with proteins of the JUN family, thereby forming the 
transcription factor complex AP-1. As such, the FOS proteins have 
been implicated as regulators of cell proliferation, differentiation, and 
transformation.   
17 ENSG00000280175.1 AL354828.2 -7.001060767 1.30E-05 lnc‑MKRN2‑42:1 targets AL354828.2 
18 ENSG00000125740.13 FOSB -7.11886449 7.25E-153 
FOSB Proto-Oncogene encodes leucine zipper proteins that can 
dimerise with proteins of the JUN family, thereby forming the 
transcription factor complex AP-1. As such, the FOS proteins have 
been implicated as regulators of cell proliferation, differentiation, and 
transformation. 





Antisense RNF135 (Ring Finger Protein 135 -involved in protein-protein 
and protein-DNA interactions)  
 
 
Table 4.5: Genes under or overexpressed in persistently NDV-infected VR Caco-2 cells in comparison with uninfected Caco-2 cells 
Sr. 
No. 
Gene ID Gene name LFCs padj Function 
1 ENSG00000134321.11 RSAD2 15.42625176 2.84E-30 
Interferon-inducible iron-sulphur (4FE-4S) cluster-binding antiviral 
protein which plays a major role in the cell antiviral state induced by type-
I and type-II interferon. 
2 F F 14.27000281 6.24E-60 NDV-Fusion protein involved in viral entry and egress 
3 L L 14.24826748 9.87E-28 NDV-Large RNA polymerase, viral RNA synthesis 
4 P P 14.00538752 1.42E-24 NDV-Phosphoprotein, forms RNP complex  
5 ENSG00000137965.10 IFI44 13.79872114 7.35E-10 
This protein aggregates to form microtubular structures, participate in 
immune response 
6 NP NP 13.41890592 3.12E-30 
The NDV-Nucleocapsid protein binds to viral RNA and forms RNP 
complex 
7 HN HN 13.05284591 1.71E-36 
NDV-HN protein, possess haemagglutinin (HA) and neuraminidase (NA) 
activities and receptor binding 
8 M M 13.01888602 8.34E-40 NDV-Matrix protein responsible for viral assembly 
9 ENSG00000134326.11 CMPK2 12.88674322 5.99E-21 
Cytidine/Uridine Monophosphate Kinase 2, catalyses the 
phosphorylation of uridine and cytidine 
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10 ENSG00000169248.12 CXCL11 11.89230585 9.38E-20 
Chemotactic for interleukin-activated T-cells but not unstimulated T-cells, 
neutrophils or monocytes 
11 ENSG00000249346.6 LINC01016 -9.068806052 6.21E-10 
Long Intergenic Non-Protein Coding RNA 1016, associated with Breast 
cancer 
12 ENSG00000109610.5 SOD3 -9.1358896 5.03E-10 
Protect the extracellular space from the toxic effect of reactive oxygen 
intermediates by converting superoxide radicals into hydrogen peroxide 
and oxygen 
13 ENSG00000113492.13 AGXT2 -9.206935161 2.05E-10 
Alanine-Glyoxylate Aminotransferase 2, metabolize asymmetric 
dimethylarginine (ADMA)-a potent inhibitor of nitric-oxide (NO) synthase 
14 ENSG00000224652.1 LINC00885 -9.231189025 1.47E-10 
Long Intergenic Non-Protein Coding RNA 885, affiliated with the lncRNA 
class 
15 ENSG00000186910.3 SERPINA11 -9.430285938 6.19E-11 Serine-type endopeptidase inhibitor 
16 ENSG00000188803.14 SHISA6 -9.937239463 1.82E-12 
Involved in maintenance of high-frequency synaptic transmission at 
hippocampal CA3-CA1 synapses 
17 ENSG00000225756.1 DBH-AS1 -10.14549397 1.38E-12 DBH (Dopamine Beta-Hydroxylase) Antisense RNA 1 
18 ENSG00000263961.6 C1orf186 -10.46125752 9.73E-14 
Acts as a signalling transduction factor of the EPO-EPOR signalling 
pathway promoting erythroid cell differentiation 
19 ENSG00000146477.5 SLC22A3 -11.15651349 1.50E-15 
Solute Carrier Family 22 Member 3 protein mediates potential-dependent 
transport of a variety of organic cations 
20 ENSG00000167755.13 KLK6 -12.44877645 2.93E-19 
S1 family of serine proteases are implicated in carcinogenesis, and some 






Table 4.6: Genes under or overexpressed in persistently NDV-infected VR Caco-2 cells in comparison with acutely  
NDV-infected Caco-2 cells 
Sr. 
No. 





Antisense RNF135 (Ring Finger Protein 135 -involved in protein-protein 
and protein-DNA interactions)  
2 ENSG00000127954.12 STEAP4 8.88137341 2.43E-08 
Six transmembrane epithelial antigens of prostate express on Golgi 
apparatus and functions as a metalloreductase that has the ability to 
reduce both Fe (3+) to Fe (2+) and Cu (2+) to Cu (1+), using NAD (+) as 
acceptor. 
3 ENSG00000134321.11 RSAD2 8.733407549 2.24E-29 
Interferon-inducible iron-sulphur (4FE-4S) cluster-binding antiviral 
protein which plays a major role in the cell antiviral state induced by type-
I and type-II interferon. 
4 ENSG00000163565.18 IFI16 8.612546879 3.07E-12 
Interferon Gamma Inducible Protein 16, interacts with p53 and 
retinoblastoma-1, modulation of p53 function inhibits cell growth in the 
Ras/Raf signalling pathway 
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5 ENSG00000137959.15 IFI44L 8.571449464 9.80E-10 
Interferon Induced Protein 44 Like, exhibits a low antiviral activity against 
hepatitis C virus.  
6 ENSG00000148346.11 LCN2 8.259449423 3.27E-07 
Lipocalin family protein involved in the transport of small hydrophobic 
molecules such as lipids, steroid hormones and retinoids 
7 ENSG00000128422.15 KRT17 7.874557344 1.45E-72 
Keratin 17, regulates protein synthesis and epithelial cell growth through 
binding to the adapter protein SFN and by stimulating Akt/mTOR 
pathway  
8 ENSG00000198774.4 RASSF9 7.699679129 1.27E-19 
Ras Association Domain Family Member 9 perinuclear endosomal 
protein, may play a role in regulating vesicular trafficking in cells 
9 ENSG00000177409.11 SAMD9L 7.640052869 3.52E-21 
A cytoplasmic protein that acts as a tumour suppressor but also plays a 
key role in cell proliferation and the innate immune response to viral 
infection 
10 ENSG00000163739.4 CXCL1 7.334585611 2.38E-21 
C-X-C Motif Chemokine Ligand 1 plays a role in inflammation and as a 
chemoattractant for neutrophils. Aberrant expression of this protein is 
associated with the growth and progression of certain tumours 
11 ENSG00000237825.9 RGL2 -11.33073939 1.96E-26 
Probable guanine nucleotide exchange factor. Putative effector of Ras 
and/or Rap. Associates with the GTP-bound form of Rap 1A and H-Ras 
in vitro 
12 ENSG00000188803.14 SHISA6 -11.4072178 1.51E-15 
Involved in maintenance of high-frequency synaptic transmission at 
hippocampal CA3-CA1 synapses 
13 ENSG00000146477.5 SLC22A3 -11.4087811 9.05E-16 
Solute Carrier Family 22 Member 3 protein mediates potential-dependent 
transport of a variety of organic cations 
14 ENSG00000235692.8 PFDN6 -11.50504825 5.42E-21 
Prefoldin Subunit 6 protein binds specifically to cytosolic chaperonin (c-
CPN) and transfers target proteins to it. Binds to nascent polypeptide 
chain and promotes folding in an environment in which there are many 
competing pathways for non-native proteins 
15 ENSG00000167755.13 KLK6 -12.14103661 5.77E-18 
S1 family of serine proteases are implicated in carcinogenesis, and some 
have potential as novel cancer and other disease biomarkers 
16 ENSG00000204435.13 CSNK2B -12.95881742 4.21E-20 
Casein Kinase 2 Beta protein, a ubiquitous protein kinase which 
regulates metabolic pathways, signal transduction, transcription, 
translation, and replication 
17 ENSG00000204220.10 PFDN6 -14.14317051 1.87E-24 Chaperone-mediated protein complex assembly 
18 ENSG00000224841.9 RGL2 -14.87774209 5.30E-27 
Ral Guanine Nucleotide Dissociation Stimulator Like 2 protein is probable 
guanine nucleotide exchange factor and putative effector of Ras and 
Rap. Associates with the GTP-bound form of Rap 1A and H-Ras in vitro  
19 ENSG00000237441.9 RGL2 -14.87922383 5.64E-27 
20 ENSG00000228736.9 RGL2 -14.88458331 5.38E-27 
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Numerous genes overlapped in upregulation and downregulation and while most DEGs 
were specific to two comparisons, some were restricted to one pairwise comparison, and a 
few hundred were identified across all three pairwise comparisons as well (Figure 4.3 B). 
In total, 203 genes were upregulated, and 477 genes were downregulated across all three 
comparisons. Persistent NDV infection in VR Caco-2 cells compared to acute NDV infection 
in Caco-2 cells induced exclusive upregulation of 529 genes and downregulation of 737 
genes. However, 471 genes are exclusively overexpressed and 369 genes 
underexpressed in acutely NDV-infected Caco-2 cells compared to uninfected Caco-2 
cells. Whereas 1635 genes are exclusively overexpressed and 1063 genes 
underexpressed in persistently infected VR Caco-2 cells in contrast with uninfected Caco-
2 cells. NDV infection regardless of the acute or persistent status has resulted in the 
regulation of numerous genes in Caco-2 cells and VR Caco-2 cells. There is clear evidence 
of a trend of broader changes in regulation in persistently infected cells, compared to 
acutely infected ones.  
 
Interestingly, sets of 1774 genes are downregulated and 1813 genes upregulated in acutely 
infected Caco-2 cells, but these genes are inversely regulated respectively in the 
persistently infected VR Caco-2 cells compared to the acute infection. These DEGs are 
most likely a response to the high amount of virus during acute infection. There are 1005 
genes upregulated and 1323 genes downregulated in both acute and persistent infection 
phases in a similar trend. The substantial similarity and dissimilarity of gene regulation 
observed in acute and persistent NDV infection in Caco-2, and VR Caco-2 cells in 
comparison with uninfected Caco-2 cells could explain changed behaviour of VR Caco-2 
cells from parental uninfected Caco-2 cells. 
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Figure 4.3. Venn diagram summarising distribution pattern of differentially 
expressed genes (DEGs) (FDR<0.01) in three pairwise comparisons (Pairwise 
comparisons are made between acutely NDV-infected Caco-2 cells, persistently infected 
VR Caco-2 cells, and uninfected Caco-2 cells). (A) Total number of DEGs overlapped 
across all pairs of conditions (B) Gene clusters showing significant upregulation or 
downregulation across all pairwise comparisons 
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The relationship of all three pairwise comparisons of LFC quantiles appeared to be 
correlated or anticorrelated. The mutual comparison of LFC of acute and persistent 
infection compared to the no infection fall in a weak positive monotonic relationship within 
both conditions indicated by rs=0.309  (Spearman’s correlation coefficient). A strong 
positive monotonic relationship with rs=0.63315 was found in the mutual comparisons 
between LFCs of persistently infected VR Caco-2 compared with uninfected Caco-2 cells 
and acutely NDV-infected Caco-2 cells, demonstrating regulation of genes following similar 
trend in correlation within VR Caco-2 cells compared to the acutely NDV-infected Caco-2 
cells shown in Figure 4.4. In both the comparisons, a strong association is found among 




Figure 4.4. Quantile-quantile distribution of log2-fold changes across different 
pairwise conditions. The pattern of most upregulated and downregulated genes between 
different conditions indicated by apeGLM-shrinked log2-fold changes (FDR<0.01 with 
multiple-testing correction using the Benjamini-Hochberg method). 
 
After identifying statistically significant DEGs based on DESeq2 LFCs and adjusted p-
values in at least one of the three pairwise comparison among Caco-2 cells (FDR<0.05 and 
LFC>4), a hierarchical clustering approach based on log10 RPKM expression values was 
used to determine the expression profiles in time, comparing uninfected Caco-2 cells to 
acutely infected Caco-2 cells at 18 h and 36 h post-NDV infection and persistently NDV-
infected VR Caco-2 cells. All 913 DEGs clustered according to the similar gene expression 
profile into nine different clusters, as shown in Figure 4.5. Upregulated expression of NDV 
viral genes with a clear difference between acute infection time points (18 h and 36 h) and 
VR Caco-2 cells are demonstrated in cluster 8. The gene expression profile of cluster 1 
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showed abrupt downregulation of 185 genes in VR Caco-2 cells, whereas these genes 
remained unaffected in the uninfected and acutely NDV-infected Caco-2 cells. However, in 
cluster 2, 170 genes were (continuously) downregulated in both acute infection and 
persistent NDV infection compared to the uninfected Caco-2 cells. In clusters 3 (164 genes) 
and 4 (163 genes), expression profiles demonstrated upregulation of genes in the VR Caco-
2 cells with the opposite behaviour compared to clusters 1 and 2, respectively. In all clusters 
from 1 to 4 downregulation and upregulation of genes was not correlated to the amount of 
viral gene expression in acutely and persistently infected VR Caco-2 cells. 
Surprisingly, VR Caco-2 cells established the regulation of some of the intestinal markers, 
which are primarily known to play a role in intestinal cell differentiation. Drummond et al. 
(2016) reported the expression of several genes associated with intestinal epithelial 
differentiation in Caco-2 cells when comparing transition from 2-Dimensional (2D) model to 
3-Dimensional (3D) models, which attained a more complex structure from the 2D 
heterogeneous model in 21 days of culturing. These included downregulation of PDGFRA 
(platelet-derived growth factor receptor alpha), protease-activated transporter SLC10A1 
(Solute Carrier Family 10 Member 1) and upregulation of the transmembrane mucins 
abundantly expressing in the intestine like MUC1, MUC13, and MUC17. A downregulation 
of Orm2 (Orosomucoid 1), SLC38A4 (Solute Carrier Family 38 Member 4), and ALB 
(Albumin) genes in an early stage of culturing as well as downregulation of PDGFRA in a 
later stage of culturing (249). In VR Caco-2 cells, overexpression of MUC17 and 
underexpression of SLC10A1, MS4A10 (Membrane Spanning 4-Domains A10), Orm2, 
SLC38A4, and ALB genes have been observed in RNA-seq analysis. The similar trend of 
notified differentiation markers in VR Caco-2 suggested an increase in complexity of VR 
Caco-2 cells related to the one observed in the 3D model of Caco-2 cells. Reactive oxygen 
species (ROS) produced by NADPH oxidases (NOX)- NOX2 and NOX4 genes are found 
to be downregulated (Cluster 1) in VR Caco-2 cells. Several genes responsible for antiviral 
cellular responses were found to be overexpressed in VR Caco-2 cells but not in acutely 
NDV infected Caco-2 cells like IL-15, OASL, IFIT1, C3, CASP1, DDX60 etc. (cluster 3 and 
4) were upregulated significantly in comparison with acute NDV-infection and no infection 
in Caco-2 cells. There were plenty of genes that are highly overexpressed (clusters 5 and 
8) or underexpressed (clusters 6 and 9) only in an acute NDV infection and not in uninfected 
Caco-2 and VR Caco-2 cells, in direct relation to highly expressed NDV genes. 
Overall, 913 significantly differentially expressed genes in acute and persistent NDV 
infected Caco-2 cells resulted in profound changes in VR Caco-2 cells, which hinder the 
capacity to pinpoint specific mechanisms acquired to define NDV-specific resistance. 
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Figure 4.5. Cluster analysis of gene expression profiles. Gene expression (log10 
RPKM) profiles are shown for uninfected, acutely infected (18 hpi and 36 hpi, NDV 
MOI=0.01), and persistently infected VR Caco-2 cells and for all genes with significant 
differential expression (FDR<0.05 and LFC>4) between any pair of conditions, rescaled 
and grouped in hierarchical 9 clusters. In each cluster, a few representative genes are 
outlined. The thick black line represents the average gene expression, while a dotted line 
indicates the basal level.  
 
Gene Ontology and pathway overrepresentation analysis were performed using significant 
DEGs from all Caco-2 cells conditions to understand which GO (Gene Ontology) biological 
processes and Reactome pathways would play a role. However, only a few significant 
signals could be found after multiple test corrections, due to the reduced numbers of genes 
and the complexity of the infection. For this reason, we used a different approach, 
combining enrichment analysis and time profile reconstruction. First, we obtained adjusted 
p-values for all GOs and pathways using PantherDB; then, we inferred the trend in time 
from the significance of the p-values, and we grouped these trends in 9 clusters, each 
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representing different functional roles of genes in the infection process. Figure 4.6 
illustrated this dynamic classification of the regulation of processes and pathways relative 
to uninfected Caco-2 cells, representing an overall of 707 differentially expressed 
processes/pathways grouped in 9 clusters with representative examples. In cluster 1 
(Figure 4.6) almost 134 processes are significantly downregulated in VR Caco-2 cells only 
while remained unchanged in uninfected Caco-2 cells and in acutely NDV-infected Caco-2 
cells, where metabolic processes involved downregulation of glucose metabolism, pyruvate 
and citric acid (TCA) cycle, and respiratory electron transport chain mechanism amongst 
other processes. In cluster 5 (54 processes) and 8 (6 processes) (Figure 4.6) showed 
significant upregulation of processes involving IFN-mediated antiviral pathways and 
gradual increase in cytokine-mediated responses in response to persistent NDV infection 
in VR Caco-2 cells only whereas in acutely NDV-infected and uninfected Caco-2 cells 
remained unaffected. 
In summary, pathways and processes underexpressed (in cluster 1) and overexpressed (in 
cluster 5 and 8) are regulated independently of viral load in Caco-2 cells similar to gene 
expression profiles (from Figure 4.5 clusters 1, 2, 3, and 4). In clusters 2, 6, 7, and 9 all 
predicted pathway/processes were correlated to the viral load as significant upregulation 
(clusters 2, 7, and 9) and downregulation (cluster 6) was seen only in acutely NDV-infected 
Caco-2 cells and basal levels maintained in the uninfected Caco-2 and VR Caco-2 cells. 
All the upregulated and downregulated processes are expected in acutely NDV-infected 
Caco-2 cells as a result of active viral replication; upregulated processes involved the 
processing of 3 prime RNA synthesis, increased regulation of cell cycle phases and 
checkpoints, RNA transcription and transport, as well as ribonucleoprotein biosynthesis etc. 
However, cell division is downregulated in VR Caco-2 cells, and ribonucleoprotein 
biosynthesis is upregulated compared to no infection in Caco-2 cells. Whereas, 
downregulated processes included extracellular signal-regulated kinases (ERKs)-
ERK1/ERK2 mediated cell survival mechanism, cellular differentiation and developmental 
process. Few pathways and metabolic processes are downregulated (cluster 3: 83 
processes; like lipid metabolism, lipoprotein assembly in the plasma membrane, and 
regulated exocytosis etc.) and upregulated (cluster 4: 23 processes, including defence 
response to virus and generic transcription pathways) equally in both acute and persistent 
NDV infection of Caco-2 cells irrespective of the amount of active viral replication.  
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Figure 4.6. Dynamic classification of the functional profile of GOs (gene ontologies) 
and pathways in differentially regulated pathways in uninfected, acutely, and 
persistently NDV-infected Caco-2 cells. An example of metabolic process for each 
cluster written in the respective cluster, where dotted line indicated the basal level of 
expression of collective processes in uninfected Caco-2 cells. 
 
Likewise, Ingenuity Pathway Analysis (IPA) pathway was used for overrepresentation 
analysis using significant DEGs from all Caco-2 cells conditions.  IPA analysis showed a 
total of 99 canonical pathways differentially regulated across the conditions in Caco-2 cells 
grouped in 9 clusters, as illustrated in Figure 4.7. In cluster 1, 17 different pathways are 
downregulated in NDV-infected Caco-2 cells irrespective of the viral load, pathways include 
Dermatan Sulfate Biosynthesis (Dermatan sulfate (DS) is a glycosaminoglycan present in 
the extracellular matrix of the skin as well as i)n numerous other tissues), Liver X receptors 
(LXR)/ Retinoid X receptors (RXRs) pathway activation, and Cell division control protein 42 
homolog (CDC42) signalling pathway. Whereas in cluster 2, a total of 9 canonical 
Chapter 4 – An integrated analysis of persistently NDV-infected VR Caco-2 cells using 
transcriptomic and proteomic approaches 
150 
 
processes are upregulated in NDV-infected Caco-2 and VR Caco-2 cells irrespective of the 
viral load, pathways include the role of PRRs in recognition of pathogens (Bacteria and 
Viruses), Activation of IRF (IFN-regulated factors) by cytosolic PRRs, and LPS 
(lipopolysaccharide) / IL-1 mediated inhibition of RXR function. However, as a result of 
active virus replication in acutely NDV-infected Caco-2 cells resulted in the downregulation 
of pathways in clusters 4 (6 pathways; example eNOS signalling pathway), 5 (9 pathways; 
example Acute phase response and TNFR2 signalling pathways), and 7 (3 pathways; 
example Endothelin-1 signalling pathway). VR Caco-2 cells showed significant 
upregulation and downregulation of pathways compared to the acute NDV-infection, and 
no change in uninfected Caco-2 cells in clusters 3 and 8 (upregulation) and clusters 6 and 
9 (downregulation). In cluster 3 (22 pathways with the significant increase in VR Caco-2 
cells) include IFN signalling, VEGF signalling, Death receptor signalling, cell cycle G2/M 
DNA Damage Checkpoint Regulation and PI3K/AKT signalling pathways. In cluster 8 (8 
pathways with a slight increase in VR Caco-2 cells) processes include the role of CHK 
(checkpoint serine/threonine kinase) proteins in cell cycle checkpoint control, IL-17A 
signalling in Gastric Cells, and NRF2 (Nuclear factor erythroid-2-related factor 2)-mediated 
oxidative stress response pathways. Similarly, the downregulated pathways in cluster 6 (21 
pathways) and 9 (3 pathways) include Sumoylation and cAMP-mediated signalling 
pathways respectively. IPA analysis also has confirmed significant regulation on the 






Chapter 4 – An integrated analysis of persistently NDV-infected VR Caco-2 cells using 





Figure 4.7. Clustering of the time profile of pathways from the Ingenuity Pathway 
Analysis (IPA).  IPA analysis showed regulation of pathways in uninfected, acutely, and 
persistently NDV-infected Caco-2 cells. An example of metabolic processes for each 
cluster written in the respective cluster, where dotted line indicated the basal level of 
expression of collective processes in uninfected Caco-2 cells. 
 
 
4.2.3. Comparative transcriptomics and proteomics data analysis 
An integrated approach of transcriptomic and proteomic data analysis was used to detect 
relevant pathways and functions further. First, we examine the correlation between 
regulation of transcription and translation of host and viral genes in response to the 
persistent NDV infection in VR Caco-2 cells with the uninfected Caco-2 cells. After 
comparing LFCs quantile of most significantly differentially expressed genes and proteins 
with highly significant p values with FDR p<10-12, the 359 candidates have shown a 
moderate correlation between transcription and translation processes in response to the 
persistent NDV infection in VR Caco-2 cells normalised with respect to the uninfected Caco-
2 cells, as confirmed by Pearson correlation coefficient, R2=0.4658 and illustrated by 
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distribution plot as shown in Figure 4.8. The expected reason behind moderate relationship 
in expressed proteins and genes could be explained by multiple factors controlling 
translation regardless of the mRNA abundance. NDV F and P proteins along with ISG15, 
L1CAM, KRT17, SP100 and RGCC proteins were significantly upregulated and proteins 
like ORM1, EPN3, APOA1, and PAGE4 downregulated with the strongest correlation with 




Figure 4.8. Quantile-quantile distribution of fold changes in mRNA abundance (RNA-
seq) and protein abundance between VRCaco-2 and uninfected Caco-2 cells. 
Correlation analysis between the most significant differentially expressed genes and 
proteins in persistent NDV-infected VR Caco-2 cells relative to uninfected Caco-2 cells 
using only strongly differentially expressed genes (FDR (false discovery rate)<10-12). (FC-
fold change) 
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Figure 4.9. Comparison of pathways/GOs detected by proteomics and RNA-seq in 
persistently NDV-infection VR Caco-2 cells compared to the uninfected Caco-2 cells. 
Quantile-quantile distribution of differential expression (DE) scores for VRCaco-2 cells. DE 
scores are defined by -log10 (p-value) of Panther statistical enrichment analysis between 
VR Caco-2 and uninfected Caco-2 cells, multiplied by the sign of the difference the 




The comparative analysis of significant DEGs and proteins expressed in VR Caco-2 
compared to uninfected Caco-2 cells summarised in terms of GO biological processes and 
Reactome pathways demonstrated the weak relationship between proteomics and 
transcriptomics data, as illustrated in Figure 4.9. Analysis of Biological processes showed 
a strong correlation only in highly overexpressed pathways; otherwise, it is weak (rs=0.085) 
in overall comparison, biological processes are summarised in Table 4.7. A total of 204 
and 155 biological processes were highly upregulated and downregulated, respectively. 
The upregulated processes include antiviral responses such as responses to the virus, 
TNF-mediated signalling pathway, negative regulation of the virus life cycle, whereas 
downregulated processes included negative regulation of autophagy and acute 
inflammatory responses. However, Reactome analysis demonstrated slightly better 
correlations (rs=0.25) in proteomics and RNA-seq data compared to the biological 
processes. Highly upregulated (139) and downregulated (32) Reactome pathways are 
summarised in Table 4.8; upregulated pathways include p53 independent DNA damage 
responses, p53 dependent G1/S DNA damage responses, regulation of apoptosis etc. and 
downregulated pathways include regulation of TLRs by endogenous ligands and Rho 
GTPase cycles. 
 
Both GO biological processes, and Reactome pathways analysis demonstrated the 
regulation of functions/pathways in response to NDV to maintain virus replication below a 
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threshold and cell health by regulating pathways/functions controlling cell cycle and virus-
induced damage in VR Caco-2 cells. 
 
 
Table 4.7: Summary of Biological processes regulated in VR Caco-2 cells compared 





































































































mRNA 3'-end processing (GO:0031124) 
Response to a virus (GO:0009615) 
Viral process (GO:0016032) 
IL-1-mediated signalling pathway (GO:0070498) 
Negative regulation of viral genome replication (GO:0045071) 
TNF-mediated signalling pathway (GO:0033209) 
Negative regulation of the viral life cycle (GO:1903901) 
Viral latency (GO:0019042) 
Mitochondrial transport (GO:0006839) 




An acute inflammatory response (GO:0002526) 
Negative regulation of autophagy (GO:0010507) 
Canonical Wnt signalling pathway (GO:0060070) 
Plasma membrane organization (GO:0007009) 
Regulation of Ras protein signal transduction (GO:0046578) 
Regulation of small GTPase mediated signal transduction 
(GO:0051056) 
Cell morphogenesis involved in differentiation (GO:0000904) 
regulation of cell communication (GO:0010646) 
 
Table 4.8: Reactome pathway analysis of VR Caco-2 cells compared to Caco-2 cells 














































































































Mitotic Metaphase and Anaphase (R-HSA-2555396) 
Cell Cycle Checkpoints (R-HSA-69620) 
p53-Independent G1/S DNA damage checkpoint (R-HSA-69613) 
p53-Independent DNA Damage Response (R-HSA-69610) 
Infectious disease (R-HSA-5663205) 
p53-Dependent G1/S DNA damage checkpoint (R-HSA-69580) 
p53-Dependent G1 DNA Damage Response (R-HSA-69563) 
Regulation of Apoptosis (R-HSA-169911) 
NIK-->noncanonical NF-kB signalling (R-HSA-5676590) 
ER-Phagosome pathway (R-HSA-1236974) 
Influenza Infection (R-HSA-168254) 
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Gene Silencing by RNA (R-HSA-211000) 
TNFR2 non-canonical NF-kB pathway (R-HSA-5668541) 
Glycolysis (R-HSA-70171) 





Regulation of TLR by endogenous ligand (R-HSA-5686938) 
Rho GTPase cycle (R-HSA-194840) 
Plasma lipoprotein assembly (R-HSA-8963898) 
p130C as linkage to MAPK signalling for integrins (R-HSA-
372708) 




4.2.4. Comparative data analysis 
 
4.2.4.1. NDV and Coxsackievirus infection in Caco-2 cells  
The general effect of virus infection in Caco-2 cells was studied by comparing RNA-seq 
data from NDV infected, and Coxsackievirus B (CVB) infected Caco-2 cells. 
 
Here RNA-seq data from Caco-2 cells grown in 2D or 3D cultures with or without CVB 
infection were used for two main reasons: First, CVB is a well-known oncolytic virus which 
has been studied by Drummond et al. (2016), where they established 3D Caco-2 cell model 
to replicate and study CVB infection efficiency due to lack of in vivo models to study 
enteroviruses such as CVB. Second, Caco-2 cells are heterogeneous when grown in 2D 
and 3D culture models using rotating wall vessel it mimicked properties of the intestinal 
epithelium, with apical-basolateral polarity, brush borders, the formation of well-developed 
tight junctions and multicellular complexity  (249). The generated RNA-seq data 
demonstrated not only the CVB infection efficiency in the 3D model but also the impact of 
its oncolytic properties in Caco-2 cells. It also has demonstrated the complexity achieved 
by heterogenous Caco-2 cells. The comparison of Caco-2 in 2D/3D models with or without 
CVB infection with the Caco-2 cells with acute or persistent NDV infections have potentials 
to demonstrate similarities and dissimilarities not only in two different clonal populations of 
Caco-2 cells cultured differently but also the impact of two different oncolytic RNA viruses. 
A) Comparison of NDV and CVB infection in Caco-2 cells 
The RNA-seq data from Drummond et al. were analysed and compared with RNA-seq data 
from acutely NDV-infected Caco-2 cells and persistently infected VR Caco-2 cells. The 
LFCs quantile comparative analysis between CVB and NDV in Caco-2 cells demonstrated 
weak positive correlation (rs=0.28) between standard sets of genes upregulated, 
Chapter 4 – An integrated analysis of persistently NDV-infected VR Caco-2 cells using 
transcriptomic and proteomic approaches 
156 
 
downregulated, and unchanged in both virus infections in the Caco-2 cells, as shown in 
darker colours at the top-right and bottom-left in Figure 4.10 A. However, there are sets of 
genes explicitly regulated in response to each virus primarily. The mutual regulation of the 
cellular mechanism in response to virus demonstrated generic antiviral responses 
irrespective of its differential mechanisms of infection in Caco-2 cells. In contrast, LFCs are 
weakly correlated between VR Caco-2 cells and CVB-infected Caco-2 cells (Figure 4.10 
B). Notably, highly upregulated or downregulated genes are less consistently shared 
between persistent NDV-infection and acute CVB-infection in Caco-2 cells, and there is a 
large number of genes that are upregulated in one infection and downregulated in the other 
(Figure 4.10 B). 
 
 
Figure 4.10. Quantile-quantile distribution of log2-fold changes between infected and 
uninfected Caco-2 cells. (A) Comparison between acute infections of NDV and Coxsackie 
virus in Caco-2 cells. (B) Comparison between acute Coxsackie virus in Caco-2 cells with 
persistent NDV-infection in VR Caco-2 cells 
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B) VR Caco-2 cells compared with Caco-2 cells grown in 2D and 3D culture models 
Heatmap analysis of significant DEGs across all conditions of Caco-2 cells in Figure 4.11 
B demonstrated that NDV acute and persistent infection and no infection in Caco-2 cells 
differ primarily from the CVB-infected and uninfected Caco-2 cells in 2D and 3D cultures. 
The drastic changes confirmed in NDV-infected Caco-2 and VR Caco-2 cells in a large 
number of gene clusters covering approximately ten thousand genes irrespective of acute 
and persistent infection with a significant difference than uninfected Caco-2 cells. However, 
CVB infection in 2D and 3D Caco-2 cell cultures showed comparatively fewer changes in 
gene cluster regulation (Figure 4.11 B). 
 
The similarity of Caco-2 cells grown in 2D and 3D cultures with or without CVB infection 
compared with the NDV-infected Caco-2, VR Caco-2, and uninfected Caco-2 cells was 
investigated by comparing log10RPKM values of gene expressions differing by a factor of 
more than 10 across all conditions. Correlation coefficients revealed a very weak but 
positive correlation of the expression of VR Caco-2 cells with the Caco-2 cells cultured in 
3D (Figure 4.11 A), whereas NDV-infected and uninfected Caco-2 cells resembled more 
the Caco-2 cells grown in 2D culture. The weaker correlation between 3D Caco-2 cells with 
VR Caco-2 cells also confirmed with the comparison analysis using LFCs and DEGs across 
both the conditions relative to the Caco-2 3D cells and uninfected Caco-2 cells respectively, 
as illustrated in Figure 4.11 C. The primary difference between Caco-2 cells in 2D and 3D 
cultures is intestinal cell differentiation with apical-basolateral polarity, brush borders, the 
formation of well-developed tight junctions and multicellular complexity. The weaker 
relationship can be explained by the expression of intestinal differentiation markers like 
MUC 17, SLC10A1, MS4A10, Orm2, SLC38A4, and ALB as shown in Figure 4.5.   
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Figure 4.11. Comparative analysis of RNA-seq data from NDV-infected, persistently 
NDV-infected VR Caco-2 and uninfected Caco-2 cells with CVB-infected or 
uninfected Caco-2 cells grown in 2D and 3D cultures (Here genes only with values of 
RPKM variable more than a factor of 10 across conditions considered and values rescaled 
by the lowest correlation for each of uninfected and NDV-infected Caco-2 cells). (A) 
Differential correlation analysis revealed a weaker relationship of VR Caco-2 cell culture 
with only Caco-2 cells grown in 3D culture confirmed by Pearson correlation between 
expression of normalised log10 (RPKM) values in individual samples of both datasets. (B)  
Heatmap of DEGs in log10 (RPKM) values across all the conditions of the Caco-2 cells 
culturing method with and without virus infection. (C) Scatter plot representing a 
comparison of apeGLM-shrinked log2-fold changes in Caco-2 cells in 2D/3D setup and 
persistent NDV-infection of VR Caco-2 cells compared to uninfected Caco-2 cells. Genes 
are shown in red (if differentially expressed in both comparisons, FDR<0.01) or orange (if 
differentially expressed in only one comparison).  
 
 
4.2.4.2. NDV infection in Caco-2 and CEF cells  
The impact of NDV infection in human cancer cells and also in chicken cells (chicken 
embryo fibroblast cells) was compared to understand how the NDV host-virus relationship 
depends on its host. RNA-seq data from Caco-2 cells acutely infected with NDV at MOI 0.1 
for 18 and 36 h along with the persistently NDV-infected VR Caco-2 cells were compared 
with RNA-seq data from NDV-infected CEF cells at MOI 1 for 12 h studied by Liu et al. 
(2018) (248). A comparative analysis of the fraction of reads aligned to the NDV genome 
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relative to all host and viral reads demonstrated that 2% and 10% of reads are from NDV 
genes in 18 h and 36 h NDV-infected Caco-2 cells respectively, whereas in VR Caco-2 
cells just 0.2% are viral reads, i.e. the number of viral transcripts in VR Caco-2 cells is 10-
times and 50-times lower than in acutely NDV-infected Caco-2 cells at 18 h and 36 h, 
respectively. If we neglect potential differences in regulation of viral expression between 
cell types, the amount of viral transcript should be correlated with the number of infected 
cells. The NDV reads from infected CEF cells at MOI of 1 for 12 h are > 6%. Hence, it is 
confirmed that persistent NDV-infection in VR Caco-2 cells maintained at significantly lower 
levels of viral mRNA compared to the acutely NDV infected Caco-2 and CEF cells, as 
illustrated in Figure 4.12 A.  
 
The distribution of LFCs of DEGs was analysed by DESeq2 using RNA-seq data in acutely 
NDV-infected Caco-2 cells was compared with NDV-infected CEF cells (chicken cells), 
persistently NDV-infected VR Caco-2 cells, CVB-infected Caco-2 cells by plotting violin 
plots (Figure 4.12 B). Interestingly the distribution of all LFCs and DEGs in VR Caco-2 cells 
to other acutely infected cells corresponds to the broadest distribution across all 
comparisons, i.e. to the most significant expression LFCs, irrespective of 50-times lower 
viral reads to acute NDV infection. The comparison of the distribution of LFCs of DEGs in 
acutely NDV infected Caco-2 and CEF cells demonstrated that similar drastic changes are 
not achieved in CEF cells. Similarly, the width of the distribution is shrunk in CVB-infected 
Caco-2 cells, concluding that NDV infections have an enormous effect on the regulation of 
Caco-2 cells irrespective of the amount of virus found in acute and persistence state of 
NDV in Caco-2 and VR Caco-2 cells. 
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Figure 4.12. Comparative analysis of the effects of NDV infection in Caco-2, VR Caco-
2, and CEF cells. (A) The relative amount of NDV reads in all NDV-infected cells where 
the fraction of NDV reads totalled to all aligned reads of each sample. (B) Violin plots 
demonstrating the full distributions of log2-fold changes of genes expression amongst 
virus-infected compared with respective uninfected cells. Fold changes were estimated 
from RNA-seq data using DESeq2. Acutely NDV-infected cells (Blue) comparison with 
NDV-infected CEF cells (Brown), CVB-infected Caco-2 cells (Green) and persistently NDV-
infected VR Caco-2 cells (Red). 
As a further confirmation of the significant differences in NDV-infected Caco-2 cells 
compared to NDV-infected CEF cells, we examined the trend of transcription of NDV genes 
using normalised log10 RPKM values of all viral genes in the Caco-2 cells in comparison 
with natural host cells (Figure 4.13 A). A significant difference in the pattern of transcription 
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of NDV genes is observed in Caco-2 cells and CEF cells from 3 prime leader to 5 prime 
trailer genome orientation, whereas the trend of transcription of all viral genes is relatively 
similar in Caco-2 and VR Caco-2 cells irrespective of the number of transcripts. The amount 
of NP transcripts was most abundant as required for initiation of transcription process (as 
well as replication process), whereas P, M, F, and HN at transcripts were maintained 
relatively low abundance across all conditions in Caco-2 cells. The M and HN transcripts 
were slightly more abundant than NP, F, and L transcripts in the natural host (CEF cells) of 
NDV, with lower abundance of P transcripts. Surprisingly, the last gene at 5 prime end i.e. 
the large RNA polymerase L transcript, was kept at a significantly lower relative abundance 
in infected Caco-2 and VR Caco-2 cells compared to its higher abundance in chicken cells. 
The lower abundance of P transcripts to the NP and M transcripts could be partially 
explained by viral RNA polymerase mediated P mRNA editing to synthesise V (+G) and W 
(+GG) transcripts by adding non-template G residue/s at 484th nucleotide position of P 
transcript from 3’ end, although the impact of co-transcriptional editing on mRNA level is 
unclear. 
 
The proportion of P transcripts as well as the edited V and W transcripts were quantified in 
infected Caco-2, VR Caco-2 cells, and infected CEF cells, which demonstrated unusual 
proportion ratios in across conditions in all cells (Figure 4.13 B). The P transcripts were 
significantly more abundant in CEF cells (**** p< 0.0001) than Caco-2 and VR Caco-2 cells, 
whereas V and especially W transcripts were significantly more abundant (**** p< 0.0001) 
in NDV-infected Caco-2 and VR Caco-2 cells than in CEF cells (Figure 4.13 B). NDV-
infected CEF cells showed a negligible level of W transcripts as well as a lower abundance 
of V transcripts. The W/V ratio is significantly lower in CEF cells compared to the NDV-
infected Caco-2 and VR Caco-2 cells (Figure 4.13 C). Accessory V protein plays an 
essential role in evasion of IFN system in chicken, and the function of W protein is unknown, 
but the higher abundance of V in IFN-defective Caco-2 cancer cells both in persistent and 
acute NDV infection is fascinating and possibly could have a role in oncolysis rather than 
infection in CEF cells. 
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Figure 4.13. Expression analysis of NDV genes and P mRNA editing in infected Caco-
2, VR Caco-2, and CEF cells. (A) The account of transcription trend of NDV genes in 
infected cells demonstrated by reading depth along the NDV genome, considered only 
reads/bases with mapping/base quality >30. (B) A comparative account of all transcripts 
from edited P mRNA in % transcripts reads, showing a significant difference in P/V/W 
mRNAs in CEF and Caco-2 cells. Data (mean ± SD) represented is analysed by Two-way 
ANOVA and Tukey’s multiple comparisons test (**** p< 0.0001). (C) The % W/V ratio is 
significantly different between Caco-2, VR Caco-2 and CEF cells. Data (mean ± SD) 
represented is analysed by One-way ANOVA and Tukey’s multiple comparisons test (*p< 
0.023 and **p<0.0023). 
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Figure 4.14. Assessment of acute NDV infection in Caco-2 and CEF cells. Quantile-
quantile distribution of Differential Expression scores for Caco-2 compared with CEF cells. 
DE scores defined by -log10 (p-value) of PantherDB statistical enrichment analysis 
between acutely NDV infected and uninfected cells, multiplied by the sign of the difference 
of activation. Spearman correlations are (rs) 0.23 and 0.32, respectively. 
 
The comparative analysis of significant DEGs expressed in NDV-infected Caco-2 and CEF 
cells summarised in terms of GO Biological processes, and Reactome pathways 
demonstrated that approximately the 5-10% more differentially over/under-expressed 
functions/ pathways tend to be shared across host species, but overall correlations are 
weak rs=0.23 and rs=0.32 respectively, as shown in Figure 4.14. All shared highly 
over/under-expressed Biological processes and Reactome pathways summarised in Table 
4.9 and Table 4.10. A comparison of total of highly upregulated (271) and downregulated 
(399) biological processes shared between infected CEF and Caco-2 cells. The 
upregulated biological processes include DNA repair process, DSBs repair via a 
nonhomologous end-joining mechanism, and dsRNA processing etc., whereas highly 
downregulated processes include regulation of the apoptotic process, regulation of cell 
population proliferation, and regulation of ERK1 and ERK2 cascades etc. We also 
considered a total of highly 50 upregulated and 44 downregulated Reactome pathways 
shared by infected CEF and Caco-2 cells. Highly upregulated pathways include p53-
Dependent G1/S DNA damage checkpoints and cell cycle checkpoints, whereas 
downregulated pathways include regulation of TLR by endogenous ligand and Initial 
triggering of complement cascades. 
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Shared processes and pathways confirmed that some responses of CEF and Caco-2 cells 
are universal irrespective of the host species, such as activation of DNA repair pathways, 
responses against dsRNA, p53 dependent G1/S DNA damage checkpoint and deactivation 
of TLR regulation by endogenous ligands, complement responses, regulation of MAPK 
pathways indicating the involvement of universal machinery to combat the NDV infection. 






































































DNA repair (GO:0006281) 
DNA metabolic process (GO:0006259) 
Cell cycle G2/M phase transition (GO:0044839) 
Mitotic cell cycle checkpoint (GO:0007093 
Double-strand break repair via nonhomologous end-joining 
(GO:0006303) 
Viral process (GO:0016032) 
dsRNA processing (GO:0031050) 
Interleukin-2 secretion (GO:0070970) 




Regulation of programmed cell death (GO:0043067) 
Negative regulation of interleukin-1 production (GO:0032692) 
Regulation of apoptotic process (GO:0042981) 
Regulation of cell population proliferation (GO:0042127) 
Positive regulation of MAPK cascade (GO:0043410) 
Regulation of ERK1 and ERK2 cascade (GO:0070372) 
Canonical Wnt signalling pathway (GO:0060070) 
 









































































Cell Cycle Checkpoints (R-HSA-69620) 
p53-Dependent G1/S DNA damage checkpoint (R-HSA-69580) 
p53-Dependent G1 DNA Damage Response (R-HSA-69563) 
Regulation of RAS by GAPs (R-HSA-5658442) 
Nucleotide Excision Repair (R-HSA-5696398) 




Complement cascade (R-HSA-166658) 
EGFR interacts with phospholipase C-gamma (R-HSA-212718) 
Regulation of TLR by endogenous ligand (R-HSA-5686938) 
Initial triggering of complement (R-HSA-166663) 
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4.3. Discussion  
The objective of this chapter was to analyse the effects of acute NDV infection and 
persistent NDV-infection on gene expression profiles in Caco-2 and VR Caco-2 cells, 
respectively. Caco-2 cells are confirmed a useful model system to study oncolytic 
properties of NDV, where avirulent strains induced significant oncolysis in a dose-
dependent manner. Despite high levels of oncolysis caused by NDV in Caco-2 cells, NDV 
managed to establish persistent infection in Caco-2 cells. Earlier shown that persistent 
NDV-infection of VR Caco-2 cells resulted in dramatic changes where VR Caco-2 cells 
acquired slower cell proliferation, produced replicating virus, NDV-specific resistance to 
NDV re-infection while maintaining susceptibility to avian influenza and VSV virus. The 
analysis of gene expression profile has identified the number of changes and potential 
pathways/functions affected by acute and persistent NDV infection in Caco-2 and VR Caco-
2 cells. 
 
Very little information is available on genome-wide gene expression profile in NDV-infected 
cells, and most of them were conducted using cDNA microarray. Munir et al. (2006) have 
studied gene expression profile using a 2950 element of chicken cDNA microarray chip in 
a velogenic Texas GB strain of NDV infected CEF cells and found 22 genes upregulated 
and 33 genes downregulated (250). Krishnamurthy et al. (2006) have studied genome-wide 
cDNA microarray in NDV-infected HT-1080 human fibrosarcoma cells and CCD-1122Sk 
normal human skin fibroblasts, where 399 genes were differentially regulated (104). Balogh 
et al. (2104) have studied genome-wide transcriptome in more detail in MTH-68/H-infected 
rat PC12 pheochromocytoma cells using the Affymetrix exon chip and found 729 genes 
upregulated and 612 genes downregulated in PC12 cells (251). However, Liu et al. (2018) 
utilised RNA-seq based approach in highly virulent NDV Herts/33 strain and the avirulent 
LaSota strain infected CEF cells and found 7603 (Herts/33) and 4105 (LaSota) transcripts 
differentially expressed in response to NDV infection out of which 3259 (Herts/33) and 1890 
(LaSota)  transcripts were related to interferon-stimulated genes (ISGs) (248). 
B1 avirulent strain of NDV upon acute infection in Caco-2 cells demonstrated that 7160 
genes differentially expressed and persistent infection in VR Caco-2 cells expressed 11012 
genes compared to the uninfected Caco-2 cells whereas 10039 genes were differentially 
expressed in persistently infected VR Caco-2 cells compared to the acutely NDV-infected 
Caco-2 cells. The persistent NDV-infection in VR Caco-2 cells induced enormous changes 
while maintaining lower viral reads compared to the acute infection. VR Caco-2 cells were 
found to have a weaker positive correlation with Caco-2 cells grown in 3D culture by 
Drummond et al. (248), where key difference between Caco-2 cells in 2D and 3D cultures 
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was an intestinal cell differentiation to the intestinal epithelium, with apical-basolateral 
polarity, brush borders, the formation of well-developed tight junctions and multicellular 
complexity. VR Caco-2 cells have shown overexpression of MUC 17 and underexpression 
of SLC10A1, MS4A10, Orm2, SLC38A4, and ALB intestinal markers in RNA-seq analysis 
similar to the Caco-2 cells grown in 3D culture (248). The weaker correlation of VR Caco-
2 cells with 3D Caco-2 cells has demonstrated that NDV persistent NDV infection-induced 
changes resulted in higher complexity of heterogenous Caco-2 cells. A hierarchical 
clustering approach of DEGs, Gene Ontology and pathway overrepresentation analysis, 
and Ingenuity Pathway Analysis have confirmed the upregulation of antiviral responses 
associated with ISGs in VR Caco-2 cells compared to uninfected and acutely NDV-infected 
Caco-2cells: involved DEGs such as IL15, OASL, IFIT1, C3, CASP1, DDX60 etc., and 
pathways included IFN-signalling, cytokine regulation and TLR activation by endogenous 
ligands.  
Ryan et al. (2016) have reported that RNA viruses such as Hepatitis C virus (HCV), 
Influenza A virus (IAV), and retroviruses HIV-1  activate DNA damage response (DDR) 
pathways by inducible nitrous oxide synthase (iNOS) and augmented release of ROS 
(138). The build-up of iNOS and ROS are known to induce double-stranded breaks (DSBs) 
in the infected cell DNA and activation of genetic abnormalities due to non-homologous end 
joining (NHEJ) repair involvement and trigger apoptosis, instigation of inflammatory 
responses, and promotion of genomic instability leading to the increased risk of 
tumourigenesis (138). Similar effects have been confirmed by Saeed et al. (2019), where 
they have analysed cellular DNA content in highly pathogenic NDV AF2240 strain infected 
GBM cells and reported the loss in DNA in treated cells in G1, S and G2/M phases of the 
cell cycle (140). The disruption of the cell cycle was reported to induce apoptotic cell death 
as indicated by typical features such as morphologic changes of apoptosis, including 
shrinkage and blebbing of the membrane (140). Here the integrated analysis of VR Caco-
2 cells in comparison with the uninfected Caco-2 cells using proteomics and RNA-seq data 
have shown activation of p53-Independent G1/S DNA damage checkpoint, p53-Dependent 
G1 DNA damage response, and regulation of apoptosis. A similar trend has been observed 
from the analysis of RNA-seq data in acutely NDV-infected Caco-2 and CEF cells indicating 
that NDV does activate DDR pathways irrespective of the host cell upon infection. Ultra-
microscopic observations in NDV infected Caco-2 and VR Caco-2 cells would validate the 
role of NDV in DNA damage alongwith identifying the triggers for NDV-induced cell death. 
Interestingly NDV has shown significantly different transcription trend of all genes in the 
Caco-2 and CEF cells, and the P mRNA editing also found significantly different in both the 
cells. The amount of V and especially W transcripts compared to the P transcripts were 
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found substantially higher in Caco-2 and VR Caco-2 cells compared to the CEF cells. 
Mebatsion et al. (2001) reported that 68% P-encoding mRNA, 29% V-encoding mRNA, and 
2% W-encoding mRNAs were produced from the P gene in NDV-infected chicken cells 
(91). In contrast to that approximately 65% P, 25% V, and 10% W transcripts were found 
in NDV-infected Caco-2 and VR Caco-2 cells, whereas 94% P, 6% V, and 1% W transcripts 
in NDV-infected CEF cells. The NDV P protein plays a vital role in viral RNA synthesis by 
forming the RNP complex where P protein binds to NP and L proteins (81). The edited V 
and W mRNA encode accessory proteins, V protein has IFN antagonistic properties, and 
W protein expression and its function is unclear in NDV (81). Recently, Karsunke et al. 
(2019) have reported the expression of W protein in QM9 cells (quail muscle cells clone 9) 
transfected plasmids coding for NDV Cl30 W (252). Karsunke et al. also reported a nuclear 
accumulation of W protein nuclear localisation sequence (NLS) within its unique C-terminal 
end revealed by confocal microscopic analyses of infected cells (252). In this study, 
proteomic data analysis showed approximately 4-times log2 fold change in W protein 
expression in VR Caco-2 cells compared with uninfected Caco-2 cells (demonstrated in 
appendix). So, in future nuclear accumulation and localisation of W protein in VR Caco-2 
and infected Caco-2 cells can be studied. The persistent infections caused by 
paramyxoviruses is common in vitro and in vivo cultures; however, the molecular 
mechanism is unknown. Recently Young et al. (2019) have reported the single mutation in 
one of the phosphorylation sites of P protein drive the switch between lytic to persistent 
infection of parainfluenza virus type 5 (PIV5) in A549 cells (253). Qui X et al. (2016) have 
identified the phosphorylation sites in NDV-P protein which are T44, S48, T271, S373 and 
T111 (254). The sequence analysis of NDV P mRNA transcripts from acutely NDV-infected 
and persistently NDV-infected VR Caco-2 cells have not reported any mutations/amino acid 
changes in the reported phosphorylation site; however, there are few other mutations in the 
P protein which can be investigated further to find out its role in the NDV replication as well 
as the P mRNA editing. 
Defective viral genomes (DVGs) of several RNA viruses such as RSV, human 
metapneumovirus, Zika, chikungunya, and Ebola are known to persist infections in vitro 
and in vivo cultures (255). Timm et al. (2014) have identified and characterised the DVGs 
produced by vesicular stomatitis virus (VSV) cultured in BHK host cells by deep sequencing 
and validated by quantitative reverse transcription-PCR (256). Murra et al. (2017) have 
characterised DVGs produced by recombinant measles virus in infected human cells and 
found that non-encapsidated 5 prime copy-back DVGs (DVGs template where RNA 
template and polymerase attachment site is closer to 5 prime end (257)) were recognised 
by TLRs such as RIG-I and LGP2 which play a role in antiviral responses (244).  Not much 
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is known about the DVGs produced by NDV unlike other paramyxoviruses such as Sendai 
virus, measles virus etc. DVGs have shown to play a role in antiviral responses as well as 
persistent infections in host cells (255). Using deep sequencing approaches, DVGs 
produced by NDV in human cancer cells, and CEF cells could be identified and 
characterised in the future to find out the role of DVGs in the elevated antiviral status of 
persistently infected VR Caco-2 cells by NDV infection. 
Overall, A total of 10039 genes were significantly differentially expressed in persistently 
NDV-infected VR Caco-2 cells compared to acute NDV-infection in Caco-2 cells resulted 
in profound changes in VR Caco-2 cells, which suggest a complex process of 
transformation from Caco-2 to VR Caco-2 cells and that hindered our ability to pinpoint 
specific mechanisms acquired to define NDV-specific resistance. The heterogeneous 
nature of Caco-2 cells also must have a potential role in the establishment of persistent 
infection. Recently, Russell et al. (2019) have shown that single-cell sequencing approach 
in influenza-infected A549 cells to understand the impact of genetic variation of the virus 
population on antiviral responses (258). Single-cell sequencing and epigenomics could be 
applied in future to assess the effects of heterogeneity of Caco-2 cells and virus population 



















5 Newcastle disease virus (NDV)-mediated p62/SQSTM1 
degradation 
5.1. Introduction 
Autophagy is a highly regulated self-destruction process mediated through lysosomal 
clearance of cellular organelles and cytoplasmic components to maintain the homeostasis 
by recycling mechanism inside the cell (259). Autophagy in cells can be induced by multiple 
factors including metabolic stress like growth factors or nutrient deprivation, hypoxia, 
reactive oxygen species (ROS), DNA damage, misfolded protein aggregates, damaged 
organelles, and pathogen invasion. The autophagic process initiates with membrane 
isolation by de novo synthesis known as phagophore formation. Phagophore sequesters 
damaged cellular components by invagination to form the double-membraned vesicle 
known as an autophagosome. The autophagosome then fuses with multivesicular 
endosomes to create an acidified mature autophagosome by the activation of endosomal 
proton pumps. Later, as the lysosome gets docked and merged with the matured 
autophagosome to become an autophagolysosome, where damaged organelles are 
degraded by lysosomal enzymes (260).  The general scheme of the autophagic process is 





Figure 5.1. Schematic representation of the autophagic process, adapted from White 
et al., 2015 (261). Various types of stress induce the autophagic process within cell initiated 
by membrane isolation for phagophore formation, invagination to sequester damaged 
protein aggregates and cellular organelles by vesicle elongation to form autophagosome. 
Lysosome fuses with autophagosome to clear cargo by autophagolysosome formation.  
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Autophagy is an evolutionarily conserved cardinal process for normal cellular homeostasis 
where non-selective bulk degradation of damaged cytoplasmic components occurs, but 
selective elimination of undesirable elements such as dysfunctional organelles, abnormal 
proteins and lipid aggregates as well as invading pathogens is achieved by selective 
autophagy (262).  Several types of selectve autophagy are known based on selective 
removal of damaged cellular organelle such as mitophagy (mitochondria), ER-phagy 
(endoplasmic reticulum), pexophagy (peroxisomes), and aggrephagy where protein 
aggregates are removed mediadted by ribosomes (263).  Mitochondria are important 
organelles in the cell where that function in a variety of bioenergetic, metabolic, and 
developmental processes, so cells trigger numerous quality control mechanisms to 
maintain the functional integrity of mitochondria. Hence, clearance of damaged 
mitochondria through mitophagy is cardinal process in stressed cells to maintain cellular 
homeostasis.    
  
Autophagic adaptors like p62/ SQSTM1 (sequestosome 1) and NBR1 (neighbour of Brca1 
gene) are key regulators involved in the binding of ubiquitinated substrates (damaged 
cytoplasmic components) to microtubule-associated protein 1 light chain 3 (LC3) and 
gamma-aminobutyrate receptor-associated protein (GABARAP) receptors leading to 
degradation in selective autophagy (264).  
 
Meng et al. reported mesogenic strain Beaudette C of NDV at MOI 10 triggered autophagy 
in human glioma U251 cells to enhance virus replication (141). Cheng et al. (2016), 
demonstrated NDV NP and P proteins induced autophagy in A549 human lung cancer cells 
mediated through endoplasmic reticulum (ER) stress-related unfolded protein response 
(UPR) pathways. Degradation of p62/SQSTM1 was confirmed in NDV NP, and P protein 
transfected A549 cells (265). Kang et al. also reported the degradation of p62/SQSTM1 
and conversion of LC3-I to LC3-II in NDV-infected chicken embryo fibroblast (CEF) cells. 
They also demonstrated that inhibition of apoptosis resulted in enhanced autophagy, 
increased cell survival, and viral replication (266).  
 
Human p62/ SQSTM1 is a multidomain and multifunctional protein encoded by the sqstm1 
gene located on chromosome 5 comprising eight exons including 16 kb long DNA 
sequence. The p62/SQSTM1 has five structural domains (PB1, ZZ, TB, LIR, and UBA) 
utilised in interactions with molecules involved in autophagy and signalling pathways 
(Figure 5.2A). The PB1 is an oligomerisation domain at N-terminal end made up of Phox 
and Bpem1 (PB1) elements responsible for the homodimerisation of p62 or 
heterodimerisation with NBR1, atypical protein kinase C (aPKC), and extracellular signal-
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regulated kinase (ERK). Next two are signalling domains consists of ZZ-type zinc finger 
(ZZ), and tumour necrosis-associated factor 6 (TRAF6)-binding site (TBS) domains 
responsible for the interactions with receptor-interacting serine/threonine-protein kinase 1 
(RIP1),  TRAF6,  and interaction with mTOR raptor which plays an essential role in nutrient 
sensing for mTORC1 pathway (267). Autophagy domain consists of LC3 interacting region 
(LIR) and ubiquitin-associated (UBA) proteasomal activity domain at C-terminal end (268). 
The mechanism of SQSTM1-mediated balance between cell survival and apoptotic cell 
death is explained in Figure 5.2B.  
 
Figure 5.2. Cellular mechanisms of p62/SQSTM1 adapted from Moscat et al. 2009 
(268). 
(A) SQSTM1 structural domains and interacting partners. P62/SQSTM1 consists of five 
different interacting domains include; the oligomerisation domain at N-terminal Phox 
and Bpem1 (PB1) regulates self-oligomerisation of p62 as well as interacts with a p62 
homologue protein NBR1, atypical PKC (aPKC) or ERK1. Next consists of two 
signalling domains ZZ-type zinc finger (ZZ) and TRAF6-binding site (TBS) domains bind 
with RIP1 and TRAF6 to regulate NF-KBpathway. Then followed by autophagy domain 
comprises LC3 interacting region (LIR) and last ubiquitin-associated (UBA) domain at 
C-terminal controlling proteasomal activity. 
(B) Role of p62/SQSTM1 speckles in maintaining cellular homeostasis to balance cell 
survival and cell death. The particles of p62 promote oligomerisation of caspase-8 and 
TRAF6 regulating apoptotic cell death or NF-kB pathway-mediated cell survival. 
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(C) p62/SQSTM1 accumulation results in tumorigenesis. In autophagy-deficient cancer 
cells, metabolic stress triggers increased p62 aggregates, and damaged mitochondria 
activating reactive oxygen species (ROS) formation leading to the genomic DNA 
instability and tumorigenesis. 
 
 
Cell stimulator downstream of transcription factor NF-kB such as interleukin-1 (IL-1), 
receptor activator of nuclear factor kappa-Β ligand (RANKL), or nerve growth factor (NGF) 
promote interaction of the PB1 domain of p62 with aPKC. Self-oligomerised p62, p62-aPKC 
heterodimer, and ubiquitinated p62 bound protein aggregates bind with TRAF6 and 
caspase-8. TRAF6 is a lysine 63 (K63) E3 ubiquitin ligase that activates self-
polyubiquitination, which activates the NF-kB pathway leading to the cell survival, whereas 
death receptors DR4 and DR5 activate TNF-related apoptosis-inducing ligand (TRAIL) 
promoting cullin-3 (E3) ubiquitin ligase mediated caspase-8 ubiquitination which interacts 
with the UBA domain of p62 and activates executioner caspases leading to apoptotic cell 
death (Figure 5.2B) (268). 
 
Allelic exclusion of autophagy regulator beclin-1 results in autophagy deficiency in most 
cancer cells. Where, metabolic stress in autophagy-defective cancer cells promotes the 
accumulations of p62/SQSTM1 speckles, ROS, damaged organelles, and genomic DNA 
instability. Disruption in genomic DNA in autophagy-defective tumour cells leads to 
extensive tumorogenesis. Mathew et al. (269) demonstrated that p62 elimination resulted 
in the suppression of p62-mediated tumorigenesis, as illustrated in Figure 5.2C. 
 
The role of p62 as a signalling pivot through its multidomain to control the balance of cell 
death and cell survival in cells and the accumulation of p62 speckles in autophagy-defective 
cancer cells leading to tumorigenesis, makes p62 as attractive candidate to study in virus-
infected cancer cells to underpin the mechanisms involved in virus-induced cell death. 
Already, a group of researchers (141, 266) have confirmed NDV-mediated autophagy in 
various cells benefiting the virus replication by promoting cell survival. Here in this chapter, 
based on others findings, the status and role of p62/SQSTM1 were investigated primarily 
using indirect immunofluorescence (IF) and western blot analysis to confirm that NDV 
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5.1.1. Chapter objectives 
• Establish NDV-induced mitophagy in Caco-2 cells using a mito-mRFP-EGFP dual 
reporter plasmid 
• Confirm NDV-induced p62/SQSTM1 degradation in Caco-2 cells 
• Time-course study to detect p62/SQSTM1 degradation 
• Investigate individual NDV protein role in p62/SQSTM1 degradation in Caco-2 cells 
• CRISPR/Cas9-mediated p62/SQSTM1 knockout (KO) in Caco-2 cells to investigate the 





5.2.1. Confirmation of mitophagy in Caco-2 cells 
 
A sensitive dual reporter vector mito-mRFP-EGFP expressed in-frame red fluorescent 
protein (RFP) and enhanced green fluorescent protein (EGFP) regulated by mitochondrial 
COX VIII promoter in transfected Caco-2 cells (section 2.2.1.2). The principle of pH-based 
stability of fluorescent proteins is used to detect the induction of mitophagy in stressed 
Caco-2 cells. EGFP is a pH-sensitive fluorescent protein, which degrades in acidic pH, 
whereas RFP has better resistance in an acidic environment (270). When mito-mRFP-
EGFP vector-transfected Caco-2 cells were stressed either with mitophagy inducer 
chemical CCCP (carbonyl cyanide m-chlorophenyl hydrazone) treated for 6 h or NDV Ulster 
2C-infection for 18 h, demonstrated reduced numbers of EGFP puncta relative to the RFP 
puncta in stressed Caco-2 cells. Figure 5.3 shown the detection of NDV-induced 
mitophagy in mito-mRFP-EGFP vector-transfected Caco-2 cells using the confocal 
microscope. Under no stress, transfected Caco-2 cells showed in-frame mitochondrial 
expression of RFP and EGFP proteins that created the bright yellow overlapping pattern of 
mitochondrial expression throughout the cell cytoplasm. However, NDV infection and 
CCCP treatment disrupted mitochondrial membrane potential and the induction of 
mitophagy, indicated by reduced EGFP puncta in stressed cells due to drop in pH because 
of fusion of lysosome with the autophagosome to form autophagolysosome. In the 
autophagolysosome, lysosomal enzymes degrade damaged mitochondria confirmed NDV-
induced mitophagy in Caco-2 cells. 
 




Figure 5.3. Confirmation of NDV-induced mitophagy in Caco-2 cells. A sensitive dual 
fluorescence reporter mito-mRFP-EGFP vector-transfected Caco-2 cells upon infection 
with Ulster 2C for 18 h and 20 µM CCCP treated for 6 h positive control demonstrated 
reduced green puncta formation as a result of reduced pH due to autophagolysosome 
formation. Mitochondrial COX VIII promoter drove expression of RFP (shown in red) and 
EGFP (shown in green), cell nuclei stained with DAPI (scalebar 7.5 µm, n=3). 
 
5.2.2. p62/SQSTM1 degradation study using the IF assay 
Once NDV-induced mitophagy was confirmed in Caco-2 cells, the status of p62/SQSTM1 
protein with or without NDV infection was investigated in Caco-2 cells. It has been 
demonstrated that the cancer cells attain autophagy-deficient status due to allelic exclusion 
of autophagy regulator beclin 1, where metabolic stress in autophagy-deficient cancer cells 
activates accumulations of p62/SQSTM1 aggregates, ROS, and damaged mitochondria. 
Caco-2 cells with or without NDV-infection were fixed with 4% paraformaldehyde and 
probed for p62/SQSTM1 expression and reporter virus replication (section 2.2.1.7), as 
shown in Figure 5.4. IF staining of p62/SQSTM1 (red) protein revealed an accumulation of 
endogenous p62/SQSTM1 protein in Caco-2 cells.  NDV infection with reporter virus B1-
GFP (green) at MOI 2 for 24 h resulted in a significant reduction of endogenous 
p62/SQSTM1 expression, as well as the accumulation of ectopically expressed 
p62/SQSTM1 in NDV-infected Caco-2 cells.  




Figure 5.4. NDV-induced p62/SQSTM1 degradation in Caco-2 cells. NDV infection post 
24 h demonstrated p62/SQSTM1 degradation at the endogenous as well as overexpressed 
level in Caco-2 cells. Fixed cells were probed with primary rabbit anti-SQSTM1 antibody 
and then incubated with Alexa Fluor® 568 goat anti-rabbit antibody (shown in red), NDV 
replication confirmed with GFP expressing reporter virus (shown in green), and cell nuclei 
stained with DAPI (shown in blue) (scalebar 25 µm, and n=3). 
 
 
5.2.3. Time-course study of p62/SQSTM1 degradation in Caco-2 
cells using IF and western blot assay 
The time-course study was planned to detect the time of NDV-induced p62/SQSTM1 
degradation in Caco-2 cells using IF (section 2.2.1.8), and western blotting (section 
2.2.3.10) approaches. Caco-2 cells with or without pBABEpuro-HA-p62 transfection and 
NDV-B1-GFP infection were fixed with 4% paraformaldehyde and stained for expression of 
p62/SQSTM1 (red), reporter virus replication indicated by GFP expression (green), and 
nucleic acid stain DAPI (blue) detected using a confocal microscope (Figure 5.5). IF of 
p62/SQSTM1 (red) demonstrated evidence of p62 degradation at 24 hpi and 48 hpi in both 
endogenous and ectopic levels of p62/SQSTM1 in infected Caco-2 cells compared to 
uninfected Caco-2 cells. 





Figure 5.5. Time-course study for p62/SQSTM1 degradation in NDV-infected Caco-2 
cells using indirect immunofluorescence (IF) assay.  NDV infection demonstrated 
degradation of p62/SQSTM1 in Caco-2 cells 24 hpi and 48 hpi at MOI of 2. Fixed cells were 
probed with primary rabbit anti-SQSTM1 antibody and then incubated with Alexa Fluor® 
568 goat anti-rabbit antibody (shown in red), NDV replication confirmed with GFP 
expressing reporter virus (shown in green), and cell nuclei stained with DAPI (shown in 
blue) (scalebar 50 µm, and n=2). 




Figure 5.6. Time-course study for p62/SQSTM1 degradation in NDV-infected Caco-2 
cells using western blotting. (A) Significant p62/SQSTM1 protein degradation on western 
blot was confirmed in Caco-2 cells 24 hpi and 48 hpi at MOI of 2. (B) Graph represents 
relative SQSTM1 band intensities in relation to the control GAPDH (n=3). Data (mean±SD) 
represented here were statistically analysed with Two-way ANOVA with Tukey’s multiple 
comparison test (** p < 0.05 and * p < 0.01). 
 
Cell lysates collected from untreated, B1-GFP (MOI of 2) infected, and pBABEpuro-HA-p62 
vector-transfected Caco-2 cells at 0, 12, 24, and 48 h were used to estimate the 
degradation of 62 kD p62/SQSTM1 at each time point. Western blot analysis of cell lysates 
from all time points confirmed significant degradation of p62/SQSTM1 at 24 h (**p<0.05) 
and 48 h (* p<0.01) post-infection compared to uninfected Caco-2 cells illustrated in Figure 
5.6A and B. 
Both IF and western blot analysis revealed that ectopic expression levels of p62/SQSTM1, 
mediated by a pBABEpuro-HA-p62 vector, were not significantly different in Caco-2 cells. 
Whereas, p62/SQSTM1 degradation at 0 hpi and 12 hpi remained unchanged as a result 
of minimal NDV replication (indicated by negligible GFP expression in B1-GFP infected 
Caco-2 cells), as shown in Figure 5.5. 
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5.2.4.   Investigation of role of each NDV protein in p62/SQSTM1 
degradation 
 
After establishing the NDV-induced p62/SQSTM1 degradation in Caco-2 cells, the role of 
each NDV protein in the p62/SQSTM1 degradation was investigated in cells transfected 
with plasmid constructs expressing individual NDV proteins.  NDV genes (NP, P, M, F, and 
V) were cloned into V5-tagged pEFplink.2 plasmid, and NDV-HN gene was cloned in V5-
tagged pEFplink.2 and pcDNA3.1(+) EGFP vectors. Caco-2 cells were transfected with 
plasmids encoding NDV genes for 48 h before cell lysate preparation (section 2.2.3.10). 
The cell lysates from transfected cells with or without NDV infection were examined on 
western blot to confirm NDV and p62/SQSTM1 protein expression using mouse anti-V5-
antibodies or NDV-specific chicken serum, and anti-p62/SQSTM1 antibodies, respectively. 
Western blot analysis revealed the expression of NP, P, and V proteins only (Figure 5.7 
A), and NDV M, F, and HN proteins were undetected by V5-antibodies or anti-NDV chicken 
sera. IF staining was used for the detection of NDV proteins in transfected Caco-2 cells. 
Only NDV  NP, P, M, and V proteins (green) and nucleic acid stain DAPI (blue) were 
detected using a confocal microscope (Figure 5.7 B). 
 
Figure 5.7. The investigation of the role of individual NDV protein in p62/SQSTM1 
degradation.  (A)  Western blot analysis of each NDV protein participating in p62/SQSTM1 
protein degradation 48 hpi in Caco-2 cells detected on the blot (n=2). Results showed that 
only NP, P, and V viral proteins were expressed and none of them induced p62/SQSTM1 
degradation. (NDV clones expressing NDV proteins: HN-A→ HN cloned in V5-tagged 
pEFplink.2 vector, HN-B→  pcDNA3.1(+) EGFP vector, and NP/P/M/F/V cloned in V5-
tagged pEFplink.2 vector) (B) IF assay detected expression of NDV proteins in transfected 
Caco-2 cells, where fixed cells probed with primary mouse anti-V5  antibody (V5 tagged 
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NDV NP, P, M, and V proteins) and anti-NDV chicken sera (NDV-F) then incubated with 
Alexa Fluor® 488 goat anti-mouse antibody (shown in green) and Alexa Fluor® 568 goat 
anti-chicken antibody (shown in red), and cell nuclei stained with DAPI (shown in blue) 
(scalebar NP, P, and M=25 µm; V and F=50 µm, and n=2). 
 
 
However, the NDV F protein (red) (Figure 5.7 B) was detected only using anti-NDV chicken 
sera in IF assay under a confocal microscope. The anti-V5 antibody had not worked to 
detect NDV F protein expression, as V5-tag was at N-terminal of F plasmid construct. The 
V5-tag got cleaved with signal peptide during F protein transmembrane translocation as 
predicted using SignalP 4.0 (Figure 5.8). The HN protein expression also had not been 
detected using anti-NDV chicken sera or V5-tag in Caco-2 cells. None of the individual NDV 
proteins that were detected in the transfected Caco-2 cells demonstrated degradation of 
p62/SQSTM1, suggesting that interaction of all NDV proteins or active viral replication are 
needed for SQSTM1 degradation in Caco-2 cells (Figure 5.7A). 
 
 
Figure 5.8. Prediction of signal peptide cleavge site in fusion protein sequence of 
NDV B1 strain.  Signal peptide of fusion protein predicted using SignalP 4.0 confirmed 
cleavage site between 31 and 32 amino acids from N-terminal (highlighted as a rectangle). 
NDV F protein expressed by V5 tagged  pEFplink.2 vector. F protein had V5 tag at N-
terminal in close proximity of cleavage site of signal peptide. 
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5.2.5.  CRISPR/Cas9 based p62/SQSTM1 Knockout approach in 
HEK-293 cells 
To investigate the role of NDV and host protein interactions, p62/SQSTM1 knocked out 
Caco-2 cells would have a significant role in defining NDV-induced of p62 degradation in 
Caco-2 cells. The hypothesis was based on the interaction of NDV proteins with Caco-2 
cell proteins with or without p62/SQSTM1 expression could shed light on the mechanisms 
of NDV-induced cell death in Caco-2 cells.  
Initially, p62/SQSTM1 was knocked down using 21-nucleotide long siRNA that targeted 
SQSTM1 mRNA transcript for degradation in Caco-2 (section 2.2.1.8). The concentration 
of anti-SQSTM1 siRNA was optimised in Caco-2 cells for efficient silencing of the SQSTM1, 
a 100 nM concentration was resulted in maximum knockdown of SQSTM1 transcripts 
(Figure 5.9 B). IF staining of 100 nM anti-SQSTM1 siRNA-treated Caco-2 cells showed 
significant knockdown of SQSTM1 (red) compared to the negative control non-specific 
siRNA-treated and untreated Caco-2 cells together with B1-GFP virus replication (green) 
using a confocal microscope (Figure 5.9 A). Cell lysates prepared from anti-SQSTM1 
siRNA silenced Caco-2 cells with or without B1-GFP infection at MOI of 2 for 48 h were 
used to detect NDV proteins (NP, P, and V) expression using anti-NDV chicken sera on 
western blot (Figure 5.9 C).   




Figure 5.9. p62/SQSTM1 siRNA silencing in Caco-2 cells. (A) IF analysis demonstrated significant p62/SQSTM1 silencing in Caco-2 cells 
24 hpi using the anti-SQSTM1 siRNA or negative control siRNA. NDV infection degraded SQSTM1 protein in Caco-2 cells. Fixed cells were 
probed with primary rabbit anti-SQSTM1 antibodies and then incubated with Alexa Fluor® 568 goat anti-rabbit antibodies (red), NDV replication 
confirmed with GFP expressing reporter virus (green), and cell nuclei stained with DAPI (blue) (scalebar 100 µm). (B)  Western blot analysis 
confirmed the effective concentration of anti-SQSTM1 siRNA 24 h post-transfection in Caco-2 cells (n=3). (C)  NDV replication remained 
unchanged irrespective of p62/SQSTM1 silencing 48 hpi at MOI of 2 in Caco-2 cells, NDV proteins detected on the blot (n=2). 
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Western blot analysis of anti-SQSTM1 siRNA silenced Caco-2 cells with or without NDV 
infection confirmed no change in NDV replication compared to untreated NDV-infected 
Caco-2 cells.  
Efficient NDV replication in p62/SQSTM1 knocked down Caco-2 cells is encouraging to 
study the NDV interaction with Caco-2 cell proteins in the absence or presence of SQSTM1 
protein. Hence, instead of transient siRNA-based knockdown of SQSTM1 in Caco-2 cells, 
a CRISPR/Cas9 based stable KO of SQSTM1 approach was planned. 
CRISPR/Cas9 use RNA-guided DNA endonuclease Cas9 enzyme-mediated target gene 
editing by introducing double-strand breaks (DSBs) upstream to PAM (protospacer 
adjacent motif) associated with the target DNA sequence. The DSBs are repaired in a cell 
by two effective mechanisms: imprecise non-homologous end joining (NHEJ) and precise 
homology-directed repair (HDR). NHEJ pathway is error-prone where ends of DSBs 
processed by endogenous DNA repair machinery and re-joined resulting in 
insertions/deletions (indel) mutations at the site of the junction. The indel mutations in the 
coding region cause frameshifts, resulting in the KO of the gene by the creation of 
premature stop codons. In the HDR pathway, the repair template provided by sister 
chromatid allows precise editing and governs high fidelity. 
Here, NHEJ based SQSTM1 CRISP/Cas9 KO was planned to use three guide RNAs 
(gRNAs) to target the sqstm1 gene in Caco-2 cells (enlisted in Figure 5.9 A table). ‘All in 
one’ custom synthesised lentiviral plasmid pLV01 (see vector map in Figure 5.9 B) 
provided by Sigma was used for SQSTM1 KO. The pLV01 plasmid is 12.627 kb in size 
consists of 3’, and 5’ LTR sequences useful in stable transfection of target cells. pLV01 
vector expresses gRNA targeting sqstm1 under the mammalian U6 promoter and a 
puromycin N-acetyltransferase (PAC), Cas9, and GFP under EF-1a promoter. In-frame 
expression of PAC, Cas9 and GFP genes separated by 2A sequences which encode self-
cleaving peptides, PAC and GFP expressions allow easy monitoring and selection of KO 
cells. 
All three pLV01 vectors were named pLV01-p62-18, pLV01-p62-19 and pLV01-p62-20 
based on Sigma target ID of gRNAs HS0000134618, HS0000134619, and HS0000134620 
respectively. All three plasmids separately transfected in human embryonic kidney-293 
(HEK-293) cells and Caco-2 cells (section 2.2.1.9); HEK-293 cells were used as control 
cells because of its high transfection efficiency. 




Figure 5.10. The strategy of lentiviral vector-based CRISPR/Cas9 KO of SQSTM1 in 
Caco-2 and HEK-293 cells. (A) Sequences of guide RNAs (gRNA) to KO human 
p62/SQSTM1 transcripts. (B) Lentiviral pLV01 vector map showing all-in-one custom gRNA 
expression plasmid provided by Sigma-Merck expresses gRNA under mammalian U6 
promoter and Cas9, GFP, and a puromycin N-acetyltransferase (PAC) under EF-1a 
promoter. 
 
Cell lysates were prepared from pLV01-p62-18, pLV01-p62-19 and pLV01-p62-20 plasmid-
transfected Caco-2 cells, and HEK-293 cells and used for analysing the KO efficiency of 
plasmids in cells using western blot analysis to detect of 62 kDa p62/SQSTM1 on blot 
(Figure 5.11). Western blot analysis demonstrated SQSTM1 remained undisrupted in 
Caco-2 cells, perhaps because of the poor transfection efficiency of 12.627 kb long pLV01 
plasmids, whereas HEK-293 cells had higher transfection efficiency and SQSTM1 
expression was undetected in all three-gRNA transfected HEK-293 cells indicating KO of 
the SQSTM1 gene only in HEK-293 cells.  
Furthermore, pLV01-p62-20-transfected HEK-293 cells were cultured manually in single-
cell clones (section 2.2.1.9) based on GFP expression to identify the SQSTM1 KO by PCR 
(section 2.2.3.2) and western blot (section 2.2.3.10) analysis. PCR analysis of genomic 
DNA isolated from single-cell clones confirmed partial KO of SQSTM1 on an agarose gel 
of pLV01-p62-20-transfected HEK-293 cells, where three different 700, 900, and 1055-
nucleotide long KO products were detected confirming disruption of sqstm1 gene at several 
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sites in comparison with the wild type non-transfected HEK-293 cells, as shown in Figure 
5.12A. Cell lysates prepared from isolated pLV01-p62-20-transfected HEK-293 single-cell 
clones used in western blot analysis to detect the expression of 62kD p62/SQSTM1 protein 
confirmed the KO of the gene in HEK-293 cells, as illustrated in Figure 5.12B. 
 
 
Figure 5.11. Identification of p62/SQSTM1 protein KO in Caco-2 and HEK-293 cells. 
Caco-2 and HEK-293 cells transfected with pLV01 plasmids expressing gRNA preparations 
confirmed SQSTM1 KO only in HEK-293 cells. 
 
Figure 5.12. Confirmation of p62/SQSTM1 protein KO in HEK-293 cells. (A) Agarose 
gel electrophoresis of partial KO of p62/SQSTM1 in selected HEK-293 clones showing 
multiple KO products. (B) Western blot analysis of p62/SQSTM1 KO clones confirmed the 
complete deletion of SQSTM1 protein HEK-293 cells. 





Autophagy is the cardinal process to regulate cellular homeostasis by recycling mediated 
through lysosomal degradation of damaged cytoplasmic components and cytoplasmic 
organelles in the cell (259). Generally, autophagy non-selectively sequesters cellular 
organelles in bulk for nutrient recycling under metabolic stress. However, the clearance of 
unnecessary and undesired components such as misfolded proteins and lipid droplets, 
damaged DNA, defective organelles, and virus infections initiate selective autophagy of 
several types such as mitophagy (mitochondria), ER-phagy (endoplasmic reticulum), and 
pexophagy (peroxisomes) in stressed cells (271). In selective autophagy, p62/SQSTM1 
plays a vital role as an adapter in tethering ubiquitinated cargo to the autophagy receptors 
such as LC3 leading to the elimination of damaged cargo (260, 268). SQSTM1 is a 
multifunctional, multidomain signalling hub that interacts with multiple partners to form 
either p62/SQSTM1 homodimers or heterodimers with proteins such as ERK, aPKC, and 
NBR1. Sanz et al. (2000) and Moscat et al., (2006) have demonstrated the active 
interaction of aPKC with PB1 domain stimulating NF-kB pathway by IL-1, RANKL, NGF cell 
stimulator activation downstream to the transcription factor NF-kB. TRAF6 self-ubiquitinises 
and interacts with the UBA domain of activated p62/SQSTM1 aggregates to activate NF-
kB pathway leading to cell survival (272, 273). Likewise, Jin et al. (2009) have 
demonstrated p62/SQSTM1-mediated activation of extrinsic apoptotic pathways occur 
through the interaction with the ubiquitinated caspase-8. Cell surface death receptors such 
as DR4 and DR5 activate caspase-8 and TRAIL promote cullin-3-dependent caspase-8 
ubiquitination leading to apoptotic cell death (274). Duran et al. (2011) have shown 
p62/SQSTM1-dependent regulation of nutrient-sensitive mTORC1 pathway, where the 
region between ZZ and TBS signalling domains of p62/SQSTM1 interacts with mTOR and 
raptor complex as well binds with Rag GTPases to form Rag dimer, and mTORC1 
activation (267). 
Similarly, Umemura et al. (2016) demonstrated the oncogenic transformation of non-tumour 
mice liver activated by overexpression of p62/SQSTM1. Ectopic expression of 
p62/SQSTM1 was reported, being required for instigation of NRF2 and mTORC1 in mice 
hepatocellular carcinoma (275). Both studies by Duran et al. and Umemura et al. have 
showed that upregulated p62/SQSTM1 aggregates in autophagy-deficient cells led to 
mTORC1 pathway mediated tumourigenesis. In contrast, Mathew et al. (2009) confirmed 
the suppression of tumorigenesis due to degradation of p62/SQSTM1 via autophagy (269). 
The role of p62/SQSTM1 in autophagy and other signalling pathways such as NF-kB and 
mTORC1 helps to strike a balance between cell death and survival depending on cell 
stimulators activation and type of stress in various cells. Nihira et al. (2014), have 
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demonstrated suppression of cell proliferation and induction of autophagic cell death in 
human adenocarcinoma and squamous cell carcinoma cell lines by inhibition of 
p62/SQSTM1 through siRNA-mediated silencing and chemical modulation of p62 (276). 
 
Based on the importance of autophagy in cellular homeostasis under metabolic stresses 
like DNA damage, mitochondrial damage, and viral infection; several studies had been 
done to understand the significance of virus-induced selective autophagy. Meng et al. 
(2012) demonstrated that infection by the mesogenic strain of NDV Beaudette C at MOI of 
10 in human glioma U251 cells resulted in the elevated conversion of LC3-I to LC3-II and 
degradation of p62/SQSTM1 with the involvement of class III phosphatidylinositol 3-kinase 
(PI3K)/Beclin-1 pathway (141). Jiang et al. (2014), demonstrated that NDV/FMV strain 
triggered autophagy in paclitaxel-resistant A549 cells by chemical modulation targeting the 
autophagy inhibiting the class-I PI3K/Akt/mTOR/p70S6K pathway. Chemotoxic autophagy 
modulators enhanced  NDV-induced oncolysis in drug-resistant A549 cells (277). Cheng et 
al. (2016) have reported that NDV NP and P protein transfection alone were sufficient to 
induce autophagy in A549 cells through endoplasmic reticulum stress-related unfolded 
protein response (UPR) pathway (265). However, in this study, NP and P protein 
transfections were not sufficient to degrade p62/SQSTM1 protein in Caco-2 cells, as shown 
in Figure 5.7 A. Sun et al. (2014) reported the benefits of autophagy for NDV replication in 
chicken cells and tissues. Their study reported NDV-induced autophagy in DF-1 and CEF 
cells evident by the presence of double-membrane vesicle formation and LC3-I to LC3-II 
conversion. Inhibition of autophagy via RNA silencing and chemical modulators reduced 
virus replication, suggesting the importance of autophagy in NDV replication in chicken 
cells (278).  
 
In all the above studies, NDV-induced autophagic fluctuation mediated by degradation in 
p62/SQSTM1 and LC3-II conversions were noticed. In this chapter, only the status of 
p62/SQSTM1 and impact of NDV replication on p62/SQSTM1 in NDV-infected Caco-2 cells 
was examined. The lentogenic NDV strain Hitchner B1 clearly induced p62/SQSTM1 
degradation at MOI of 2, 24 hpi. However, experiments to examine the direct role of NDV 
proteins in p62/SQSTM1 degradation showed that at least NDV NP and P and V proteins 
expressed alone were not enough to cause degradation of p62/SQSTM1 in infected Caco-
2 cells (Figure 5.7 A). These findings suggested that interaction of some or all NDV 
proteins, and/or active viral replication, may perhaps be required. Additional detailed 
studies are required to understand the role of autophagy in Hitchner B1-induced oncolysis 
and pathways involved in Caco-2 cells.  
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The lack of working monoclonal antibodies (mAbs) targeting NDV F and HN proteins 
restricted the detection of their expression by western blot analysis. Further studies in the 
future using different cloning approaches and use of mAbs targeting NDV F and HN 
proteins, along with other NDV proteins, for a detailed examination of all interacting partners 
of p62/SQSTM1 are required to identify pathways involved in p62/SQSTM1 degradation 
and NDV replication in Caco-2 cells.  
 
Poor transfection efficiency of Caco-2 cells posed limitations in establishing CRISPR/Cas9 
based SQSTM1 KO in Caco-2 cells using stable transfection method. In future, by 
employing replication-defective lentiviral particles expressing pLV01 vector leading to 
perpetual expressions of gRNA targeting SQSTM1, Cas9, PAC, and GFP can be achieved 
using transduction approaches to produce SQSTM1 KO Caco-2 clones. Comparison of 
SQSTM1-deleted Caco-2 cells with wild type Caco-2 cells can be used to study NDV-host 
protein interaction as well as to understand the role of p62-dependent autophagic cell death 

















6  Genomic diversity and evolution of quasi-species in 
Newcastle Disease Virus (NDV) infections 
 
Note: This chapter is produced out of interest after gathering interesting results from the 
bioinformatic analysis of RNA-Seq data generated from acutely or persistently NDV-
infected and uninfected Caco-2 cells in this PhD project. Prof Chan Ding (Shanghai 
Veterinary Research Institute, China) has kindly provided the RNA-seq data from LaSota 
or Herts/33 infected chicken embryonic fibroblasts (CEF) cells for the NDV quasi-species 
analysis. All evolutionary analyses were executed by Dr Luca Ferretti and Dr Lele Zhao 
(Big Data Institute, University of Oxford). I, the author of this thesis, have contributed in 
generating samples from B1-GFP infected Caco-2 cells (18 hpi and 36 hpi), VR Caco-2 
cells, and uninfected Caco-2 cells (3 replicates of VR Caco-2 and Caco-2 cells) for RNA-
seq analysis and I have contributed in writing the introduction and explaining the results of 
Figure 6.1 and Figure 6.2. Dr Luca Ferretti has done most of the bioinformatics analysis 
of the RNA-seq data, interpretation of the results and writing of the rest of the chapter. 
 
6.1. Introduction 
RNA viruses often have high mutation rates due to the error-prone nature of RNA 
polymerases (279, 280). Inside a host, viral RNA polymerases induce roughly 10-4 
mutations per nucleotide copied due to low fidelity, and this may result the formation of a 
viral swarm, i.e. a pool of similar genotypes differing only by a handful of mutations (279, 
280). This is a distinctive pattern of intra-host genetic variability in organisms with high 
mutation rates. In viral infections, this is frequently related to quasi-species dynamics, with 
complex interactions between the viruses in the swarm (279, 280). Viral quasi-species is 
defined as an assortment of closely-related viral genomes subjected to a continuous 
process of genetic variation, competition between the generated variants, and selection of 
the fittest distributions in a specified environment (281).  
 
NDV is thought to have a relatively low mutation rate per site per year among RNA viruses 
(282). However, recent phylogenetic estimates of the substitution rate are large enough to 
suggest the presence of within-host diversity (283). In fact, NDV infections are well known 
to harbour quasi-species, and a significant amount of research has been focused on the 




different profiles of virulence determined by mutations in the fusion protein cleavage site. 
These mutations are sometimes polymorphic within NDV quasi-species and can transform 
avirulent lineages into highly pathogenic ones (284, 285) representing, therefore, a 
potential risk for animal health. 
 
Despite this, very little is known or has been done about the characterisation of the genomic 
patterns of diversity and selection in NDV viral swarms. Mutational biases in NDV quasi-
species have been recently described (286), but without any discussion of the patterns of 
variants across different strains, genes or hosts. 
 
In this chapter, we have used the RNA-seq short-read data obtained for the transcriptomic 
analysis (Table 6.1) to extract information about the genomic patterns of variability and the 
signatures of selection within NDV swarms. The RNA-seq data include samples from 
acutely B1 strain infected Caco-2 cells (18 hpi and 36 hpi at 0.1 MOI), persistently NDV-
infected VR Caco-2 cells, LaSota-infected CEF cells (12 hpi at 1 MOI) and Herts/33-
infected CEF cells (12 hpi at 1 MOI). NDV strains B1 and LaSota are avirulent/vaccine 
strains that belong to genotype II, and Hers/33 is highly pathogenic/velogenic strain 
belonging to genotype IV. Here, comparisons made for both diversity patterns and selection 
pressure at the amino acid level (i.e. dN/dS) across different genes, strains (B1 and LaSota 

























6.2.1. Genetic diversity 
The RNA-seq reads were processed as for transcriptomic analysis (Chapter 3, section 
2.2.6.). All reads with mapping quality <30 and all bases with base quality <30 were 
discarded. SNPs (single nucleotide polymorphisms) and indels (insertions/deletions) were 
called on the resulting sequences using SiNPle (287) with parameter theta=0.01, retaining 
only variants with <5% posterior probability of being sequencing/amplification errors or 
artefacts.  
All evolutionary analyses were implemented in R by Dr Luca Ferretti and Dr Lele Zhao (Big 
Data Institute, University of Oxford) using custom scripts and the APE package (288).  
For most samples, the coverage varied widely along the NDV genome, with the lowest 
coverage in the sequence coding for the L protein (Figure 6.1). The minimum of the typical 
coverage of L across samples was about 500. Read depth has a strong effect on estimates 
of genetic diversity (289). Hence, for the results to be comparable across genomic regions 
and samples, all sites with reading depth <400 were ignored. Similarly, all variants with 
frequency <0.005 (i.e. all variants in the regions with lowest read depth to be contained with 
at least two reads) were ignored. Where not specified otherwise, running averages across 














Figure 6.1. Read depth per position along the NDV genome. The green line represents 
the threshold for our analysis (read depth=400), which include most of the genome for all 
samples, where R1, R2, and R3 represents three different biological replicates of infected 




Genetic variability amongst all samples was estimated by calculating three classical 
measures across all the SNP variants (289):  
• The SNP density - i.e. the average fraction of polymorphic bases; 
• The pairwise nucleotide diversity – i.e. the fraction of bases differing among two random 
sequences; 
• The average entropy per base, which is another measure of diversity corresponding to 
Shannon’s entropy applied to the distribution of variants in each base.  
The averages per base of these different measures are illustrated in Figure 6.2 in all 
compared NDV strains in Caco-2 and CEF cells. These measures of genetic variability 
show that genetic diversity increased in B1-infected (MOI=0.1) Caco-2 cells from 18 hpi to 
36 hpi, as a result of the increased number of viral replication cycles and the consequent 
increase in the number and frequency of mutations. The genetic diversity was found to be 
even higher in persistently NDV-infected VR Caco-2 cells, which could be related to the 
selection pressure on the NDV population in VR Caco-2 cells during persistent NDV 
infection (Figure 6.2). The genetic variability of avirulent B1 strain of NDV was higher in 
Caco-2 cells at 36 hpi and in VR Caco-2 cells compared to the highly pathogenic Herts/33 




strain of NDV in chicken (CEF) cells (Figure 6.2). In chicken cells, the more virulent strain 
(Herts/33) had higher diversity than the avirulent one (LaSota) as could be expected 




Figure 6.2. Diversity measurements per base across different samples. Higher genetic 
diversity was observed in Herts/33 compared with LaSota in infected CEF cells. An 
increase in viral diversity in time was observed in B1-infected Caco-2 cells from 18 hpi to 
36 hpi and persistently NDV-infected VR Caco-2 cells. Here R1, R2, and R3 represent three 
different replicates of infected VR Caco-2 or CEF cells with different NDV strains (All 




• The SNP density is the average fraction of polymorphic bases; 
• The pairwise nucleotide diversity is the fraction of bases differing among two random 
sequences; 
• The average entropy per base, which is another measure of diversity corresponding to 
Shannon’s entropy applied to the distribution of variants in each base 





Figure 6.3. Local SNP density estimation along the NDV genome across all samples. 
The blue vertical lines represent the NDV gene boundaries (NP, P, M, F, HN, and L) in all 
samples, where R1, R2, and R3 represents three different biological replicates of infected 
VR Caco-2 or CEF cells with different NDV strains (All samples have running averages of 
250 bases, reading depth ≥400, and all variants with frequency ≥0.005).  
 
 
Figure 6.4. Measures of nucleotide diversity along the NDV genome across all the 
samples. The blue vertical lines represent the NDV gene boundaries (NP, P, M, F, HN, 
and L) in all samples, where R1, R2, and R3 represents three different biological replicates 
of infected VR Caco-2 or CEF cells with different NDV strains (All samples have running 
averages of 250 bases, reading depth ≥400, and all variants with frequency ≥0.005). 
Pairwise diversity showed in red colour and entropy in black colour. 






The patterns of SNP density along the genome differ clearly across samples and genes 
(Figure 6.3). There is a strong excess of SNPs at the 3 prime end for acute infections (B1 
36 hpi in Caco-2 cells and Herts/33 12 hpi in CEF cells) contrasted by an excess at the 5 
prime end for the other samples (B1 18 hpi in Caco-2 cells, persistent NDV in VR Caco-2 
cells, and LaSota 12 hpi in CEF cells). Some general features are the concentration of 
SNPs in noncoding regions (between two genes and 3 prime/5 prime ends). Although with 
different patterns depending on the sample: for example, mutations in Caco-2 samples lie 
mostly between P and M genes, while in Herts/33 infected CEF cells they are concentrated 
between NP and P genes. Among coding regions, only the HN gene shows peaks 
systematically in SNP density. 
The same different patterns are visible in nucleotide diversity and entropy across different 
samples and genes (Figure 6.4). There is a strong excess of pairwise diversity at the 3 
prime endfor acute infections (B1 36 hpi in Caco-2 cells and Herts/33 12 hpi in CEFcells) 
contrasted by an excess at the 5 prime end for the other samples (B1 18hpi in Caco-2 cells, 
persistent NDV in VR Caco-2 cells, and LaSota 12 hpi in CEFcells). Some general features 
are the concentration of pairwise diversity in noncoding regions of B1-infected Caco-2 cells 
at 36 hpi (between two genes and 3 prime/5 prime ends). These differences could be due 
to mutational patterns or different selection pressures. 
  
 
6.2.2. The frequency spectrum of mutations of NDV cultured in 
Caco-2 and CEF cells 
 
The frequency distribution of mutations hints at dynamic, demographic and selective 
processes within the viral population (290, 291). Most of the distributions illustrated in 
Figure 6.5 for all samples show a spectrum strongly concentrated around low frequencies. 
This is expected for viral swarms generated by a large number of slightly deleterious 
mutations. It is also expected for rapidly expanding populations, such as viral ones during 
acute infections. Even the spectrum of Herts/33 virus-infected CEF cells, despite some 
amount of common mutations, is strongly skewed towards rare mutations. 





Figure 6.5. Mutation site frequency spectrum for SNPs across all samples. They are 
shown as histograms of the number of SNPs with a given minor allele frequency. All these 
spectra are concentrated around low frequencies, as expected from population genetics 
and quasi-species theory (All samples have running averages of 250 bases, reading 
depth ≥400, and all variants with frequency ≥0.005). 
 
A simple way to visualise and quantify such an effect is the Tajima’s D statistics, which is 
defined as the relative difference of pairwise nucleotide diversity and SNP density after the 
latter is normalised by a factor of |log (minimum frequency)| to account for the different 
scale of the two statistics (290, 291). Tajima’s D statistic illustrates the deviations from the 
equilibrium between common variants (which contribute positively) and rare variants (which 
contribute negatively), and it is about 0 in neutrally evolving populations of constant size. 
The values for all datasets are illustrated in Figure 6.6.  
The viral populations in VR Caco-2 cells clearly contain many common variants. This 
excess cannot be explained purely by the fact that the population is stable as the value of 
Tajima’s D is positive for all VR Caco-2 samples (from passage 25) (Figure 6.6). Such an 
abundance of common variants suggests that the quasi-species in VR Caco-2 cells have a 
strong subpopulation structure with multiple possibly interacting components. These 
subpopulations could be maintained by complex selective pressures, ecological 
interactions or multiple niches in persistently-infected VR Caco-2 cells. These results 
suggest that a pool of complex viral population is present in the persistently NDV-infected 
VR Caco-2 cells. 
 





Figure 6.6. Tajima’s D (a measure of the relative abundance of common vs rare 
alleles) across all samples. Most values are negative, i.e. variants are mostly rare. The 
exception is VR Caco-2 samples, which displayed many common variants at intermediate 
frequencies. Herts/33 also showed a slightly higher number of common variants. 
 
 
6.2.3. Selection pressure on polymorphisms in coding sequences 
The location represents a key feature to understand selection pressure on polymorphisms 
– and by extension of the functional role – of the variants. Figure 6.7 show the frequency, 
location, and annotation of all variants in terms of whether coding or noncoding of the 
general location and the specific location within a codon.  





Figure 6.7. Location, frequency and classification of all SNPs across all samples. The 
blue vertical lines represent the NDV gene boundaries (NP, P, M, F, HN, and L) in all 
samples, where R1, R2, and R3 represents three different biological replicates of infected 
VR Caco-2 or CEF cells with different NDV strains (All samples have running averages of 
250 bases, reading depth ≥400, and all variants with frequency ≥0.005). 
 
In particular, the comparison of 1st and 2nd base of each codon with the 3rd one has made 
to estimate if selection acts at coding and noncoding region of the nucleotide sequence. 
Since mutations in 1st and 2nd bases are most often nonsynonymous and mutation in 3rd 
bases are most often synonymous, the comparison 1st/2nd versus 3rd base is a good proxy 
for nonsynonymous/synonymous comparisons and therefore for selection at the level of 
the protein sequence. The selection at the nucleotide level on coding sequences (3rd base 
only) and noncoding ones  compared to estimate if selection acts on the nucleotide 
sequence as well.  To do so, bases that are contained in the mRNA but usually not involved 
in the determination of the protein sequence are compared (i.e. the 3rd base of each codon) 
with bases that are not contained in the coding sequence at all (bases in noncoding 
regions). This approach would reveal the selection on the coding vs non-coding RNA. 
A summary of the comparisons can be seen in Figure 6.8. Purifying selection appears to 
be quite strong for acute infections, but weak for persistent or milder infections. On the 
other hand, most samples show a strong purifying selection on the 3rd base. The latter 
signal could be spurious and related to hypermutability at some of the noncoding sites as 








Figure 6.8. Measures of selection related to comparison of nonsynonymous to 
synonymous variants ratio. When these ratios are close to 1, selective pressures are 
similar for the two classes. In a red, relative number of SNPs located in 1st and 2nd base of 
codons versus 3rd base. This is a measure of selection on amino acid (protein) sequences. 
Purifying selective pressures appear to be present in acute virulent infections (acute B1 in 
Caco-2 cells and Herts/33 in CEF cells). In green, SNPs in 3rd base of codons versus 
noncoding SNPs. This is a measure of selective pressure on gene sequences at the RNA 
level. Note that hypermutability in specific noncoding regions between two genes or at 3 
prime or 5 prime end of the genome could be affecting this measure. 
 
 
6.2.4. Comparison between phylogenetic divergence and within-
sample polymorphisms divergence between different NDV 
sequences from the same genotype 
 
The comparison of the amount of polymorphic (synonymous or nonsynonymous) sites 
within and between populations – i.e. the analysis of polymorphisms versus divergence - is 
a popular tool to find regions of the genome under selection (290, 291). This comparison is 
useful because it is not affected by mutational biases favouring mutations at specific 




locations in the genome: such biases would affect polymorphisms and divergence equally, 
and therefore disappear in the comparison 
 
Patterns of NDV polymorphisms in Herts/33 virus-infected CEF cells differed from patterns 
of divergence in genotype IV (sequences in red in the tree in Figure 6.9). The divergence 
is quite homogeneous among coding regions and peaks in noncoding ones, while 
polymorphisms are skewed towards the noncoding 3 prime end of the genome and the 
noncoding region between the NP and P genes (Figure 6.11). Patterns of NDV 
polymorphisms in VR Caco-2 cells also bear little resemblance to the patterns of divergence 
in genotype II (Figure 6.12). A high level of polymorphisms in the L gene (which is quite 
conserved at the phylogenetic level) was observed possibly due to purifying selection 
pressure. The relatively low levels of noncoding polymorphism observed in the region 
between the NP and P genes. Also, relatively low levels of polymorphisms in coding regions 
of P gene. A relatively high levels of polymorphisms observed in noncoding region between 
P and M genes, and high polymorphisms at the 5 prime end of the genome of genotype II 
samples (Figure 6.10).  
 
These results point to strong differences in the patterns of  within-culture selection and the 
selective pressures between host cells. These differences could be related to the complex 
interactions between the different components of the quasi-species in VR Caco-2 cells and 
the related selective pressures. Sequences other than B1, LaSota, and Hets/33 from the 
genotype II and genotype IV were chosen randomly and were enough to represent 




Figure 6.9. Neighbour-joining tree of avirulent NDV strains (genotype II, including 
LaSota and B1) and highly pathogenic strains (genotype IV, including Herts/33) used 
for the estimates of within-genotype divergence. 






Figure 6.10. Comparison between patterns of divergence (scale on the left) and 
polymorphisms (nucleotide diversity, right) along the NDV genome for all samples 
in genotype II. (All samples have running averages of 250 bases, reading depth ≥400, and 




Figure 6.11. Comparison between patterns of divergence (scale on the left) and 
polymorphisms (nucleotide diversity, right) along the NDV genome for all samples 
in genotype IV. (All samples have running averages of 250 bases, reading depth ≥400, 
and all variants with frequency ≥0.005). 
 
For VR Caco-2 cells, the patterns of nonsynonymous/synonymous mutations compared in 
coding regions. More precisely the average within-sample polymorphism or divergence 




among genotype II sequences computed across the 1st and 2nd base in codons compared 
with the same quantities computed for the 3rd base in codons (Figure 6.12).  
 
 
Figure 6.12. The ratio between polymorphisms (pairwise nucleotide diversity) or 
divergence estimated across the 1st and 2nd base of each codon versus the same 
quantities estimated for the 3rd base. (All samples have running averages of 250 bases, 
reading depth ≥400, and all variants with frequency ≥0.005). 
 
Comparison between genotype divergence demonstrated that protein sequences are under 
strong purifying selection between cell lines derived from different hosts. On the other hand, 
polymorphisms show a trend towards positive selection (especially in NP and between HN 
and L genes) in VR Ccao-2 cells (Figure 6.12). It is contrasting with strong purifying 
selection between M and F regions as well as in a region of the L gene located about 10000 
bases from the 3 prime end of the genome which is also under strong between-host 
negative selection. This has confirmed significant differences in selection patterns within 
VR Caco-2 cells and highlights the functional role of NP, P and HN/L genes in quasi-species 
in persistent infections. The divergence genotype II analysis of VR Caco-2 cells 
demonstrated that high levels of polymorphism in HN gene where tail region of HN protein 
was found more conserved than globular head. The receptor binding avidity assay and 
comparative HN protein structure analysis of VR Caco-2 with B1 strain have confirmed  











The presence of nucleotide variants and viral swarms is a common feature of RNA viruses, 
due to the error-prone nature of RNA polymerases. However, the structure and the 
selective forces on these swarms depend on the virus and the details of virus-host 
interactions. In this chapter, the patterns of nucleotide variants have shown within NDV 
samples. NDV viral swarms with a significant number of variants observed within all 
samples. This illustrates that NDV is also prone to generating viral swarms.  
A limitation of this study is that the samples (presented in this chapter) were extracted from 
cell lines and therefore, do not necessarily share the same dynamics of viral populations 
from host tissues. Nevertheless, our findings suggest that such swarms could be found 
within NDV natural hosts as well. They could play a role both in the infection process and 
in the evolution of the virus, as happens for other RNA viruses.  
It is already well known that variants in the NDV F (fusion) protein cleavage site can create 
a mixed population of lentogenic and velogenic viruses, which has a strong impact on the 
pathogenicity of the virus, but we do not observe any variant of significant frequency in that 
region (285, 292). 
Purifying selection on viral swarms is likely to be partially shared at the within-host and 
between-host scales, because of structural constraints on proteins and RNA. Purifying 
selection could be weaker within hosts because of the lack of transmissibility constraints 
on viral sequences. A surprising amount of purifying selection was observed within the cell 
cultures: polymorphic bases were concentrated in small regions of the genome, most often 
in the noncoding areas, suggesting strong selection on the coding sequences. A possible 
alternative explanation for these findings could be hypermutability at some (noncoding) 
sites or even recombination hotspots, but there is no direct evidence of any of these 
phenomena.  
The strongest signals of purifying selection on protein sequences were found in the 
samples from highly pathogenic infections. Viral populations in these samples are expected 
to have experienced recent rapid expansion, reducing the impact of any form of selection, 
which is in contrast with the above observation. More samples and longer times post-
infection, or longitudinal studies, would be needed to clarify the relevance of this effect.  
Intra-host variants are often shaped by selective forces that act within host tissues or cell 
cultures and can be extremely different from the ones observed between hosts. In fact, a 
comparison between the genomic distribution of polymorphisms and substitutions revealed 
a mismatch among selection pressures in cultures and between hosts. However, the 




number of variants was often not large enough to enable these patterns to be studied in 
detail. 
Variants in viral swarms may interact, for example via complementation or positive selection 
on viral diversity itself. Such complex interactions represent the hallmarks of the so-called 
“quasi-species” dynamics. Rare variants characterise the quasi-species structure observed 
in NDV populations from acute infections, and it is typical of expanding viral swarms. No 
evidence was found of complex quasi-species structure or interactions, although it would 
be difficult to observe them in the early phase of acute infections, because of the small 
number of variants and their low frequency.  
On the other hand, persistently infected VR Caco-2 cells revealed a rich and complex quasi-
species structure. Variants at intermediate frequency suggest the presence of multiple 
subpopulations, possibly related to the heterogeneity of the host cell line or the complexity 
of the system and the different niches therein. These patterns suggest that these cells could 
harbour complex quasi-species dynamics in the proper sense. The profiles of variability 
observed here could indicate which genes are actually involved in these complex 
interactions. Variants in NP and HN were more abundant than expected based on the 
divergence between sequences belonging to genotype II, suggesting that those genes are 
involved in quasi-species dynamics. A nonsynonymous/synonymous 
polymorphism/divergence analysis of the quasi-species showed evidence of strong 
selection against amino acid polymorphisms in L, M and F, while amino acid polymorphisms 
in NP and P appear to be neutral on average, which is consistent with the potential role of 
these two genes in quasi-species interactions; amino acid variants in a region between HN 
and L was favoured by selection in VR Caco-2 cells, pointing to this genomic region as a 
further determinant of such interactions.  
The role of quasi-species in the interaction between the viral population and Caco-2 cells 
is unclear, although the quasi-species structure could be related to the changes between 
naïve and persistently infected cells. Further deep sequence data from persistently infected 









7 General Discussion 
 
Oncolytic viruses (OVs) are gaining augmented attraction as a modern-day cancer therapy 
and are being utilised in extensive clinical trials worldwide (293).  The United States Food 
and Drug Administration and the European Union in 2015 have already approved 
IMLYGIC™ (T-VEC/Talimogene Laherparepvec), a genetically engineered live-attenuated 
HSV-1, to treat post-operative melanoma in an advanced state (38, 39). The Chinese Food 
and Drug Administration in 2005 has also approved the only adenovirus-based Oncorine 
vaccine for the treatment of advanced head and neck cancer with a combination of 
chemotherapy (31). There are more than 40 OVs such as adenoviruses, poxviruses, 
HSV‑1, coxsackieviruses, poliovirus, measles virus, Newcastle disease virus (NDV), 
reovirus etc., belonging to over 10 different viral families are presently used in ongoing 
clinical trials either as a combination therapy or monotherapy to study various malignancies 
(26). NDV is an avian pathogen and known for its oncolytic properties over five decades. It 
has also demonstrated its potential to be an effective oncovirotherapeutic in several phase-
I/-II clinical trials (154, 294). 
 
This thesis set out to test the oncolytic properties of avirulent strains of NDV such as 
Hitchner B1, B1-GFP, LaSota, LaSota-GFP, and Ulster in various human cancer cell lines 
(Caco-2, A549, HeLa, Hep G2, and PC3). The Hitchner B1, B1-GFP, and LaSota strains 
demonstrated effective oncolysis in a heterogenous colorectal Caco-2 cell line. The 
oncolytic potential of naturally occurring Hitchner B1 and Ulster strains were demonstrated 
in several pancreatic cancer cell lines (295). The Hitchner B1 strain was genetically 
modified by altering the cleavage site in F protein to polybasic cleavage site of 
hyperfusogenic F protein and also by the addition of the gene for  GFP and luciferase. A 
genetically engineered B1 strain demonstrated increased oncolytic potential in murine 
colon cancer cell line (CT26) in vitro as well as in vivo CT26 tumour bearing mouse model 
(163) and also in human pancreatic, breast, thyroid, head and neck, and gastric cancers, 
as well as human and murine malignant melanoma cell lines (168). Here, naturally 
occurring Hitchner B1 and genetically modified B1-GFP both have demonstrated induced 
significant cytotoxicity in vitro in Caco-2 cells.  
Despite the high levels of NDV-induced cell cytotoxicity in Caco-2 cells, all avirulent strains 
(Hitchner B1, B1-GFP, LaSota, and LaSota-GFP) of NDV used in this PhD project were 
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able to establish persistent infection in small a proportion of Caco-2 cells. The isolated 
persistently NDV-infected Caco-2 cells were named VR Caco-2 (virus-resistant Caco-2) 
cells. VR Caco-2 cells (persistently NDV-infected Caco-2 cells) developed different 
behaviour compared to uninfected Caco-2 cells, which included 2-times slower cell 
proliferation, and continuous production of recoverable replicating NDV viral particles with 
lower virus titres. The persistent NDV infection of cell lines is not a novel phenomenon, and 
it already has been demonstrated in infected with a highly pathogenic strain of NDV 
(Victoria) infected pancreatic mucinous cystic neoplasms (L(MCN)) cells (296), highly 
pathogenic AF2240 strain of NDV-infected colorectal cancer cell line SW480 (237), and 
moderately pathogenic strain 73T-GFP of NDV-infected ovarian cancer cell line OVCAR3 
(238). Here, for the first time demonstrated that lentogenic/non-pathogenic strains of NDV 
established persistent infection in Caco-2 cells.  All persistently NDV-infected cells (MCN, 
SW480, and OVCAR3) produced replicating NDV particles at lower viral titres than B1 and 
B1-GFP strains of NDV, and a similar outcome has been demonstrated in VR Caco-2 cells. 
The resistance to heterologous viruses such as VSV (vesicular stomatitis virus) and 
homologous viruses (NDV) superinfection have been demonstrated in persistently NDV-
infected L(MCN) cells, and the resistance was potentially explained by non-infectious viral 
particles and IFN production in L(MCN) cells (296). A similar trend of resistance to 
superinfection with heterologous or homologous viruses has been demonstrated in 
persistently NDV-infected OVCAR3 cells, and the acquired resistance was demonstrated 
to be due to the production of IFN-β but not because of defective interfering viral particles. 
Persistently NDV-infected OVCAR3 cells have achieved an antiviral immune status by 
constitutive expression of type-I IFN and IFN-induced antiviral proteins such as RIG-I, 
MDA5, and Mx1 (238). 
 
In contrast, the susceptibility of VR Caco-2 cells to other viruses such as AIV (avian 
influenza-H9N2) and VSV infections demonstrated while maintaining specific resistance to 
re-infection with NDV. The VSV infection has resulted in increased cell cytotoxicity of VR 
Caco-2 cells.  Both Caco-2 and VR Caco-2 cells were demonstrated inefficient in the 
induction of IFN-β and ISG15 mRNAs in response to various stimuli (viruses and synthetic 
mimic of dsRNA), suggesting that VR Caco-2 cells lacked the active type-I IFN-mediated 
antiviral immune response. The establishment of persistent NDV infection was investigated 
in A549 cells. The A549 cells were moderately susceptible to NDV-induced cytotoxicity only 
at higher viral doses. The persistent infection was not observed in A549 cells, potentially 
explained by active type-I IFN responses recorded as a significant induction of IFN-β and 
ISG15 mRNAs upon NDV infection. Perhaps it suggests that the active type-I IFN pathways 
prevents NDV from establishing persistent infection in A549 cells. 
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In studies using VSV infection of BHK cell cultures, next-generation sequencing (NGS) 
approach has been utilised to characterise VSV defective interfering particles (DIPs) in 
BHK cell cultures and validated by quantitative reverse transcription-PCR (256). A similar 
approach can be used in future to examine the role of DIPs in VR Caco-2 cells to study its 
impact on persistent NDV infection.  
 
The NDV in persistently infected OVCAR3 cells has confirmed the hyperfusogenic nature 
because of reported mutation in the cleavage site of NDV F protein at F117S and altered 
receptor binding of HN protein due to mutation in the second sialic acid binding site at 
HN169R (238).  Also recently a switch from lytic to persistent infection of parainfluenza virus 
type 5 (PIV5) has been demonstrated in A549 cells due to the single mutation in one of the 
phosphorylation sites of P protein of PIV5 (253). The sequence analysis of F, HN, and P 
mRNA transcripts of NDV produced in VR Caco-2 cells have not identified any of the 
reported mutations in either of the protein. However, I have identified several mutations 
surrounding the antigenic site 23, HA, and NA active sites of HN protein as well as several 
sites in P protein of NDV produced from VR Caco-2 cells, which need further investigation 
to detect the effect of each mutation on persistent NDV infection in VR Caco-2 cells. I have 
also demonstrated that NDV from VR Caco-2 cells have 6-times higher receptor binding 
avidity to partially sialic acid depleted cRBCs than B1-GFP strain of NDV. 
 
The integrated approach using RNA-seq and proteomic data was employed to estimate the 
impact of persistent NDV infection in VR Caco-2 cells in comparison with uninfected Caco-
2 cells. The integrated analysis has shown the activation of p53-independent G1/S DNA 
damage checkpoint, p53-Dependent G1 DNA damage response, and regulation of 
apoptosis in VR Caco-2 cells. The DNA damage response (DDR) pathways activation have 
been reported in various RNA virus-infected cells responsible for the instigation of 
inflammatory responses, activation of apoptotic cell death, and promotion of genomic 
instability leading to the increased risk of tumourigenesis (138). The activation of apoptotic 
cell death has been demonstrated in highly pathogenic NDV AF2240 strain infected GBM 
cells, which was identified by the loss in DNA in treated cells in G1, S and G2/M phases of 
the cell cycle, and shrinkage and blebbing of the membrane (140). The RNA-seq data from 
acutely NDV-infected Caco-2 and CEF cells have also confirmed the activation of DNA 
damage pathways. The PIV5 virus mutant P/V-CPI has demonstrated to establish 
persistent infection in human laryngeal cancer HEp-2 cells, and persistently infected cells 
have demonstrated an increase in sensitivity to cisplatin-induced DNA damage and cell 
death.  The persistently infected HEp-2 cells have also shown the increased basal caspase 
activation, and cell viability was dependent on the activity of cellular inhibitors of apoptosis 
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(IAPs) such as survivin and XIAP. Also, cisplatin-induced cell death was found to be 
associated with DNA damage signalling pathways such as Chk1 phosphorylation and 
nuclear translocation of damage-specific DDB1 protein (DNA damage binding protein 1) 
(297). Likewise, the investigation of various DDR pathways in acute and persistent NDV-
infected Caco-2 cells is required to understand the mechanism of NDV-induced oncolysis 
as well as to identify pathways exploited by the virus in order to survive persistent NDV 
infection. 
 
The RNA-seq data analysis of persistently NDV-infected VR Caco-2 cells has 
demonstrated extensive changes in the regulation of 10039 genes while maintaining 50-
times lower viral burden compared to acute NDV-infection 36 hpi at 0.1 MOI in Caco-2 cells. 
The transcriptomic analysis has revealed the upregulation of antiviral responses associated 
with ISGs such as IL15, OASL, IFIT1, C3, CASP1, DDX60 etc., and pathways included 
IFN-signalling, cytokine regulation and TLR activation by endogenous ligands in VR Caco-
2 cells compared to uninfected and acutely NDV-infected Caco-2 cells. These pathways 
and ISGs need to be validated in both persistently and acutely NDV- infected Caco-2 cells. 
Caco-2 cells are heterogeneous cell line and when grown as a 3D (3-Dimensional) culture 
in rotating wall culture vessel attains multicellular complexity by an intestinal cell 
differentiation to the intestinal epithelium, with apical-basolateral polarity, brush borders, 
the formation of well-developed tight junctions (249).  The RNA-seq data analysis has 
shown that VR Caco-2 cells have attained more complexity by regulating intestinal 
differentiation markers such as MUC 17, SLC10A1, MS4A10, Orm2, SLC38A4, and ALB 
compared to the acutely NDV-infected and uninfected Caco-2 cells. It seems that the 
complexity of Caco-2 and VR Caco-2 cells with or without NDV need to be investigated 
further by culturing in the 3D model. The heterogeneity of Caco-2 cells and NDV infection 
seems to play a role in persistent infection apart from its inefficient IFN-β mRNA induction. 
The heterogeneity of Caco-2 cells and NDV population can be investigated further by 
considering the single-cell sequencing and epigenomics study.  
 
NDV is also known to induce autophagy upon infection and activates several signalling 
pathways leading to cell death. SQSTM1/p62 is a multifunctional and multidomain 
signalling adapter molecule required for selective autophagy. The induction of autophagic 
cell death has been demonstrated in human cancer cells (141, 265, 277) and chicken cells 
(266, 278) by observing the fluctuation in SQSTM1/p62 protein along with the conversion 
of LC3-II with or without NDV infection. I have demonstrated degradation of SQSTM1/p62 
in NDV-infected Caco-2 cells, and detailed investigation is required to identify the 
importance of autophagy in NDV-infected Caco-2 cells. 
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According to the International Agency for Research on Cancer (IARC) 2018 report, 
colorectal cancer was the second most common cause of cancer death worldwide. The 
Caco-2 cells can be an excellent model to study virotherapy, given its heterogeneous 
complexity and confirmed susceptibility to NDV-induced oncolysis. However, to understand 
the mechanism of NDV-induced oncolysis in Caco-2 cells the persistent infection and its 
impacts on NDV-induced oncolysis need to be addressed in vitro as well as in vivo studies 
before considering the development of NDV vaccines for clinical trials. The results 
generated in this PhD project strongly suggest that NDV establish not only persistent 
infection but also reduce NDV-induced cytotoxicity while regulating thousands of genes in 
Caco-2 cells.  
 
In this PhD project, the main focus was on identifying the immune response and antiviral 
mechanisms underlying the persistence of the NDV in VR-Caco-2 cells. However, 
persistent infection in Caco-2 cells resulted only from a small population of surviving cells. 
It opens up the possibility to investigate the role of cancer stem cells (CSCs) in Caco-2 cells 
for the establishment of persistent NDV infection. The CSCs are class of self-renewing 
pluripotent cancer cells having an ability to participate in tumour development, cell 
proliferation, metastatic dissemination, drug resistance, and tumour recurrence in various 
types of cancers such as breast, brain, liver, lung, gastric, colon, prostate etc. (298). 
Several cell surface markers have been identified for colorectal CSCs such as CD44, 
CD133, CD24, EpCAM, LGR5 and ALDH (299). Recently the expression profiles of all 
identified surface markers of colorectal CSCs in 8 different colorectal cancer cell lines 
including Caco-2 cells, demonstrating the heterogeneous population of Caco-2 cells 
expressing different CSCs markers from large CD133+CD26high and CD133high/CD26high 
subsets (300). In future, the availability of detailed data on the transcriptome of Caco-2 and 
VR-Caco-2 cells will allow in-depth analysis of expression of CSC markers and metabolic 
pathways that can throw light as to whether the VR-Caco-2 cells have a distinct profile that 
has enabled them to overcome the NDV-induced cytotoxic killing, leading to different virus-
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The data generated from the mass spectrometry (MS) analysis of persistently NDV-infected 
VR Caco-2 and uninfected Caco-2 cells is shown in this Appendix. Here Figure 8.1 and 
Figure 8.2 represents the heat maps of MS analysis in both samples, whereas Table 8.1 
represents most differentially expressed proteins in VR Caco-2 in comparison with the 
uninfected Caco-2 cells. Table contains proteins sharing the same set or subset of peptides 
as a protein group, protein identifier (protein ID), protein accession name (accession), the 
confidence score, (-10Log(P)), the percentage of protein sequence covered by identified 
peptides (Coverage %), the total number of distinct peptide sequences identified in the 
protein group (peptides), the number of peptide sequences that are unique to the protein 
group (the peptides that are common to the proteins of a protein group and which do not 
occur in the proteins of any other group-Unique peptides), any post-translational 
modifications found on the peptides (PTM) and description of the protein (description). For 
each protein, the confidence score was calculated (-10lgP), which is the cumulative value 
of p; the probability of the identified peptide sequence occurring randomly, for each unique 
peptide identified. The higher the confidence score, the higher the confidence in protein 
identification. Scores above 20 (p< 0.01) were seen as high confidence, and anything below 
was eliminated. The data was further filtered by setting the coverage percentage to 1% to 
reduce false discovery. The results were also filtered for the data to only include proteins 
with 2 or more unique peptides to increase confidence further. 
 
Viral proteins (P, F, and W) overexpressed in VR Caco-2 cells are highlighted in Figure 8.1 











Figure 8.1. The sets and subsets of highly overexpressed proteins in VR Caco-2 
cells. The proteins are shown in dark brown colour are significantly abundant in VR Caco-
2 cells in comparison with the uninfected Caco-2 cells. 
 




Figure 8.2. The sets and subsets of highly underexpressed proteins in VR Caco-2 
cells. The proteins are shown in green colour are significantly lower in abundance in VR 
Caco-2 cells in comparison with the uninfected Caco-2 cells. There are more proteins 
significantly under-expressed in VR Caco-2 cells. 






















Histone H1.0 OS=Homo sapiens OX=9606 
GN=H1F0 PE=1 SV=3 
25 1596 137421 P28838|AMPL_HUMAN 128.65 8 4 4 TMT6plex 
Cytosol aminopeptidase OS=Homo sapiens 
OX=9606 GN=LAP3 PE=1 SV=3 
26 1508 137905 P61769|B2MG_HUMAN 116.89 30 4 4 
Carbamidomethylation; 
TMT6plex 
Beta-2-microglobulin OS=Homo sapiens 
OX=9606 GN=B2M PE=1 SV=1 




Calcium-binding and coiled-coil domain-
containing protein 2 OS=Homo sapiens 
OX=9606 GN=CALCOCO2 PE=1 SV=1 
28 1161 137616 P17301|ITA2_HUMAN 132.11 5 4 4 TMT6plex 
Integrin alpha-2 OS=Homo sapiens OX=9606 
GN=ITGA2 PE=1 SV=1 




Endoplasmic reticulum chaperone BiP 
OS=Homo sapiens OX=9606 GN=HSPA5 
PE=1 SV=2 
30 2514 139105 Q9BRT2|UQCC2_HUMAN 75.22 16 2 2 TMT6plex 
Ubiquinol-cytochrome-c reductase complex 
assembly factor 2 OS=Homo sapiens OX=9606 
GN=UQCC2 PE=1 SV=1 




Cadherin-17 OS=Homo sapiens OX=9606 
GN=CDH17 PE=2 SV=3 
32 2611 139471 Q9H4X1|RGCC_HUMAN 117.64 37 2 2 TMT6plex 
Regulator of cell cycle RGCC OS=Homo 
sapiens OX=9606 GN=RGCC PE=1 SV=1 
33 652 136342 P18206|VINC_HUMAN 258.91 19 17 17 
Carbamidomethylation; 
TMT6plex 
Vinculin OS=Homo sapiens OX=9606 GN=VCL 
PE=1 SV=4 
34 724 137456 P30048|PRDX3_HUMAN 165.37 22 5 5 TMT6plex 
Thioredoxin-dependent peroxide reductase 
mitochondrial OS=Homo sapiens OX=9606 
GN=PRDX3 PE=1 SV=3 
35 1128 137056 Q7Z6B0|CCD91_HUMAN 147.48 17 8 8 
Carbamidomethylation; 
TMT6plex 
Coiled-coil domain-containing protein 91 
OS=Homo sapiens OX=9606 GN=CCDC91 
PE=1 SV=2 

















49 1418 137615 Q86SQ4|AGRG6_HUMAN 100.47 4 5 5 TMT6plex 
Adhesion G-protein coupled receptor G6 
OS=Homo sapiens OX=9606 GN=ADGRG6 
PE=1 SV=3 
50 1940 137827 Q16651|PRSS8_HUMAN 112.49 14 4 4 
Carbamidomethylation; 
TMT6plex 
Prostasin OS=Homo sapiens OX=9606 
GN=PRSS8 PE=1 SV=1 
51 1282 138388 O14561|ACPM_HUMAN 91.82 15 2 2 
TMT6plex; Oxidation 
(M) 
Acyl carrier protein mitochondrial OS=Homo 
sapiens OX=9606 GN=NDUFAB1 PE=1 SV=3 
52 2604 139043 Q96E11|RRFM_HUMAN 72.25 7 2 2 TMT6plex 
Ribosome-recycling factor mitochondrial 
OS=Homo sapiens OX=9606 GN=MRRF PE=1 
SV=1 
53 2587 143378 P50120|RET2_HUMAN 73.89 7 2 2 TMT6plex 
Retinol-binding protein 2 OS=Homo sapiens 
OX=9606 GN=RBP2 PE=1 SV=3 




Cytochrome c oxidase assembly factor 4 
homolog mitochondrial OS=Homo sapiens 
OX=9606 GN=COA4 PE=1 SV=2 
55 677 136590 P05556|ITB1_HUMAN 230.65 14 12 12 
Carbamidomethylation; 
TMT6plex 
Integrin beta-1 OS=Homo sapiens OX=9606 
GN=ITGB1 PE=1 SV=2 
56 1700 137765 Q7KZF4|SND1_HUMAN 98.59 5 3 3 TMT6plex 
Staphylococcal nuclease domain-containing 
protein 1 OS=Homo sapiens OX=9606 
GN=SND1 PE=1 SV=1 
57 1347 137779 Q99623|PHB2_HUMAN 130.18 11 3 3 TMT6plex 
Prohibitin-2 OS=Homo sapiens OX=9606 
GN=PHB2 PE=1 SV=2 
58 649 137524 P21741|MK_HUMAN 173.3 36 6 6 
Carbamidomethylation; 
TMT6plex 
Midkine OS=Homo sapiens OX=9606 
GN=MDK PE=1 SV=1 
59 1253 137729 Q16553|LY6E_HUMAN 136.91 40 7 7 
Carbamidomethylation; 
TMT6plex 
Lymphocyte antigen 6E OS=Homo sapiens 
OX=9606 GN=LY6E PE=2 SV=1 
60 2169 138486 Q96IU2|ZBED3_HUMAN 83 11 2 2 
Carbamidomethylation; 
TMT6plex 
Zinc finger BED domain-containing protein 3 
OS=Homo sapiens OX=9606 GN=ZBED3 
PE=1 SV=1 
61 1869 137915 Q86VP1|TAXB1_HUMAN 79.31 4 3 3 TMT6plex 
Tax1-binding protein 1 OS=Homo sapiens 
OX=9606 GN=TAX1BP1 PE=1 SV=2 
















62 424 136551 P27824|CALX_HUMAN 248.86 25 13 13 
Carbamidomethylation; 
TMT6plex 
Calnexin OS=Homo sapiens OX=9606 
GN=CANX PE=1 SV=2 
63 2252 140661 Q9NRV9|HEBP1_HUMAN 78.53 10 2 2 TMT6plex 
Heme-binding protein 1 OS=Homo sapiens 
OX=9606 GN=HEBP1 PE=1 SV=1 
64 2443 138177 Q8IV56|PRR15_HUMAN 88.58 22 2 2 TMT6plex 
Proline-rich protein 15 OS=Homo sapiens 
OX=9606 GN=PRR15 PE=2 SV=1 
65 1330 137269 P0DP91|ERPG3_HUMAN 150.67 5 4 4 
Carbamidomethylation; 
TMT6plex 
Chimeric ERCC6-PGBD3 protein OS=Homo 
sapiens OX=9606 GN=CSB-PGBD3 PE=1 
SV=1 
66 1330 137279 Q03468|ERCC6_HUMAN 150.67 4 4 4 
Carbamidomethylation; 
TMT6plex 
DNA excision repair protein ERCC-6 
OS=Homo sapiens OX=9606 GN=ERCC6 
PE=1 SV=1 
67 543 136836 Q96BZ8|LENG1_HUMAN 167.96 35 8 8 TMT6plex 
Leukocyte receptor cluster member 1 
OS=Homo sapiens OX=9606 GN=LENG1 
PE=1 SV=1 




containing protein 1 OS=Homo sapiens 
OX=9606 GN=CHCHD1 PE=1 SV=1 
69 1937 137595 P62333|PRS10_HUMAN 128.46 11 4 4 TMT6plex 
26S proteasome regulatory subunit 10B 
OS=Homo sapiens OX=9606 GN=PSMC6 
PE=1 SV=1 
70 1412 138008 Q96A73|P33MX_HUMAN 124.9 11 3 3 TMT6plex 
Putative monooxygenase p33MONOX 
OS=Homo sapiens OX=9606 GN=KIAA1191 
PE=1 SV=1 
71 1135 137090 P62753|RS6_HUMAN 147.31 20 7 7 TMT6plex 
40S ribosomal protein S6 OS=Homo sapiens 
OX=9606 GN=RPS6 PE=1 SV=1 
72 337 136370 P50895|BCAM_HUMAN 305.43 31 18 18 
Carbamidomethylation; 
TMT6plex 
Basal cell adhesion molecule OS=Homo 
sapiens OX=9606 GN=BCAM PE=1 SV=2 
73 2314 138006 P55786|PSA_HUMAN 108.22 3 2 2 TMT6plex 
Puromycin-sensitive aminopeptidase 
OS=Homo sapiens OX=9606 GN=NPEPPS 
PE=1 SV=2 
















74 468 136670 Q96MH2|HEXI2_HUMAN 211.06 29 10 8 
Carbamidomethylation; 
TMT6plex 
Protein HEXIM2 OS=Homo sapiens OX=9606 
GN=HEXIM2 PE=1 SV=1 




Remodeling and spacing factor 1 OS=Homo 
sapiens OX=9606 GN=RSF1 PE=1 SV=2 
76 1082 137254 P31942|HNRH3_HUMAN 200.45 13 5 5 
TMT6plex; Oxidation 
(M) 
Heterogeneous nuclear ribonucleoprotein H3 
OS=Homo sapiens OX=9606 GN=HNRNPH3 
PE=1 SV=2 
77 635 136353 Q86UU0|BCL9L_HUMAN 260.63 14 17 17 
TMT6plex; Oxidation 
(M) 
B-cell CLL/lymphoma 9-like protein OS=Homo 
sapiens OX=9606 GN=BCL9L PE=1 SV=1 
78 1535 137835 P28290|ITPI2_HUMAN 120.76 3 3 3 TMT6plex 
Protein ITPRID2 OS=Homo sapiens OX=9606 
GN=ITPRID2 PE=1 SV=3 
79 791 137330 Q99519|NEUR1_HUMAN 145.28 12 7 7 
Carbamidomethylation; 
TMT6plex 
Sialidase-1 OS=Homo sapiens OX=9606 
GN=NEU1 PE=1 SV=1 




Heterogeneous nuclear ribonucleoprotein M 
OS=Homo sapiens OX=9606 GN=HNRNPM 
PE=1 SV=3 
81 2359 138357 A6NKD9|CC85C_HUMAN 91.51 7 2 2 TMT6plex 
Coiled-coil domain-containing protein 85C 
OS=Homo sapiens OX=9606 GN=CCDC85C 
PE=1 SV=1 
82 2095 139407 P20933|ASPG_HUMAN 75.33 5 2 2 
Carbamidomethylation; 
TMT6plex 
N (4) - (beta-N-acetylglucosaminyl)-L-
asparaginase OS=Homo sapiens OX=9606 
GN=AGA PE=1 SV=2 
83 1193 137045 Q15417|CNN3_HUMAN 154.77 18 5 5 
TMT6plex; Oxidation 
(M) 
Calponin-3 OS=Homo sapiens OX=9606 
GN=CNN3 PE=1 SV=1 
84 2605 139122 P26447|S10A4_HUMAN 61.71 17 2 2 TMT6plex 
Protein S100-A4 OS=Homo sapiens OX=9606 
GN=S100A4 PE=1 SV=1 
85 1928 138287 O00625|PIR_HUMAN 57.38 6 2 2 TMT6plex 
Pirin OS=Homo sapiens OX=9606 GN=PIR 
PE=1 SV=1 




Perilipin-3 OS=Homo sapiens OX=9606 
GN=PLIN3 PE=1 SV=3 
87 1185 138269 Q6PJG2|EMSA1_HUMAN 111.99 3 2 2 TMT6plex 
ELM2 and SANT domain-containing protein 1 
OS=Homo sapiens OX=9606 GN=ELMSAN1 
PE=1 SV=2 




















Radixin OS=Homo sapiens OX=9606 GN=RDX 
PE=1 SV=1 
89 607 136646 Q99961|SH3G1_HUMAN 178.73 31 14 14 TMT6plex 
Endophilin-A2 OS=Homo sapiens OX=9606 
GN=SH3GL1 PE=1 SV=1 




Protein FAM168A OS=Homo sapiens OX=9606 
GN=FAM168A PE=1 SV=2 
91 1343 137335 P11586|C1TC_HUMAN 96.23 7 5 5 
Carbamidomethylation; 
TMT6plex 
C-1-tetrahydrofolate synthase cytoplasmic 
OS=Homo sapiens OX=9606 GN=MTHFD1 
PE=1 SV=3 
92 2139 138735 P25686|DNJB2_HUMAN 88.07 6 2 2 TMT6plex 
DnaJ homolog subfamily B member 2 
OS=Homo sapiens OX=9606 GN=DNAJB2 
PE=1 SV=3 
93 1592 138547 Q9Y4Y9|LSM5_HUMAN 116.07 46 3 3 
TMT6plex; Oxidation 
(M) 
U6 snRNA-associated Sm-like protein LSm5 
OS=Homo sapiens OX=9606 GN=LSM5 PE=1 
SV=3 
94 581 136585 Q8IVM0|CCD50_HUMAN 202.21 37 11 11 
Carbamidomethylation; 
TMT6plex 
Coiled-coil domain-containing protein 50 
OS=Homo sapiens OX=9606 GN=CCDC50 
PE=1 SV=1 
95 2413 138137 Q92997|DVL3_HUMAN 79.52 3 2 2 TMT6plex 
Segment polarity protein dishevelled homolog 
DVL-3 OS=Homo sapiens OX=9606 GN=DVL3 
PE=1 SV=2 
96 412 136348 P49454|CENPF_HUMAN 252.72 9 25 25 
Carbamidomethylation; 
TMT6plex 
Centromere protein F OS=Homo sapiens 
OX=9606 GN=CENPF PE=1 SV=3 
97 1214 137764 P53634|CATC_HUMAN 208.66 7 7 7 
Carbamidomethylation; 
TMT6plex 
Dipeptidyl peptidase 1 OS=Homo sapiens 
OX=9606 GN=CTSC PE=1 SV=2 
98 1474 138047 Q96B45|BORC7_HUMAN 110.38 32 3 3 TMT6plex 
BLOC-1-related complex subunit 7 OS=Homo 
sapiens OX=9606 GN=BORCS7 PE=3 SV=2 
99 1758 137864 Q14254|FLOT2_HUMAN 88.64 8 3 3 TMT6plex 
 
Flotillin-2 OS=Homo sapiens OX=9606 
GN=FLOT2 PE=1 SV=2  
















100 1230 137324 Q96MY1|NOL4L_HUMAN 128.94 10 6 6 TMT6plex 
Nucleolar protein 4-like OS=Homo sapiens 
OX=9606 GN=NOL4L PE=1 SV=2 
101 755 136818 P98175|RBM10_HUMAN 182.81 9 10 8 TMT6plex 
RNA-binding protein 10 OS=Homo sapiens 
OX=9606 GN=RBM10 PE=1 SV=3 
102 2131 137945 Q96T51|RUFY1_HUMAN 84.83 6 3 3 
Carbamidomethylation; 
TMT6plex 
RUN and FYVE domain-containing protein 1 
OS=Homo sapiens OX=9606 GN=RUFY1 
PE=1 SV=2 




Proliferation marker protein Ki-67 OS=Homo 
sapiens OX=9606 GN=MKI67 PE=1 SV=2 




Charged multivesicular body protein 1a 
OS=Homo sapiens OX=9606 GN=CHMP1A 
PE=1 SV=1 
105 2357 138263 Q6VMQ6|MCAF1_HUMAN 94.11 2 2 2 
Carbamidomethylation; 
TMT6plex 
Activating transcription factor 7-interacting 
protein 1 OS=Homo sapiens OX=9606 
GN=ATF7IP PE=1 SV=3 
106 1421 140563 Q9UNN8|EPCR_HUMAN 66.66 8 2 2 TMT6plex 
Endothelial protein C receptor OS=Homo 
sapiens OX=9606 GN=PROCR PE=1 SV=1 
107 759 136658 P49959|MRE11_HUMAN 211.47 15 11 11 
TMT6plex; Oxidation 
(M) 
Double-strand break repair protein MRE11 
OS=Homo sapiens OX=9606 GN=MRE11 
PE=1 SV=3 





Neuroblast differentiation-associated protein 
AHNAK OS=Homo sapiens OX=9606 
GN=AHNAK PE=1 SV=2 
109 798 137356 Q96CP2|FWCH2_HUMAN 164.56 64 7 7 
Carbamidomethylation; 
TMT6plex 
FLYWCH family member 2 OS=Homo sapiens 
OX=9606 GN=FLYWCH2 PE=1 SV=1 
110 1680 138062 Q9Y605|MOFA1_HUMAN 142.52 38 3 3 TMT6plex 
MORF4 family-associated protein 1 OS=Homo 
sapiens OX=9606 GN=MRFAP1 PE=1 SV=1 
















111 1573 137643 Q15773|MLF2_HUMAN 114.64 16 4 4 TMT6plex 
Myeloid leukemia factor 2 OS=Homo sapiens 
OX=9606 GN=MLF2 PE=1 SV=1 
112 529 137528 Q9HCY8|S10AE_HUMAN 172.95 46 4 4 
Carbamidomethylation; 
TMT6plex 
Protein S100-A14 OS=Homo sapiens OX=9606 
GN=S100A14 PE=1 SV=1 
113 1073 137101 O60885|BRD4_HUMAN 144.02 4 6 6 TMT6plex 
Bromodomain-containing protein 4 OS=Homo 
sapiens OX=9606 GN=BRD4 PE=1 SV=2 
114 1402 137814 Q96EQ0|SGTB_HUMAN 99.9 11 4 3 TMT6plex 
Small glutamine-rich tetratricopeptide repeat-
containing protein beta OS=Homo sapiens 
OX=9606 GN=SGTB PE=1 SV=1 
115 1274 138101 Q96A19|C102A_HUMAN 109.5 7 3 3 TMT6plex 
Coiled-coil domain-containing protein 102A 
OS=Homo sapiens OX=9606 GN=CCDC102A 
PE=1 SV=2 
116 777 136500 Q5UIP0|RIF1_HUMAN 197.26 5 11 11 
Carbamidomethylation; 
TMT6plex 
Telomere-associated protein RIF1 OS=Homo 
sapiens OX=9606 GN=RIF1 PE=1 SV=2 
117 119 137036 P20962|PTMS_HUMAN 248.97 90 17 17 TMT6plex 
Parathymosin OS=Homo sapiens OX=9606 
GN=PTMS PE=1 SV=2 





PSME3-interacting protein OS=Homo sapiens 
OX=9606 GN=FAM192A PE=1 SV=1 
119 1686 137420 O96013|PAK4_HUMAN 135.72 7 4 4 TMT6plex 
Serine/threonine-protein kinase PAK 4 
OS=Homo sapiens OX=9606 GN=PAK4 PE=1 
SV=1 
120 656 136638 Q68CZ2|TENS3_HUMAN 193.6 8 11 11 
Carbamidomethylation; 
TMT6plex 
Tensin-3 OS=Homo sapiens OX=9606 
GN=TNS3 PE=1 SV=2 
121 1444 137660 Q13153|PAK1_HUMAN 120.59 4 3 2 TMT6plex 
Serine/threonine-protein kinase PAK 1 
OS=Homo sapiens OX=9606 GN=PAK1 PE=1 
SV=2 
122 1546 137307 O15014|ZN609_HUMAN 116.6 3 5 5 
Carbamidomethylation; 
TMT6plex 
Zinc finger protein 609 OS=Homo sapiens 
OX=9606 GN=ZNF609 PE=1 SV=2 
















123 615 138055 P50238|CRIP1_HUMAN 174.82 52 9 9 
Carbamidomethylation; 
TMT6plex 
Cysteine-rich protein 1 OS=Homo sapiens 
OX=9606 GN=CRIP1 PE=1 SV=3 
124 1356 137942 Q9H9B1|EHMT1_HUMAN 87.83 2 3 3 TMT6plex 
Histone-lysine N-methyltransferase EHMT1 
OS=Homo sapiens OX=9606 GN=EHMT1 
PE=1 SV=4 
125 2361 138429 Q99081|HTF4_HUMAN 74.18 6 2 2 TMT6plex 
Transcription factor 12 OS=Homo sapiens 
OX=9606 GN=TCF12 PE=1 SV=1 
126 1960 138007 O14641|DVL2_HUMAN 65.85 5 4 4 TMT6plex 
Segment polarity protein dishevelled homolog 
DVL-2 OS=Homo sapiens OX=9606 GN=DVL2 
PE=1 SV=1 
127 1703 138250 Q8TEU7|RPGF6_HUMAN 59.66 1 3 2 TMT6plex 
Rap guanine nucleotide exchange factor 6 
OS=Homo sapiens OX=9606 GN=RAPGEF6 
PE=1 SV=2 
128 1851 137753 Q9H4A3|WNK1_HUMAN 101.88 1 3 3 TMT6plex 
Serine/threonine-protein kinase WNK1 
OS=Homo sapiens OX=9606 GN=WNK1 PE=1 
SV=2 
129 787 137068 Q9Y6W5|WASF2_HUMAN 158.25 10 7 7 TMT6plex 
Wiskott-Aldrich syndrome protein family 
member 2 OS=Homo sapiens OX=9606 
GN=WASF2 PE=1 SV=3 
130 2090 138549 P78344|IF4G2_HUMAN 77.69 2 2 2 TMT6plex 
Eukaryotic translation initiation factor 4 gamma 
2 OS=Homo sapiens OX=9606 GN=EIF4G2 
PE=1 SV=1 
131 563 136763 Q13177|PAK2_HUMAN 235.97 23 11 10 TMT6plex 
Serine/threonine-protein kinase PAK 2 
OS=Homo sapiens OX=9606 GN=PAK2 PE=1 
SV=3 
132 1203 137833 Q9UPN4|CP131_HUMAN 120.17 3 3 3 TMT6plex 
Centrosomal protein of 131 kDa OS=Homo 
sapiens OX=9606 GN=CEP131 PE=1 SV=3 
133 1775 137909 Q96B01|R51A1_HUMAN 63.32 12 4 4 TMT6plex 
RAD51-associated protein 1 OS=Homo 
sapiens OX=9606 GN=RAD51AP1 PE=1 SV=1 
134 694 137443 P13987|CD59_HUMAN 181.37 39 7 7 
Carbamidomethylation; 
TMT6plex 
CD59 glycoprotein OS=Homo sapiens 
OX=9606 GN=CD59 PE=1 SV=1 
135 865 137133 Q6FI81|CPIN1_HUMAN 182.19 20 5 5 
Carbamidomethylation; 
TMT6plex 
Anamorsin OS=Homo sapiens OX=9606 
GN=CIAPIN1 PE=1 SV=2 




















ADP-ribosylation factor GTPase-activating 
protein 3 OS=Homo sapiens OX=9606 
GN=ARFGAP3 PE=1 SV=1 
137 2658 140599 Q9BUT9|MCRI2_HUMAN 85.57 22 2 2 TMT6plex 
MAPK regulated corepressor interacting protein 
2 OS=Homo sapiens OX=9606 GN=MCRIP2 
PE=1 SV=2 





nucleotidohydrolase mitochondrial OS=Homo 
sapiens OX=9606 GN=DUT PE=1 SV=4 
139 2064 137999 Q15054|DPOD3_HUMAN 90.43 6 3 3 TMT6plex 
DNA polymerase delta subunit 3 OS=Homo 
sapiens OX=9606 GN=POLD3 PE=1 SV=2 
140 1855 138649 Q53T59|H1BP3_HUMAN 119.83 5 2 2 TMT6plex 
HCLS1-binding protein 3 OS=Homo sapiens 
OX=9606 GN=HS1BP3 PE=1 SV=1 
141 2089 138298 Q9Y2H2|SAC2_HUMAN 74.72 2 2 2 TMT6plex 
Phosphatidylinositide phosphatase SAC2 
OS=Homo sapiens OX=9606 GN=INPP5F 
PE=1 SV=3 
142 1050 137231 Q9P021|CRIPT_HUMAN 174.36 44 8 8 
Carbamidomethylation; 
TMT6plex 
Cysteine-rich PDZ-binding protein OS=Homo 
sapiens OX=9606 GN=CRIPT PE=1 SV=1 
143 390 136372 Q9UEE9|CFDP1_HUMAN 231.89 56 20 20 
TMT6plex; Oxidation 
(M) 
Craniofacial development protein 1 OS=Homo 
sapiens OX=9606 GN=CFDP1 PE=1 SV=1 
144 195 137117 P06454|PTMA_HUMAN 271.36 47 15 15 TMT6plex 
Prothymosin alpha OS=Homo sapiens 
OX=9606 GN=PTMA PE=1 SV=2 




Eukaryotic translation initiation factor 4E-
binding protein 2 OS=Homo sapiens OX=9606 
GN=EIF4EBP2 PE=1 SV=1 
146 1006 137402 Q9Y2S6|TMA7_HUMAN 135.17 58 8 7 
TMT6plex; Oxidation 
(M) 
Translation machinery-associated protein 7 
OS=Homo sapiens OX=9606 GN=TMA7 PE=1 
SV=1 
147 1620 137917 Q99622|C10_HUMAN 135.41 40 3 3 TMT6plex 
 
Protein C10 OS=Homo sapiens OX=9606 
GN=C12orf57 PE=1 SV=1  
















148 722 137785 Q9UQN3|CHM2B_HUMAN 111.83 17 4 4 TMT6plex 
Charged multivesicular body protein 2b 
OS=Homo sapiens OX=9606 GN=CHMP2B 
PE=1 SV=1 
149 381 136666 P07858|CATB_HUMAN 276.88 27 25 25 
Carbamidomethylation; 
TMT6plex 
Cathepsin B OS=Homo sapiens OX=9606 
GN=CTSB PE=1 SV=3 
150 945 137053 P08590|MYL3_HUMAN 171.48 23 6 4 TMT6plex 
Myosin light chain 3 OS=Homo sapiens 
OX=9606 GN=MYL3 PE=1 SV=3 




Ribosome-binding protein 1 OS=Homo sapiens 
OX=9606 GN=RRBP1 PE=1 SV=5 
152 1089 137692 Q5T7N3|KANK4_HUMAN 105.19 3 3 2 TMT6plex 
KN motif and ankyrin repeat domain-containing 
protein 4 OS=Homo sapiens OX=9606 
GN=KANK4 PE=1 SV=1 
153 1828 137533 Q86YS3|RFIP4_HUMAN 112.97 5 3 3 TMT6plex 
Rab11 family-interacting protein 4 OS=Homo 
sapiens OX=9606 GN=RAB11FIP4 PE=1 SV=1 
154 2469 138285 Q9NYZ3|GTSE1_HUMAN 64.93 3 2 2 
Carbamidomethylation; 
TMT6plex 
G2 and S phase-expressed protein 1 
OS=Homo sapiens OX=9606 GN=GTSE1 
PE=1 SV=3 




Alpha-1-antitrypsin OS=Homo sapiens 
OX=9606 GN=SERPINA1 PE=1 SV=3 




protein 2 OS=Homo sapiens OX=9606 
GN=PAIP2 PE=1 SV=1 




Mitotic spindle organizing protein 2A OS=Homo 
sapiens OX=9606 GN=MZT2A PE=1 SV=2 




Ubiquitin carboxyl-terminal hydrolase 10 
OS=Homo sapiens OX=9606 GN=USP10 
PE=1 SV=2  
159 1997 140617 Q9BUA3|SPNDC_HUMAN 63.27 4 2 2 TMT6plex 
Spindlin interactor and repressor of chromatin-
binding protein OS=Homo sapiens OX=9606 
GN=SPINDOC PE=1 SV=3 
















160 2510 138997 Q96JB3|HIC2_HUMAN 58.52 2 2 2 TMT6plex 
Hypermethylated in cancer 2 protein OS=Homo 
sapiens OX=9606 GN=HIC2 PE=1 SV=2 
161 828 136870 P49715|CEBPA_HUMAN 147.18 19 9 8 TMT6plex 
CCAAT/enhancer-binding protein alpha 
OS=Homo sapiens OX=9606 GN=CEBPA 
PE=1 SV=3 
162 1702 137842 P52701|MSH6_HUMAN 103.72 4 3 3 TMT6plex 
DNA mismatch repair protein Msh6 OS=Homo 
sapiens OX=9606 GN=MSH6 PE=1 SV=2 
163 1215 138374 Q3SY56|SP6_HUMAN 111.94 7 2 2 
Carbamidomethylation; 
TMT6plex 
Transcription factor Sp6 OS=Homo sapiens 
OX=9606 GN=SP6 PE=2 SV=1 
164 2442 138147 Q9GZY8|MFF_HUMAN 60.07 17 2 2 TMT6plex 
Mitochondrial fission factor OS=Homo sapiens 
OX=9606 GN=MFF PE=1 SV=1 
165 207 136302 Q02818|NUCB1_HUMAN 295.24 39 26 24 
TMT6plex; Oxidation 
(M) 
Nucleobindin-1 OS=Homo sapiens OX=9606 
GN=NUCB1 PE=1 SV=4 




Fibronectin OS=Homo sapiens OX=9606 
GN=FN1 PE=1 SV=4 
167 1112 137021 Q8N3D4|EH1L1_HUMAN 185.17 5 5 5 
Carbamidomethylation; 
TMT6plex 
EH domain-binding protein 1-like protein 1 
OS=Homo sapiens OX=9606 GN=EHBP1L1 
PE=1 SV=2 
168 871 140557 Q07654|TFF3_HUMAN 93.1 27 4 4 
Carbamidomethylation; 
TMT6plex 
Trefoil factor 3 OS=Homo sapiens OX=9606 
GN=TFF3 PE=1 SV=2 




Peptidyl-prolyl cis-trans isomerase NIMA-
interacting 4 OS=Homo sapiens OX=9606 
GN=PIN4 PE=1 SV=1  
170 1692 138178 Q92499|DDX1_HUMAN 70.59 4 2 2 
Carbamidomethylation; 
TMT6plex 
ATP-dependent RNA helicase DDX1 
OS=Homo sapiens OX=9606 GN=DDX1 PE=1 
SV=2 
171 1027 137080 Q15154|PCM1_HUMAN 130.32 2 6 5 
Carbamidomethylation; 
TMT6plex 
Pericentriolar material 1 protein OS=Homo 
sapiens OX=9606 GN=PCM1 PE=1 SV=5 




Small EDRK-rich factor 2 OS=Homo sapiens 
OX=9606 GN=SERF2 PE=1 SV=1  





















Sickle tail protein homolog OS=Homo sapiens 
OX=9606 GN=KIAA1217 PE=1 SV=2  
174 2212 138039 O14964|HGS_HUMAN 86.7 4 3 3 
Carbamidomethylation; 
TMT6plex 
Hepatocyte growth factor-regulated tyrosine 
kinase substrate OS=Homo sapiens OX=9606 
GN=HGS PE=1 SV=1 




Galectin-2 OS=Homo sapiens OX=9606 
GN=LGALS2 PE=1 SV=3 
176 306 136230 Q9ULW0|TPX2_HUMAN 297.98 35 23 23 
Carbamidomethylation; 
TMT6plex 
Targeting protein for Xklp2 OS=Homo sapiens 
OX=9606 GN=TPX2 PE=1 SV=2 




Myc box-dependent-interacting protein 1 
OS=Homo sapiens OX=9606 GN=BIN1 PE=1 
SV=1 
178 2426 138625 Q9BXS6|NUSAP_HUMAN 76.54 4 2 2 TMT6plex 
 
Nucleolar and spindle-associated protein 1 
OS=Homo sapiens OX=9606 GN=NUSAP1 
PE=1 SV=1  
179 1334 137285 P02671|FIBA_HUMAN 146.7 8 5 5 
TMT6plex; Oxidation 
(M) 
Fibrinogen alpha chain OS=Homo sapiens 
OX=9606 GN=FGA PE=1 SV=2 
180 1131 137198 Q9BRK5|CAB45_HUMAN 156.72 19 6 6 TMT6plex 
45 kDa calcium-binding protein OS=Homo 
sapiens OX=9606 GN=SDF4 PE=1 SV=1 




NPC intracellular cholesterol transporter 2 
OS=Homo sapiens OX=9606 GN=NPC2 PE=1 
SV=1 




Calpain-15 OS=Homo sapiens OX=9606 
GN=CAPN15 PE=1 SV=1  




Apolipoprotein A-I OS=Homo sapiens 
OX=9606 GN=APOA1 PE=1 SV=1  
















184 442 137673 P63313|TYB10_HUMAN 181.5 57 11 7 TMT6plex 
 
Thymosin beta-10 OS=Homo sapiens 
OX=9606 GN=TMSB10 PE=1 SV=2  
185 536 136677 Q8N6H7|ARFG2_HUMAN 213.19 17 10 10 TMT6plex 
ADP-ribosylation factor GTPase-activating 
protein 2 OS=Homo sapiens OX=9606 
GN=ARFGAP2 PE=1 SV=1 
186 1384 137591 O00592|PODXL_HUMAN 128.14 10 5 5 TMT6plex 
Podocalyxin OS=Homo sapiens OX=9606 
GN=PODXL PE=1 SV=2 
187 1636 138114 Q9P0P0|RN181_HUMAN 82.02 15 3 3 
Carbamidomethylation; 
TMT6plex 
E3 ubiquitin-protein ligase RNF181 OS=Homo 
sapiens OX=9606 GN=RNF181 PE=1 SV=1 
188 1479 137555 Q9UHG0|DCDC2_HUMAN 147.2 17 5 5 TMT6plex 
Doublecortin domain-containing protein 2 
OS=Homo sapiens OX=9606 GN=DCDC2 
PE=1 SV=2 
189 602 136797 P04792|HSPB1_HUMAN 249.99 53 14 14 TMT6plex 
Heat shock protein beta-1 OS=Homo sapiens 
OX=9606 GN=HSPB1 PE=1 SV=2 
190 1175 138181 P02763|A1AG1_HUMAN 132 16 3 3 TMT6plex 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens 
OX=9606 GN=ORM1 PE=1 SV=1 




P antigen family member 4 OS=Homo sapiens 
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